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The main aim of this thesis was to investigate the 
role of central catecholamines in the antihypertensive 
action of clonidine. This was examined by attempting to 
correlate changes in central noradrenaline levels and 
turnover in specific brain regions with the hypotensive 
action of the drug. The investigation looked for these 
effects in three rat models, normotensives, renal/DOCA 
hypertensives and spontaneously hypertensives. The inter­
action between clonidine and desmethylimipramine was also 
examined. When given twice daily for seven days, clonidine 
produced a dose related decrease in blood pressure and a 
dose related decrease in noradrenaline turnover in the 
medulla and, to a lesser extent, in the hypothalamus of all 
three animal models studied. Combined therapy with 
clonidine and DMI resulted in an antagonism of the hypo­
tensive effect of clonidine, yet a potentiation of the 
turnover effects. Little significant change was found on 
endogenous noradrenaline levels after any of the above 
treatments.
Based on the hypothesis that hypertension and elevated 
blood pressure is associated with decreased central nora­
drenaline turnover, the major conclusion drawn from the 
results of the thesis is that, although the decreases in 
blood pressure and central noradrenaline turnover are both 
brought about by clonidine treatment, the turnover effects 
are not directly related to the drug's hypotensive action. 
It is proposed that the turnover effect is by incidental 
stimulation of a-receptors located on a pre-synaptic
- X -
neurone, probably at the same synapse at which clonidine 
produces its hypotensive action by the stimulation of 
post-synaptic a-receptors.
In the course of the experiments, other drugs were 
also examined for effects on blood pressure and/or 
central catecholamines. The drugs examined included 
a-methyldopa, guanethidine, phenoxybenzamine and sotalol. 
A discussion is presented on the mechanisms by which the 
above effects may be produced and their possible 






An attempt is made in this thesis to relate the 
mechanism of action of centrally acting antihypertensive 
agents with changes in the central adrenergic mechanisms 
said to play an important role in the regulation of blood 
pressure. The particular antihypertensive agent studied 
was the imidazoline derivative, clonidine.
Also presented are the results of an investigation 
into the interaction between clonidine and certain other 
drugs, for example the tricyclic ahtidepressant, 
desmethylimipramine (DMI).
The thesis starts, therefore, with an outline of 
the discovery of the circulatory system and the disease 
of hypertension. It continues with a description of the 
role of central adrenergic mechanisms in blood pressure 
control and also their implication in hypertension 
and goes on to describe the drugs which have been developed 
for the treatment of the disease, in particular those with 
a central site of action.
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1.1 A Brief Historical Outline of the Discovery
of the Circulation
Although there are numerous references in ancient 
medical writings to the heart, the pulse and blood flow 
in general (for references see Leake, 1952), the credit 
for the discovery of the circulation of blood around the 
body is usually given to an Englishman, William Harvey 
(1578-1557), sometime lecturer in anatomy at the Royal 
College of Physicians. His treatise "De mortu cordis 
et sanguinis", published in 1628, provides the basis for 
modern thinking on cardiovascular physiology (Parkyn, 1952y, 
As early as 1700BC the ancient Egyptians and the 
Chinese realised that the heart was one of the major and 
important organs of the body and that the pulse, detected 
in the extremities, could be used as a guide to the 
condition of the heart. With these findings and the 
discoveries of later physicians and anatomists, notably 
people such as Ambriose Pare (1510-1590), Jacapo Berengaris 
de Corpi (1470-1550), Guido Guidi (1500-1569), CarOlus 
Stephanus (1500-1564), Leonardo da Vinci (1452-1519) and 
Andreas Vesalius (1514-1564), the understanding of the 
functions of the heart and the blood was greatly increased. 
However, it was left to William Harvey to postulate the 
idea of blood, driven by the heart, being circulated 
around the body. Yet, even Harvey was not able to explain 
how the blood passed from the arteries to the veins. It 
was not until the microscope had been perfected that, in
- 4 -
1661, an Italian anatomist, Malpighi, was able to observe 
and describe the networks of capillary vessels uniting 
the arteries^ and veins, thus providing the "missing link" 
in Harvey's hypothesis.
Although further work over the following years gave 
more and more insight into the structure and functions of 
the cardiovascular system, the next real advance in the 
understanding of the circulation came with the reporting 
of experiments performed by the Reverend Stephen Hales 
(1677-1761). His experiments concerned the direct 
measurement of blood pressure in a variety of animals, 
in particular horses, using brass catheters and long glass 
tubes. In these experiments, he was able to demonstrate 
pressure relationships between arteries and veins and, as 
a result, estimated systolic blood pressure in humans to 
be around seven and a half (7̂ ;) feet of blood, a figure 
that compares favourably with that obtained by modern 
blood pressure measurements.
The invention in 1896 by Scipione Riva-Rocci (1863- 
1937) of the mercury sphygnomanometer, the forerunner of 
modern blood pressure measuring instruments, helped to 
confirm that blood pressure varied with heart beat and 
respiration.
It later became clear that blood pressure had some 
clinical significance and that it could be shown to be a 
useful adjunct to the diagnosis of disturbances of the 
cardiovascular system and also certain other disease 
states.
- 5 -
This led to further analysis of the factors involved 
in the control of blood pressure and the discovery of» 
among other things:
1. the cardioinhibitory effect of the vagus;
2. the accelerator nerves to the heart 
(Bezold, 1835-68)j
3. baroreceptor reflex function of the 
carotid sinus (Bering, 1924).
More recent work has indicated that there are many 
factors which may be involved in the control and regulation 
of blood pressure. Figure 1.1 gives a diagrammatic 
representation of many of the factors.
There appear, however, to be two Major control 
mechanisms, one humoral, centred upon the kidney and 
associated with the production of renin, the other neural, 
involving mechanisms sited in the brain. Of the two, the 
latter appears to be the more important and dominant 
mechanism.
It is with these central mechanisms that this thesis 
is primarily concerned. The involvement of these 
mechanisms in blood pressure regulation will be discussed 
further in a later section.
- 6 -
FIGURE 1.1 A simplified scheme of the various factors 
and mechanisms involved in the regulation 




























The importance of blood pressure in the body is ar 
subject in itself and no attempt will be made in this 
thesis to discuss its implications. Instead, this thesis 
will be concerned more with the central controlling 
mechanisms involved in blood pressure maintenance and 
possible aberrations of these mechanisms which may result 
in elevated blood pressure or hypertension. The effects 
of drug treatment on these mechanisms will also be 
considered.
It has been suggested that the diastolic pressure is 
a better guide to the state of systemic blood pressure 
than systolic pressure. This is due to the shape of the 
pulse pressure wave which puts the mean blood pressure 
closer to the diastolic value. The diastolic pressure 
also reflects more the condition of the peripheral resist­
ance vessels (i.e. whether narrowing or decreased 
elasticity has occurred) and is less variable than 
systolic.
1.2.2 What is Hypertension?
Many medical textbooks state that "normal” blood 
pressure lies within the ranges systolic 110-120mmHg and 
diastolic 70-80mmHg. In practice, this is not so. For
— 8 —
example, it is known that blood pressure increases with 
age. In a 50-50-year old patient, the blood pressure may 
be substantially higher than the figures quoted above. 
However, when age is taken into consideration, the blood 
pressure may be considered "normal”. Conversely, in 
athletes, blood pressure may be lower than the "norm” for 
age, etc. (Pickering, 1974).
Considerable variation in blood pressure can occur 
in the "normal" person as a result of a variety of 
factors, excluding disease states. These include time of 
day (diurnal variation), environmental conditions and 
stress factors (see Pickering, 1974; Chapter 2). It is 
difficult, therefore, to state categorically a level of 
blood pressure above which a patient may be classed as 
hypertens ive.
Single blood pressure measurements can be meaningless 
for the diagnosis of hypertension, unless supported by 
other clinical evidence. However, patients who display 
a persistent elevation in blood pressure over a period of 
time and repeated observations may be classed as hyperten­
sive after age and other factors have been considered.
The question which now becomes relevant is what 
level of increase in blood pressure is considered outside 
"normal" limits and therefore unacceptable?
There now is considerable evidence that increasing 
arterial pressure is associated with a higher incidence 
of mortality. This is shown in Table 1.1 which is com­
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of America. From the lowest to the highest values of 
systolic and diastolic pressure the incidence of mortality 
increases with increasing pressure. There is no sudden 
break in the increase and the relationship is quantitative.
Although it is obvious that treatment of hypertension 
will reduce distressing symptoms of the disease, Freis 
(1970) has indicated that treatment of hypertensive 
patients may also result in a reduction of the expected 
mortality rate.
Expectation of life was improved by treatment in 
people with diastolic pressures between 95-llOmmHg, with 
greater success at the higher pressure. Hence, reduction 
of blood pressure, even in the symptomless patient, may 
produce greater benefit to the patient in terms of increased 
life expectancy. When a doctor has to decide, therefore, 
whether a patient is hypertensive, he is really deciding 
whether or not the patient needs, and will benefit from, 
the application of therapy. Indeed, the idea may be put 
forward that everyone should receive prophylactic treat­
ment against hypertension, at least until it is possible 
to predict those persons who will develop and suffer from 
the disease in later life.
This, however, poses the question of whether the 
possible benefit accrued from prophylactic treatment would 
outweigh the probable side effects of long term drug 
therapy of normal people. As this idea is therefore 
really unacceptable, basic guidelines have to be drawn to 
enable decision-making on when to treat hypertension.
— XI —
Pickering (1974, p34), accepting that females tolerate- 
higher pressures than males, states that the pressure at 
which benefit is conferred to the-patient by hypotensive 
therapy is higher in females than in males» Hence» he 
puts forward three divisions of hypertensive patient:
1. those with diastolic pressures persistently 
over llOmmHg, making hypotensive therapy 
mandatory;
2. female patients with diastolic pressures 
between lOO-llOmmHg who may benefit from 
treatment;
3. male patients with diastolic pressures 
between 95-lOOmmHg who also may benefit 
from treatment»
It would therefore appear that, to be on the safe 
side, the generality of treating all patients (allowing 
for age) presenting diastolic pressures of 95mmHg or over, 
whether presenting other clinical symptoms or not, may be 
a sound approach»
1.2.3 The Aetiology of Hypertension
Clinically, hypertension is customarily classified 
into two main divisions:
— 12 — ^
1. primary or "essential" hypertension, 
implying an unknown cause;
2. secondary hypertension, referring to a 
number of other conditions which are 
known to result or manifest in 
hypertension.
In the primary or "essential" hypertensive state, 
clinical symptoms such as retinopathy and retinal exudates 
are usually manifested as a result of the elevated blood 
pressure. The cause of the hypertension is not easily 
determined and can result from factors as far-ranging as 
heredity, changes in environmental conditions (Ledingham, 
1971; Pickering, 1974), or an imbalance of the normally 
well-balanced systems that maintain body haemodynamics 
(i.e. the mosaic theory. Page, 1974).
"Essential" hypertension is one of the "chicken or 
the egg" problems of cardiovascular pharmacology as many 
factors have been shown to be associated with the hyper­
tension but no direct evidence is available to show 
whether these factors are a result, or a cause, of the 
hypertension. For example, there is controversy about the 
roles of renin and sodium in hypertension with some workers 
showing correlations of increased renin and/or sodium 
with hypertension, yet other workers showing no correlation 
(see editorial. The Lancet 1, 345, 1976),
Secondary hypertension is usually a manifestation or
- 13 -
symptom of a known disease or clinical abnormality, of 
which probably the most common are of renal origin or 
endocrine imbalance (Ledingham, 1971), Other diseases 
and clinical states which may manifest as hypertension 
include diabetes, connective tissue diseases, co-arction 
of the aorta, phaeochromocytoma, Cushing's syndrome and 
drug therapy such as contraceptive pills and steroids.
In the experimental animal, mechanical methods of 
hypertension induction are the most commonly used and 
involve manipulation of the kidneys (see Chapter 2). The 
administration of mineralocorticoid excess is also a 
frequently used technique of hypertension induction.
These experimentally induced hypertensive states, 
resemble more closely secondary hypertension,in that they 
are precipitated by a known cause or action. "Essential" 
hypertension is probably more closely represented in the 
experimental situation by the spontaneously hypertensive 
animals (Grollman, 1972).
It is clear, therefore, that hypertension is a very 
complex disease and research into its cause and treatment 
a well subscribed topic. Two major areas of research in 
the field of hypertension are:
1. the central regulation of blood pressure 
and possible imbalances of these 
regulating systems which may result 
in hypertension; also the possible 
modification by, and effects of, drug
— 14 —
therapy on these systems (for instance, 
see Davies and Reid, 1975; Onesti et 
al,-1973 & 1976); and
2. the involvement of the renin-angiotensin 
system (see, for example, Lebel et al,
1974; Eide, 1975).
This thesis is more concerned with the former area 
of research.
1. 3 The Development of Antihypertensive Therapy
Early compounds used to treat hypertension were 
quite strong in their actions and possibly had side effects 
almost as distressing as the clinical symptoms of the 
disease. However, with the advent of modern routine 
screening of blood pressure, the disease can now be 
spotted during its development, when diastolic values may 
be raised above "normal" limits, but not excessively. This . 
type of hypertension is termed 'moderate hypertension' and 
many drugs, along with more powerful and acceptable drugs 
with which to treat the more severe cases, are now available 
to control it.
Even so, many of the available antihypertensive drugs 
unfortunately display unwanted and sometimes distressing 
side effects (e.g. postural hypotension with neurone
- 15 -
blockers, sedation and "dry mouth" with clonidine and 
a-methyl dopa, and diabetes with diazoxide). Another 
factor is that tolerance to many of the drugs nearly 
always develops to some extent*
To overcome or lessen the side effects and the. 
tolerance effect, combinations of two or more antihyper— 
tensive drugs are used at doses lower than those used • 
if the drugs were administered separately.
So the search for even more effective drugs, yet 
with less side effects, continues.
The discovery of the majority of the available anti­
hypertensive agents has occurred over the last 50 years ojt 
so. The discoveries have not progressed smoothly but 
have had alternating periods of activity and dormancy.
Some of the earliest used antihypertensive drugs were 
the veratrum alkaloids and thiocyanate, both used to treat 
the symptoms of a disease of which the cause at the time 
was unknown. Some compounds were known to have antihyper— 
tensive activity many years before they were used in 
therapy. An example is the Rauwolfia alkaloids, reported 
to show a hypotensive effect as early as 1918 (Kivtikar & 
Basu, 1918), while reserpine was not used clinically in 
western medicine until the late 1940*s.
With the development of the idea that the sympathetic 
nervous system was involved in blood pressure control, 
the 1940's saw the production and development of compounds 
to produce effects on the sympathetic nervous system. This 
led to the promotion of the neurone-blocking agents as
— 1 6 — ^
antihypertensives.
The majority of research until quite recently con­
centrated on the discovery and development of drugs which 
affected the peripheral autonomic nervous system or the 
periphery in general. Research still progresses in this 
area producing compounds such as the vasodilators, e.g. 
diazoxide and minoxidil, and new a-receptor blocking 
agents, such as prazosin and indoramin (see Wilhelm & De 
Stevens, 1976; Francis, 1976). However, much research is 
now being carried out to determine the role of central 
control mechanisms on blood pressure and the possible 
modification of these central mechanisms by drugs (see 
later section).
Table 1.2 gives a short and by no means exhaustive 
outline of the development of peripheral antihypertensive 
therapy up to the early 60's. More detailed information 
on the development and mechanism of action of the compounds 
can be found in reviews of the topic by Laverty (1973), 
Goldberg (1975) and Wilhelm and de Stevens (1976).
Figure 1.2 gives, in diagrammatic form, the probable 
sites of action and mechanisms of a variety of drugs, both 
peripherally and centrally acting, which are used in the 
treatment of hypertension. A number of interesting facts 
are apparent from this Figure. Certain drugs, originally 
thought to act by one mechanism at a particular site, are 
now known to act at a different site and sometimes by a 
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1. Œ-methyldopa, thought originally to exert 
its hypotensive effect by the production of 
a false transmitter at peripheral synapses 
(Day & Rand, 1963), has now been demonstrated 
to have its primary site of action centrally;
2. 3-blockers, shown to produce most of their 
action by effects on the heart, are now 
shown also to be, in some cases, active 
via a central mechanism (e.g. Day & Roach^ 
1975) as well as having possible side 
effects on the renin-angiotensin
system (Clarkson, 1976).
1.4 The Central Nervous System and Blood
Pressure Control
1.4.1 Central Regulation of Blood Pressure
Over the past 20 years there has been a plethora of 
evidence which demonstrates that control of the circulation is 
by some central mechanism and that this central control 
involves catecholaminergic neurones (see Hilton, 1975; 
Chalmers, 1975; Komer, 1976).
As early as the 1850*s, it was recognised that, for 
the maintenance of normal cardiovascular function, the 
central nervous system was important. It has been shown
- 20 -
that sectioning of the spinal cord in the lower cervical 
region would result in falls in blood pressure.
Recently, many papers have demonstrated that blood 
pressure can be modified (increased or decreased) by 
either the lesionirig of certain areas of the brain, or 
the application of electrical stimulation or a variety of 
drugs (Gagnon & Melville, 1968; Reis, Nathan & Doba, 1975; 
Bhargava, 1976; Philippu, 1976). There are two major areas 
in the brain, the hypothalamus and the medulla, which 
appear to be important in blood pressure regulation. The 
stimulation of many points within these areas, by drugs 
or electrical stimuli, will, depending on the exact 
location of the point of stimulation, produce either 
pressor or depressor effects on blood pressure, along with 
possible effects on heart rate and respiration. The 
consideration of the results obtained from both the above 
experiments and others indicates that the hypothalamus and 
medulla appear to be interconnected by a number of path­
ways which seems to have the result of these two areas 
working in conjunction to control blood pressure 
(Calaresu & Thomas, 1975). However, there are certainly 
other areas in the brain that are also implicated in blood 
pressure control, areas such as the orbito-frental cortex, 
the cerebellum and parts of the amygdala ( see Korner, 1976).
Figure 1.3 shows a schematic diagram of the possible 
interconnections between the hypothalamic and medullary 
regions and their possible connections to higher control 
centres in the brain and also to the periphery
- 21 -
FIGURE 1.3 : Diagram of possible functional connections
between the posteromedial hypothalamus and- 
the medulla.
(After Calaresu & Thomas, 1975)









+ = stimulatory neurone - = inhibitory neurone
Key to abbreviations on next page
- 22 -
Abbreviations used in Figure 1.3
BR - Baroreceptors
CR - Chemo receptors
NTS - Nucleus tractus solitarius
MOC - Medullae oblangatae centralis
NA - Nucleus ambiguus
PHA - Para hypoglossal area
LRN - Lateral reticular nucleus
ION - Inferior olivary nucleus
— 23 — *•
(Calaresu & Thomas, 1975).
1.4.2 Central Adrenergic Mechanisms affecting 
Blood Pressure
The presence of noradrenaline-containing neurones in 
the central nervous system has been confirmed both bio­
chemically and by histofluorescence and there is also 
considerable evidence that the amine functions as a 
neurotransmitter (for review see Anden et al, 1969).
There is also evidence that some of these noradrenaline- 
containing neurones are involved in blood pressure control 
(see Henning, 1975; Fuxe et al, 1975J. Other monoamines, 
such as serotonin, dopamine and adrenaline, have also 
been implicated in cardiovascular control (see Chalmers, 
1975).
Anatomically, central adrenergic and serotonergic 
neurones are well suited for the central control of the 
circulation. Both transmitter systems have their cell 
bodies situated predominantly in the brain stem with 
ramifications extending upwards to higher centres in the 
brain, particularly to the hypothalamus, and downwards to 
the spinal cord, especially in the lateral horns, giving 
rise to the sympathetic pre-ganglionic neurones (Figure 
1.4).
As well as considerable evidence to indicate that 
blood pressure control is elicited by central adrenergic 
mechanisms, there is increasing evidence that these
FIGURE 1.4
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Simplified schematic representation of the 








mechanisms are implicated in hypertension (Haeusler, 1976r 
Henning, 1975; Korner, 1976; Reid & Dollery, 1976)► 
Modification of these central adrenergic mechanisms by a 
variety of ways produces effects on the cardiovascular 
System. Dénérvàtioh of the carotid arid aortic sinuses in 
the rabbit results in an increase in blood pressure with 
a concommitant increase in the turnover of noradrenaline 
in the thoracic spinal cord segments (Chalmers & Wurtman»
1971). Destruction of noradrenaline-containing nerve 
endings in the brain with 6-hydroxy dopamine ( 6-̂ QHDA,
Uretsky & Iversen, 1970) prevents the rise in blood 
pressure normally resulting from baroreceptor denervation 
(Chalmers & Reid, 1972), Selective depletion of brain 
noradrenaline by this agent also produces a profound 
effect on the development of hypertension of experimental 
origin in both rats and rabbits. Haeusler et al (1972) 
showed that injection of 6-OHDA intraventricularly prevents 
the development of hypertension in rats, after such 
procedures as mineralocorticoid treatment plus saline 
feeding, and also in the spontaneously hypertensive rat. 
However, established hyper tens iph was unaffected by intra— 
ventricular 6-OHDA.
The application of exogenous noradrenaline to the brain 
can be shown to produce pressor or depressor responses 
depending on the area of the brain to which it is applied 
(Gagnon & Melville, 1968; De Jong, 1974; Chalmers, 1975; 
Philippu et al, 1971; Philippu, 1976). However, it is now 
widely accepted that, in terms of central blood pressure
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control, noradrenaline displays a predominantly inhibitory . 
influence (Gagnon & Melville, 1968; De Jong, 1974; 
Struyker-Boudier et al, 1975).
Attempts to correlate disturbances of these central 
noradrenergic mechanisms with variation in blood pressure 
and hypertension has led to a variety of interesting 
results.
Yamori et al (1970) intimated that concentrations of 
noradrenaline in the lower brain stem and hypothalamus of 
genetically hypertensive rats were significantly lower 
than in controls. However, Yamabe et al (1973) disputed 
these results on the grounds that, although a difference 
may have been present, it was not due to the hypertension 
but was due to a strain difference.
Later work on other animal models has shown that, 
although levels of endogenous noradrenaline may not be 
related to hypertension, there does appear to be a 
correlation between the rate of turnover of noradrenaline 
in certain brain areas. For example, Nakamura, Gerold and 
Thoenen (1971) have shown that, in the DOCA/saline hyper­
tensive rat, associated with the hypertension is a decrease 
in the turnover rate of noradrenaline in the hypothalamic 
and medullary brain areas. Also, along with this decrease 
in central noradrenaline turnover, there is a reciprocal 
increase in noradrenaline turnover in certain peripheral 
organs.
These results appear to provide evidence that central 
noradrenaline has an inhibitory effect on blood pressure.
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Decreased noradrenaline turnover produces a reduction in 
the availability of noradrenaline at central inhibitory 
noradrenergic synapses, hence allôwing increased sympathetic 
outflow and activity resulting in elevated blood pressure.
However, the above result only shows an association 
between turnover and hypertension. It does not clarify 
whether these changes in noradrenaline turnover play a 
causative role in, or are a result of, the hypertension.
Recent work by Ito, Tanaka and Omae (1975) has shown 
that intracistemal administration of guanethidine in rats 
produced decreases in the turnover rate of central nora- - 
drenaline along with concurrent increases in blood 
pressure. These results would seem to imply a causative 
role for the decrease in central noradrenaline turnover* 
in the hypertensive rat.
A different experiment performed by Elliott and Clark 
(1976), which involved the administration of noradrenaline 
intracerebroventricularly, has shown that associated with 
this treatment is a vasodilatation of peripheral vascular 
beds, resulting in a fall in blood pressure. So, from the 
above work, it would appear that noradrenaline centrally 
has, on the whole, an inhibitory function in controlling 
blood pressure and, as a result, it is now well established 
that the predominant central mechanism controlling blood 
pressure involves noradrenergic neurones. The application 
of exogenous noradrenaline to various brain areas has an 
inhibitory effect on blood pressure and it has also been 
demonstrated that this inhibitory effect of noradrenaline
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can be blocked by a-adrenoceptor blocking agents, such as 
yohimbine and piperoxan. The implication of this result 
is that the inhibitory effect of central noradrenaline is 
mediated by the stimulation of central a-receptors 
(Bhargava ét al, 1972; Haeusler, 1973; Van Zwieten,
1973, 1975a; Day & Roach, 1974; De Jong, 1974; Trolin, 
1975).
There also recently has been an indication that 
3-receptors may also play some part in the central regulation 
of blood pressure (Day & Roach, 1974; Share, 1973).
The connections between central a- and 3-receptor 
stimulation and central blood pressure regulation has 
become even clearer with the advent of the centrally acting 
antihypertensives, which are discussed in the following 
sections.
1.4.3 Centrally Acting Antihypertensive Drugs
At present, there are two major antihypertensive drugs 
used clinically which are said to exert their effects by 
a central mechanism. These are a-methyldopa and clonidine 
(Figure 1.5). The development and background of these and 
other antihypertensives will be discussed in later, 
separate sections.
The first indication that a drug may possess central 
antihypertensive properties may be obtained by systemic 
administration of the drug. In the case of a centrally 
acting compound, the resultant reduction in blood pressure
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would be accompanied by a bradycardia and not a reflex 
tachycardia as might be expected. This test by no means 
provides firm evidence of a central action but certainly 
provides a justification of a more detailed investigation 
of the drug.
Conclusive evidence of a central mechanism can only 
be obtained if the drug being tested is administered 
directly to the brain.
A variety of methods are available for this type of 
investigation. Some involve direct application of the 
drug to brain structures, while others present the drug to 
the brain via the blood stream. Examples of direct 
application of the drug to brain tissue include;
i) microinjection, by stereo-taxic procedures, 
allowing precise localised administration 
of the drug;
ii) iontophoresis, on to single neurones; or
iii) administration of the drug into the 
cerebrospinal fluid, by injection 
into, or perfusion of, the brain 
ventricles.
For example, the perfusion of the third and fourth 
ventricles of the cat with a-methyldopa was one of the 
techniques used to demonstrate a central site of action of
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the drug (Heise & Kroneberg, 1972).
The main advantage of the above direct techniques is 
that they a 1.1 circumvent the Blood Brain Barrier.
However, this might be a disadvantage as administration of 
drugs by this route does not allow any real comparison with 
the clinical administration of the drug.
Methods of presenting the drug to .the brain using 
the blood stream involve surgery and cannulation of the 
arteries leading to the brain. The two major routes are 
via the carotid and vertebral arteries. However, the 
carotid arteries supply mainly the higher brain regions, 
whereas the brain centres involved in the regulation of 
blood pressure are localised in the rhombencephalon and 
hypothalamus. These two areas are mainly supplied by the 
vertebral arteries.
Injection via the vertebral arteries has been used 
by a number of workers to demonstrate a central site of 
action of a-methyldopa (e.g. Henning & Van Zwieten^ 1968? 
Bock & Van Zwieten, 1971) and clonidine (Battler & Van 
Zwieten, 1967).
The technique used is a modification of a method 
first demonstrated by Sir Henry Dale in 1927.
The route provides direct access to lower brain 
structures without distribution into the peripheral 
circulatory system, as happens with normal intravenous 
injections.
The use of the above techniques has demonstrated that 
both a-methyldopa and clonidine have predominantly a central
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site of action and that they exert their effect by the 
stimulation of centrally located a-receptors, resulting in 
a reduction of sympathetic outflow to peripheral tissues 
and hence a fall in blood pressure. This has been 
supported by considerable evidence from a number of 
sources (e.g. And^n et al, 1970; Bolme & Fuxe, 1971;
Day, Roach & Whiting, 1973; Van Zwieten, 1973, 1975a; 
Kobinger & Pichler, 1974; Anden & Strombom, 1975; Finch 
et al, 1975). A more detailed account of the evidence for 
a central site of action and a-receptor stimulation by 
a-methyldopa and clonidine is presented in the following 
sections.
1.4.3.1 a-methyldopa
This drug was originally developed as an L-dopa- 
decarboxylase inhibitor to prevent the conversion of 
dopa-decarboxylase to dopamine and subsequently to nora­
drenaline in the hope that this would result in decreased 
peripheral sympathetic activity and hence lowered blood 
pressure. Indeed, the drug proved to be a potent 
inhibitor of the enzyme and was also found to display a 
significant clinical hypotensive effect. However, the 
hypotensive effect was found not to be causally related 
to the drug's enzyme inhibitory action as the duration of 
the hypotension persisted far longer than the duration of 
the enzyme inhibition. As a result, the above hypothesis 
for a mode of action of a-methyldopa was rejected
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(Henning, 1969a).
An alternative theory for the mechanism of action of 
a-methyldopa was put forward by Dây and Rand (1963, 1964). 
This was the false transmitter theory based on the idea 
that invivo, in the periphery, d-methyldbpa is converted 
to a-methylnoradrenaline (Figure 1.6) which replaced 
noradrenaline in the storage sites in the adrenergic 
neurone. On nerve stimulation, this a-methylnoradrenaline 
is released and was supposed to be less active than the 
natural compound at post synaptic receptors, resulting in 
a decreased effect of sympathetic activity. Although a 
valid theory based on the available evidence at the time, 
the idea is in conflict with a number of later experimental 
findings (Henning, 1969 a & b). For example, even after 
peripheral blockade of L-dopa-decarboxylase with other 
drugs, preventing the formation of even a-methylnora­
drenaline, the hypotensive action of a-methyldopa is still 
evident (Henning, 1969b). This implied another site of 
action which appeared to be centrally located.
The application of techniques discussed in the 
previous section confirmed that the major site of action 
of a-methyldopa was, in fact, located in the brain and in
the medullary region (Henning & Van Zwieten, 1968; Bock &
Van Zwieten, 1971; Heise & Kroneberg, 1972). Heise and 
Kroneberg (1972) showed that perfusion of the third and 
fourth ventricles of the cat with a-methyldopa or a-methyl­
noradrenaline caused falls in blood pressure and this
action was inhibited by the application of a-blocking
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compounds such as phentolamine and yohimbine, thus 
suggesting that, as well as being due to a central site of 
action, the blood pressure lowering effect of a-methyldopa 
was mediated by the stimulation of a-receptors.
It is now well accepted that a-methyldopa is itself 
not the principal active compound but that its metabolite^ 
a-methylnoradrenaline (the conversion and action suggested 
by Day and Rand and said to occur in the periphery), is 
responsible for the hypotensive effect. Reports indicate 
that this conversion occurs centrally and that a-methyl­
noradrenaline is as potent as noradrenaline in lowering 
blood pressure on central application (Heise & Kroneberg» 
1972; Finch & Haeusler, 1973; Nijkamp & De Jong, 1975; 
Nijkamp et al, 1975; Henning» 1975X.
Although it is now widely accepted that a-methyldopa 
exerts its action predominantly by the stimulation of 
central a-receptors (see Van Zwieten, 1973, 1975a)» a 
peripheral component cannot be excluded. Wepierre et al 
(1973) suggest that a-methylnoradrenaline possesses some 
peripheral 3-activity which may contribute, through vaso­
dilation, to the hypotensive effect of a-methyldopa.
1.4.3.2 Clonidine
The antihypertensive drug clonidine /2-(2,5^dichloro- 
phenylamino)-2-imidazoline hydrochloride, ST 155, or 
catepressan/ was originally produced as one of a series^ 
of compounds intended for use as decongestive agents in
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the treatment of Rhinitis. However, its potential as an 
antihypertensive agent was soon realised (Graubner &
Wolf, 1965).
In view of its structural similarity to various 
a-sympathomimetic agents, it is hot surprising that 
clonidine also produces effects by a-receptor stimulation, 
both in the periphery and in the central nervous system 
(Anden et al, 1970; Schmitt, Schmitt & Fenard, 1971;
Van Zwieten, 1973, 1975a). As a result of its hypotensive 
activity and a-sympathomimetic effects, clonidine has 
been the topic of a great deal of research (for reviews 
see Haeusler, 1973; Van Zwieten, 1973, 1975a; Kobinger, 
1975, 1976).
Clonidine has been shown to exert a dual action on 
blood pressure when injected intravenously into anaesthetised 
animals of most species (Van Zwieten, 1975a) producing a 
short-lasting increase in blood pressure followed by a 
prolonged fall. The initial increase is a result of 
peripheral a-receptor stimulation causing vasoconstriction 
and increased vascular resistance (Zaimis, 1970), while the 
fall in blood pressure is a result of stimulation of central 
a-receptors (Kobinger, 1975).
Although it is now widely accepted that clonidine's 
antihypertensive action is mediated by the stimulation of 
a-receptors located predominantly in the medullary area in 
the brain (see Kobinger, 1975, 1976; Van Zwieten, 1975a), 
the possibility of other sites of action contributing to 
the antihypertensive effect cannot be fully excluded.
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Other proposed sites of action include, for example, 
the ventral surface of the brain stem (Bousquet et al,
1975), the fQrebrain (Kievans et aT, 1973), the heart 
(Scriabine et al, 1970) and the peripheral vascular 
system.(Shaw, Hunyor & Korner, 1971);
If the above evidence as to a central site of action 
of clonidine in stimulating a-receptors is sound, two 
major questions on the mechanism of action must be 
answered:
1. where are the central a-receptors 
stimulated by clonidine? and
2. are these receptors situated on the 
"pre-" or "post-synaptic" membrane?
In answer to the first question, the available 
evidence points to the medulla as the most probable site 
of action of clonidine (for review see Kobinger, 1975), in 
particular the pathways associated with the Nucleus 
Tractus Solitari and baroreceptor reflexes (Haeusler, 1973r 
Laubie et al, 1976). However, Struyker-Boudier and Van 
Rossum (1972) have demonstrated that injection of clonidine, 
using stereo-taxic techniques, into the hypothalamus will 
also result in hypotension and bradycardia, a result that 
may fit in with the postulated interconnections between 
the hypothalamus and the medulla (Figure 1.3). Decreases 
in blood pressure have also resulted after application of
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clonidine to the ventral surface of the brain stem 
(Bloch et al, 1973, 1974).
The answer to the second question is more complex.
Briant et al (1973) suggested that, as the tricyclic 
antidepressant desmethylimipramine (DMI) had a proposed 
mode of action of uptake blockade of noradrenaline at a 
pre-esynaptic neurone site and as a clinical interaction 
occurred between DMI and clonidine resulting in a reduction 
in the hypotensive action of clonidine, the a-receptors 
stimulated by clonidine to bring about a fall in blood 
pressure were situated on the pre-synaptic neurone.
It has been suggested that, in the periphery, 
clonidine displays a higher affinity for pre-synaptic 
than post-synaptic binding sites (Starke et al, 1974).
The above would imply that the mechanism of action of 
clonidine is associated with the release of endogenous 
noradrenaline. However, evidence is available to show that 
clonidine still has a hypotensive effect even after 
central depletion of noradrenaline by reserpine and/or 
turnover inhibition by a-methyl-p-tyrosine (Haeusler, 1973, 
1974; Kobinger & Fichier, 1975, 1976).
The interaction between clonidine and DMI also appears, 
from more recent evidence,not to involve the central pre- 
synaptic neurone but to be a result of either the a- 
adrenolytic properties of DMI at a post-synaptic central 
site or the possible uptake blockade of peripheral nora­
drenaline resulting in a "physiological" interaction 
(Hoefke & Warnke—Sachs, 1974; Haeusler, 1974; Van Spanning
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Sc Van Zwieten, 1973; Van Zwieten, 1975a}.
It would therefore appear that the site of the 
a-receptors stimulated by clonidine is on a post- 
synaptic membrane. A further and more detailed discussion 
on this topic will be presented in the final Chapter of 
this thesis►
Clonidine has been used clinically with some success- 
(Conolly, 1975) but has displayed side effects which have 
made it unacceptable to some patients. The antihyperten­
sive effect of clonidine is comparable to that of a-methyl- 
dopa and both display the same principal side effects of 
sedation and dry mouth, with the severity of the side 
effects greater with clonidine treatment (Conolly et al,
1972). One other major drawback in the use of clonidine- 
is the danger that abrupt cessation of clonidine therapy 
can result in a hypertensive crisis with blood pressures 
exceeding original pre-treatment levels (Hansson et al, 
1973; Gorchein, 1974; Bailey, 1975). However, this 
crisis can be controlled by recommencing the clonidine 
therapy or by treatment with a-blocking drugs such as 
phentolamine. A possible explanation of this rebound 
hypertension will be presented in the final discussion of 
this thesis.
1.4.3.3 Other Drugs exerting an Antihypertensive 
Effect by a Central Action
A number of other drugs can be shown to display
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central hypotensive activity but not all are used clinically 
as antihypertensive agents. Examples of such drugs are 
reserpine, cocaine, amphetamine, tricyclic antidepressants, 
monoamine oxidase inhibitors and L-dopa. Their mechanism 
is probably indirect in character involving effects on 
endogenous noradrenaline and causing it to be displaced 
from the neurone and hence to stimulate central a-receptors 
inhibitory to blood pressure. Figure 1.7 shows a schematic 
representation of the probable mechanisms of action of 
various drugs producing effects via the stimulation of 
central a-receptors. A fuller explanation of their 
mechanisms of action is discussed by Van Zwieten (1975a).
Apart from research into compounds which are related 
to, or analogues of, clonidine, such as tolonidine (Cosnier 
et al, 1975), BAY 1470 (Finch, 1974; Kobinger & Pichler, 
1975) and BS 100-141 (Scholtysik et al, 1975) (structures 
are shown in Figure 1.8), and which appear to exert their 
hypotensive action in a similar way to clonidine, a new 
development in connection with centrally acting antihyper­
tensives is the synthesis of certain derivatives 
of neuroleptic agents.
One notable compound of this series is R.28935 
( Erythro -1- ( 1- ( 2- ( 1,4-benzodioxan-2-yl ) -2-OH-ethyl ) -4- 
piperidyl)-2-benzimidazolinone, a derivative of pimozide 
(Wellens et al, 1975a; Figure 1.9). This compound is said 
to be almost as potent as an antihypertensive agent as 
clonidine, yet with a central mechanism of action which 
appears to be unrelated to a-receptor stimulation (Wellens
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et al» 1975b; Van Zwieten, 1975 a & c) and, as yet, has 
not been fully elucidated.
Another series of compounds that has recently become 
the centre of research interest regarding central anti­
hypertensive activity are the 3-blocking drugs. Although 
these drugs are already extensively used in the treatment 
of hypertension (Conway & Amery, 1975), the rationale 
behind their use was based on a peripheral site of 
action.
Recent work has indicated that, in the central 
regulation of blood pressure, as well as a-receptors, a 
role may be played by 3-receptors (Share, 1973; Day & 
Roach, 1974). Subsequently, it has been demonstrated 
that certain 3-blockers can exert a hypotensive action 
via a central mechanism and that this effect may work 
in conjunction with their peripheral effects to lower 
blood pressure (Clarkson, 1976; Day et al, 1976; Kievans, 
Kovacs & Kelly, 1976).
1. 5 Basis and Aims of the Project
In the first instance, this project involved the 
comparison of normotensive and experimental hypertensive 
rats for differences in central catecholamine disposition 
and turnover, differences said to exist, and reported by 
other workers (e.g. Nakamura, Gerold & Thoenen, 1971).
Secondly, the major topic of the project was to
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examine the effects of prolonged clonidine administration 
on catecholamine levels and turnover rates in the brains 
of normotensive and hypertensive rats and relate any 
effects to the hypotensive action of clonidine»
Thirdly, it was decided to examine, in closer 
detail, the reported interaction between clonidine and 
DMI (see section 1.4.3.2 for references) in respect to 
blood pressure changes and effects on central catechol­
amines .
It was hoped that the results obtained from the 
above investigations would help to clarify how this inter­
action occurs and, indirectly, help to identify the site 
and mechanism of action of clonidine.
In the course of the experiments, other drugs were 







2.1.1 Animals and Environmental Conditions
The anijnals used in all the' experiments described in 
this thesis, with the exception of the spontaneously hyper­
tensive rats (see,Chapter 4), were male albino rats of 
the CFY strain, supplied by Anglia Laboratory Animals,
They were delivered by rail at either 200-250g or 80-90g 
weight and kept for 3-4 days in an animal holding room to 
allow recovery from stress, resulting from travel, and food 
and water deprivation before being used for experimental 
purposes.
The environment in the animal holding room was con­
trolled to give a 24-hour diurnal cycle (light on 06.OOh, 
light off 18.OOh) with temperature normally maintained at 
20-2l°C. Groups of five rats were housed in plastic animal 
cages (14” x 21” x 6”) with wire tops. Standard Oxoid 
Breeding Diet (41B) rat chow and tap water were available 
ad libitum.
All experimental procedures were carried out during 
the light phase of the diurnal cycle.
2.1.2 Choice of Species
In the planning of these experiments, the main factor 
governing the choice of animal was that of cost.
Having settled on the rat as the most reasonable 
animal for experiments involving large number of animals, 
it is possible to offer some rationalisation of the choice.
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The rat is used as an experimental animal in a 
wide variety of procedures and, as it is probably one of 
the most commonly used laboratory' animals, there is a lot 
of information available on the species. The study of 
hypertension, and antihypertensive drugs in particular» 
utlizes the rat» as it is a relatively easy model in which- 
to induce hypertension and record blood pressure (Freyburger, 
1968).
The albino rat is, on the whole, a placid animal and 
is therefore easy to handle for the purpose of administering 
drugs by various routes.
Rats are also freely available from a number of 
suppliers in a variety of consistent strains. The CFY 
strain was chosen as earlier work had indicated that it 
appeared to be a suitable strain for the experiments to be 
carried out (Grimes, unpublished observations).
2.2 The Measurement of Blood Pressure
2.2.1 Introduction
In all investigations into the effects of drugs on the 
cardiovascular system, one of the most important parameters 
is that of blood pressure. To determine blood pressure 
and other haemodynamic parameters in acute experiments, 
the anaesthetised animal is normally used, and here it is 
relatively easy to cannulate one of the major arteries
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(most commonly the carotid or femoral artery) and to 
record blood pressure directly by means of a pressure 
transducer and recording system.
As the basis of this thesis was an examination of 
the effects of prolonged administration of certain anti­
hypertensive drugs on blood pressure and central cate­
cholamine disposition, it was obviously essential to be 
able to measure blood pressure in the conscious animal, 
thus preventing any possible interference by anaesthetics 
on both blood pressure and central catecholamine levels 
and turnover.
Two common methods are available for the measurement 
of blood pressure in the conscious rat. One is an invasive 
technique involving cannulation (with extériorisation of 
the cannula) of either the abdominal aorta (Weeks & Jones, 
1950; Weeks, 1976) or one of the carotid arteries into 
the aortic arch (Popovic & Popovic, 1960). A short-term 
invasive method of blood pressure measurement is direct 
cannulation of one of the caudal arteries using flexible 
plastic cannulae (Ertama, 1976). However, this technique 
does not lend itself to repetitive blood pressure measure­
ments over more than one day because the cannulae only 
remain open for a few hours due to blood clot formation.
The other major method available for routine use is a 
non-invasive technique, measuring blood pressure in the 
caudal arteries using a tail sphygnomanometer cuff 
(Gerold & Tschirky, 1968), a technique which can be per­
formed repeatedly in conscious rats. The basic principle
- s o ­
is the same as that underlying sphygnomanometer blood 
pressure measurements in humans.
The use of the invasive techniques was rejected for a 
number of reasons. Firstly, there could be stress associated 
with the surgery necessary to insert the cannulae. This is 
possibly particularly relevant when applied to animals 
already having undergone surgery for hypertension 
induction (as described later).
Secondly, in any invasive technique, there is a 
constant danger of clot formation in the cannulae with con­
sequent failure to record blood pressure. To prevent this, 
daily flushing of the cannulae with an anti-coagulant 
solution is necessary. As, in the following experiments, 
only two blood pressure measurements were required, 
separated by a period of one week, it was thought that the 
handling of the animal and cannulae flushing would have 
subjected the animal to unnecessary additional stress.
The non-invasive tail cuff method was, therefore, 
considered more appropriate. This system has been used 
successfully by a number of workers (Gerold & Tschir)^,
1968; Finch & Leach, 1970; Nakamura, Gerold & Thoenerr,
1971). However, it was recognised that certain criticisms 
could be levelled against it (Fregly, 1963; Bunag, 1971). 
These deficiencies will be discussed in a later section 




The system used for measuring blood pressure in this 
project utilised a Rat Blood Pressure Monitor manufactured 
by Huntingdon Instruments. This was a manually operated 
monitor as opposed to automatic machines used by some 
workers (Gerold & Tschirky, 1968). The monitor utilises 
a cuff/detector unit, comprising an inflatable cuff and 
a photo-electric pulse detector combined in one. This is 
placed around the rat tail, the inflatable cuff being used 
to occlude the caudal arteries in the tail. The pressure 
inside the cuff, and hence the pressure inside the artery, 
is measured by a pressure transducer in the monitor unit.
The photo-electric pulse detector responds to changes in 
light intensity from a controlled light source incorporated 
in the cuff unit. The changes in light intensity occur as 
a result of variation in blood density which is caused by 
arterial pulsing through the occlusion created by the 
inflated cuff.
Recording of the pulse and pressure signals was achieved 
by connection of the monitor to a Devices M2 two-channel 
recording system. The pressure signal was amplified by 
a Devices DC2A pre-amp (sub-unit Ic) and the pulse signal 
by a Devices DC6 pre-amp (sub-unit 02). Trace recordings 
were produced on two-channel heat-sensitive paper.
To measure blood pressure, the rat was placed for five 
minutes in a wire restraining cage in a warming oven, set 
at 40°C, after which the cage, still containing the animal.
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was removed, wrapped in cotton wool and placed on a 
warming plate maintained at 35^C.
The cuff-detector unit was slipped on to the tail until 
a snug fit was achieved. A measure of blood pressure was 
obtained by inflating the tail cuff until the pulse signal 
disappeared. The cuff was then allowed to deflate slowly, 
until reappearance of the signal occurred. The pulse 
signal increased in amplitude until a plateau was attained 
on the trace (Figure 2.1). Reading down from the pulse to 
the pressure trace gave that pressure in the cuff at which
the pulse signal reappeared and also when it plateaued. The
pressure at which the pulse reappeared was taken as an 
indication of systolic blood pressure, while the pressure 
at which the pulse plateaued was taken as diastolic pressure*. 
These two points correspond to the changes in the 
karotkov sounds heard in conventional clinical sphygno— 
manometer cuff systems. Indeed, other tail cuff measuring 
systems employ a microphone to listen for these sounds, 
instead of using the photo-electric pulse detector system»
The above procedure was repeated at least three times 
for each animal, with the cuff on the tail being relocated 
each time. The mean value of the results obtained was 
taken as the measure of blood pressure.
2.2.3 Discussion on the Results obtained from Tail
Cuff Blood Pressure Measurements
Although the makers of the blood pressure monitoring
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figure 2.1 : Example of Blood Pressure Traces.
Trace 1 normotensive animal 
systolic 135mmHg 
diastolic SOmmHg













Blood Pressure Recording (mmHg)
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system used in this thesis claim that both systolic and 
diastolic blood pressure measurements can be ascertained» 
it was found' that, in practice, only systolic pressure was 
consistently and reliably measured.
There are a number of reasons for this. Firstly» 
it was found that many animals would not remain passive 
throughout the blood pressure measuring cycle. Any strugg­
ling was picked up by the detector unit and reproduced on 
the trace, obscuring the point at which the pulse signal 
plateaued. Secondly, in some instances, although clear 
indications of systolic pressure were obtained, an 
accurate diastolic reading was not possible,either because 
shallowness of the trace resulted in an ill-defined plateau 
or because of variation in the pulse signal itself. Hence» 
all the blood pressure values quoted in this thesis refer 
to systolic pressures only.
However, using the monitor as described above, it was 
found that the strain of rat used gave quite reproduceable 
results. As can be seen from the table below, the blood 
pressure results obtained from three groups of control 
normotensive rats, measured at different times, are very 
similar and show remarkably small variation within the 
groups.
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Group Number of Mean Blood Pressure
Number Animals (+S.E.M.)mmHq
1 10 140.8 + 1.9
2 20 144.0 + 2.0
3 10 142.3 + 2.2
Over the period of time encompassed by this thesis, it 
was found that the mean recorded blood pressure of control 
normotensive animals did vary, but consistently lay in the 
range 125-145mmHg. Possible explanations of this variation 
include differences in environmental conditions or 
seasonal variation in blood pressure.
However, the values obtained agree with those reported 
by some workers using similar systems (for example, Bunag, 
1973) but appear higher than mean values reported by others 
(for example. Finch & Leach, 1970 - approximately 120mmHg; 
Nakamura, Gerold & Thoenen, 1971 - 130mmHg; Lew, 1976 - 
130mmHg). There may be a number of reasons for this lack 
of agreement.
Firstly, it is possible that blood pressure may vary 
between strains of animals. Indeed, the results mentioned 
above are from a variety of strains including Sprague- 
Dawley, Wistar and CFY*s.
Secondly, environmental factors may also be responsible 
for differences in blood pressure, as may be handling, 
travelling, caging conditions and noise level. Certain 
forms of environmental stress have been used specifically
- 56 -
for the induction of increased blood pressure. Amongst 
these are sound-withdrawal (Marwood & Lockett, 1973) and 
overcrowding «and psychosocial stimulation (Henry et al» 
1975a).
Thirdly, some workers have measured blood pressure 
during recovery from light anaesthesia (Robertson et al» 
1968; Friedman & Dahl, 1975; Freis & Ragan, 1975). This 
is supposed to eleviate any blood pressure changes that may 
occur as a result of the animal being stressed by, or 
struggling during, the measuring procedure. However» in 
my opinion, any reduction in stress is likely to be more than 
offset by the possible variations that may occur due to 
the anaesthetic. Anaesthesia may lower blood pressure 
anyway and the degree of anaesthesia could vary markedly*
It is possible that the incidence of struggling of 
the restrained animal could be reduced by training the 
animal, before commencement of experiments involving blood 
pressure estimations, to accept the restraining apparatus.
In an attempt to reduce errors arising from the above­
factors, such as struggling and environment, control groups 
were included in all experiments, and were subjected to the 
same conditions as those experienced by experimental groups. 
This allowed direct comparison of drug-treated animals with 
matched controls, so that any changes in blood pressure 
between the groups could be attributed to drug action and 
not to the experimental conditions.
Another important factor in blood pressure estimations 
using the rat tail is that, in the rat, the tail is an
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important organ for heat regulation (Rand et al, 1955), 
dilatation or constriction of tail blood vessels increasing 
or decreasing blood flow through-the tail and hence 
regulating heat loss. In order to obtain an adequate 
pulse flow through, the tail, the vessels of the tail must 
be fully dilated. Hence, to achieve this, the animal must 
be warmed to induce heat loss. According to Fregly (1963), 
for the tail vessels to be fully dilated, the core tempera­
ture of the rat must be raised by an average of 0.8°C and 
that, to achieve this, the animal must be pre-heated at 
40°C for a minimum of five minutes and this heat maintained 
during the blood pressure measurement.
This increase in temperature may itself affect blood 
pressure, so it is again important that control animals are 
included in the experiments.
Bunag & Riley (1974) have shown that the tail cuff 
method cannot be relied upon to reflect accurately rapid 
changes in blood pressure due to acute drug administration. 
However, steady state levels (i.e. after prolonged drug 
administration) appear to be well reflected.
It can be shown that there is a good correlation 
between blood pressure measurements taken using the tail 
cuff method and those obtained by direct cannulation of the 
carotid artery or aorta.
Table 2.1 shows the results obtained from four 
anaesthetised rats in which blood pressure was measured 
simultaneously using the tail cuff and the cannulated 
carotid artery over a period of 12 minutes. Blood pressure
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TABLE 2.1 : Blood Pressure Measurements. - .
A. comparison between values, obtained using 
the taiL cuff, method, and simultaneous. . . 
measurement by cannulation of the carotid 
artery.
(Rats anaesthetised with 25% Urethane- 
(0. 6ml/100g) )
............ (Values.represent the mean of three measure­
ments taken every three minutes starting 
10 minutes after preparation of the animal 





110 105 ■+ 5
100 110 -10
100 100 + 5
100 105 - 5
110 105 + 5
110 105 + 5
155 145 +10
130 135 + 5
135 135 O
135 130 + 5
135 130 + 5
120 130= -10
140 135 + 5
115 110 + 5
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measurements from the tail cuff were consistently higher 
than the values obtained from the carotid artery, the 
mean difference being 3.44 + 1.69mmHg (mean +S.E.). 
However, the difference on the whole was constant and it 
therefore appeared that the tail cuff method was more than 
adequate for our requirements.
2.3 Experimental Hypertension
2.3.1 Introduction
It would seem logical that the screening for, and 
examination of, the mechanisms of action of antihyper­
tensive drugs should involve the use of animals that have 
elevated blood pressure.
A variety of methods have been used to produce 
chronic elevations in the normal blood pressure of animals, 
particularly rats. The methods available include:
1. renal hypertension (Grollman, 1973; Ledingham, 
1975) which can be induced by manipulation of 
the kidneys; for example, by the constriction 
of one renal artery and removal of the contra­
lateral kidney (Goldblatt et al, 1934) or by 
encapsulation of a kidney in cellophane 
(Page, 1939), producing renal compression.
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2. mineralocorticoid excess hypertension»
; involving the administration of mineralocorti- 
coids such as Deoxycorticosterone acetate or 
Aldosterone with subsequent loading of the 
animal with saline (Finch & Leach, 1970;
Hall & Hall, 1973; Gavras et al» 1975).
3. subjection of the animals to changes in 
environment , noxious stimuli or stress» 
such as the use of sound withdrawal (Marwood & 
Lockett, 1973) or overcrowding and social 
interaction (Henry et al, 1975a).
4. neurogenic hypertension, involving lesioning 
of areas of the brain, such as the Nucleus 
Tractus Solitari (Nathan & Reis» 1977) or 
the hypothalamus (Nathan & Reis, 1975), or 
by deafferentation of the arterial baro­
receptor s themselves (Komer, 1971).
5. spontaneous or genetic hypertension produced 
by selective inbreeding of specific strains 
of rats for increased blood pressure 
(Okamoto et al, 1972; Phelan et al, 1972).
The method chosen in this thesis is a modification 
of the DOCA/saline method of Finch and Leach (1970). This 
method was decided upon partly because it appears that there
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is some indication for the involvement of central 
adrenergic neurones (Nakamura, Gerold & Thoenen, 1971; 
Chalmers, 1975, 1976). Originally, an attempt was made 
to produce hypertension by the constriction of one renal 
arteryj leaving the contralateral kidney untouched and 
loading the animal with saline (the so-called "two kidney 
Goldblatt"). It was hoped that this method would have 
produced a significant hypertension without stressing the 
animal too much. However, as can be seen in Figure 2.2, 
this method was not entirely successful, producing only a 
mild hypertension approximately SOmmHg above control values.
Reinforcement of this method by the inclusion of a 
DOGA implant produced a consistent and substantial 
hypertension four weeks after surgery (Figure 2.2).
2.3.2 Method
All animals were starved by the removal of food the 
night before surgery. Anaesthesia was induced by the 
application of ether and the animal placed on a small 
operating table. An area of skin, extending caudally from 
the level of the rib cage and to the left of the spine, was 
shaved of fur and swabbed with 70% ethanol. An incision, 
approximately half an inch in length, was made through the 
skin and abdominal muscles, just to the left of the spine 
and below the level of the last rib. The left kidney was 
exposed and brought out of the abdominal cavity and kept 
moist with cotton wool soaked in isotonic saline. The
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J IT "i^ —«—20 “24
Time after Surgery (days)
— r28
Control - no treatment (n = 14X 
Sham operated - no saline (n = 6) 
Unilateral clip + saline (n = 6)
Renal/DOCA + saline (n = 11)
*** P<0.001 ** P<0.005 * P<0,01
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capsule was cleared from the kidney and the renal artery 
also cleared of tissue. The artery was then occluded by 
the application of a silver clip of internal diameter 0.2mm. 
The silver clips used were made from pieces of silver tape, 
approximately 2mm x 5mm x 0.2mm (tape supplied by Johnson 
Mathey & Co. Ltd.). The gap between the internal surfaces 
of the clip were set by bending two pieces of tape over 
one another, as shown below, using the thickness of one 
to set the gap on the other:
/ } ) n ~  Tl } }~) )TT a
The kidney was then replaced in the abdominal cavity 
and the abdominal muscle layers sutured with plain cat gut 
(Ethicon size 3/0). Before the skin incision was closed, 
a tunnel was made through the connective tissue under the 
skin of the back into the loose area of skin on the neck 
using a pair of blunt forceps. Into this area of loose 
skin was inserted a 25mg pellet of Deoxycorticosterone 
Acetate (DOCA, Organon Labs.) after which the skin was 
finally sutured with plain cat gut.
The animals were placed in separate cages during 
recovery, after which they were housed, five animals to a 
cage, in normal animal house conditions. Food was made 
available ad libitum but drinking water was replaced by a
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1 % solution of sodium chloride*
Animals were used for experimental purposes not earlier 
than four weeks after surgery, by which time they had 
developed a blood pressure that was, on average, 60-70mnHg 
higher than that of untreated or sham-operated animals 
(Figure 2*2).
This type of hypertensive animal will be referred to 
throughout this thesis as renal/DOCA hypertensives.
2.3.3 The Development of the Hypertension
In order to see how the hypertension produced by the 
above procedure developed with time, four groups of animalSL 
were manipulated in various ways and their blood pressures 
measured every three or four days for approximately five 
weeks after surgery. The groups comprised the followingt
i) control - no surgery;
ii) sham-operated - no saline;
iii) unilateral clip plus saline;
iv) renal/DOCA plus saline.
As can be seen from Figure 2.2, after four weeks the 
blood pressure of sham-operated animals did not signifi­
cantly differ from that of control animals. The unilateral 
clip animals, group iii, showed a slight increase over 
control values while the renal/DOCA animals showed a 
relatively steady increase in blood pressure to around
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210mmHg systolic, after four weeks, at which the blood 
pressure increase appeared to stabilise.
2.3.4 Observations on the Renal/DOCA Hypertensive Rats
It was noted that, if the hypertensive rats produced 
by the above methods were allowed to survive past six to 
eight weeks, a large percentage of the animals displayed 
symptoms of severe chronic hypertension. These symptoms 
included marked weight loss, seizures, strokes, etc. On 
dissection, haemorrhages were noted throughout the brain 
tissue. In some cases, the brain tissue was obviously 
oedematous and had become very pale in colour and spongy 
in texture.
Even some of the animals that did not display severe 
symptoms still had very oedematous brains. Since the 
oedema could cause significant changes in the wet weight 
of tissue, these brain samples were not included in the 
final results. Out of a sample of 35 hypertensive rat 
brains, five displayed severe oedema, increasing the 
weights of the brains to over 2g, which was substantially 
greater than the mean brain weight of the apparently 
unaffected animals (Table 2.2).
The incidence of oedematous brains, together with the 
number of hypertensive animals that died during experiments, 
resulted in some groups of animals being smaller than 
originally intended and smaller than would ideally have 
been wanted.
-  6 6  —
TABLE 2.2 ; Weights of whole brain (minus cerebellum).
Comparison, between normotensive and hyper- 
tensive rats.
Group No* Mean Weight in g (+ S.E*M*>
Normotensive 30 1.674 + 0*0-10'
Hypertensive 30 1.716 + 0.01&*
± »•<>«>
* Significantly different from 
normotensive value P*<0.05
*** significantly different fronr 
hypertensive value P-<0*001
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2,4 The Estimation of Noradrenaline and Dopamine
in Rat Brain
2.4.1 Introduction
As has been stated in the introduction to this thesis, 
one of the purposes of the investigation was to examine the 
effects of clonidine and other antihypertensive agents on 
the disposition of noradrenaline and dopamine in the central 
nervous system. Consequently, a reliable and reproduceable 
method of estimating the concentration of these cate­
cholamines in brain tissue was required.
Two main steps are involved in the estimation of 
catecholamines in any tissue. Firstly, it is important to 
be able to extract the required catecholamine from the 
tissue, removing metabolites and other substances that may 
interfere with the assay. Secondly, the assay method chosen 
needs to be specific for the catecholamine to be estimated 
and also needs to be relatively sensitive to allow measure­
ment of small differences between low concentrations.
At the commencement of this research project, apart 
from available fluorimetric methods of assay (e.g. 
Shellenburger & Gordon, 1971), newer methods of catechol­
amine estimation were becoming available, utilising 
enzymatic-isotopic techniques. One technique is based on 
the 0-methylation of catecholamines by catechol-O-methyl- 
transferase enzyme. However, although this method is 
reputed to have a sensitivity of around 15pg for nora-
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drenaline, its main drawback is that it cannot distinguish 
between noradrenaline and adrenaline (Palkovits et al, 1974), 
Another enzymatic—isotopic method' involves the conversion 
of noradrenaline to adrenaline using partially purified 
Bovine adrenal phenylethanolamine-N-methyltransferase 
(PNMT) and tritiated S-adenosyl-methionine, which is then 
selectively isolated and measured (Henry et al, 1975b).
This method also has a sensitivity of around 15-25pg. 
However, efficiency is decreased if concentrations of 
noradrenaline rise above 15ng due to substrate inhibition 
by noradrenaline of the enzyme.
The decision not to use these radioenzymatic assays 
for noradrenaline was based on a number of factors.
Firstly, as the assays were new, a lot of methodology 
would have had to be mastered. As methodology was not one 
of the main subjects of the project, it was thought that 
more well-tried methods would be more suitable. Secondly, 
there was the cost factor. Radiolabelled compounds are 
expensive and the cost of these could not be justified 
against the research budget. Thirdly, as we were interested 
primarily in gross areas of the brain, such as the hypo­
thalamus and medulla, the sensitivity of the above assays 
was thought to be far in excess of requirements.
Palkovits (1973) has developed a technique that allows 
the removal of isolated nuclei of rat brain. Combination 
of this technique with, for example, the PNMT assay may 
now, and in future research projects, allow the examin­
ation of changes of catecholamine concentration in very
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discrete and possibly more meaningful areas than the gross 
regions examined in this project. As these techniques 
were only just becoming available at the start of this 
project, it was again felt that more established techniques 
would be of value at first.
As only noradrenaline and dopamine were to be 
measured and not other amines, such as 5-hydroxytryptamine, 
a method was found in the literature that would enable 
easy extraction of catecholamines from brain tissue and 
subsequent assay by fluorimetric means (Shellenburger & 
Gordon, 1971). This method was examined and was found to 
be a relatively rapid and simple method of assaying nora­
drenaline and dopamine in discrete brain areas, with 
sufficient specificity and reproduceability to enable 
accurate and meaningful results to be obtained. It permits 
the simultaneous development and reading of fluorescence 
of both catecholamines in one sample and allows the 
detection of noradrenaline to values as low as lOng.
The extraction of catecholamines from the brain 
homogenate was achieved by adsorption on to alumina at 
alkali pH with subsequent elution in acid media (Anton & 
Sayre, 1962, as modified by Shellenburger & Gordon, 1971, 
to deal with small quantities of tissue). This gave 
extraction efficiencies of 70-90?̂ . Alumina was used 
instead of ion-exchange resins, as reported by other 
workers, as it is said to give higher recoveries (Anton & 
Sayre, 1962).
Catecholamines were assayed by oxidation to the
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fluorescent Trihydroxyindole derivatives (Figure 2.3) 
which show greater fluorescence than the natural fluor­
escence of the untreated catecholamine. Oxidation is 
brought about by the use of iodine, whereas, in earlier 
methods, the agent was ferricyanide (Anton & Sayre, 1952). 
The use of iodine produces a quicker oxidation time, 
therefore reducing assay time, and also -reduces blank 
values (Shellenburger & Gordon, 1971).
The actual methodology used is described in section 
2.4.4.
2.4.2 General Consideration of Methodology
A number of experimental variables have to be con­
sidered which may affect the reproduceability of cate­
cholamine estimations.
Probably one of the most important factors to con­
sider is that of circadian variation in the concentration 
of catecholamine in the brain. Variation certainly does 
occur in the rat brain producing, depending on the time of 
the circadian cycle, significant differences in estimated 
values ( Sheving et al, 1968; Lew, 1976). In attempting 
to overcome variation from this source, it is important 
to perform experiments, that are to be related to one 
another, at the same clock hour.
Another consideration particularly applicable to 
catecholamine estimations is that noradrenaline and dopa­
mine are unstable in the presence of oxygen and non-acid
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FIGURE 2.3 : Simplified diagram of the production of













pH (Heacock & Powell, 1972) and so have to be stabilised 
in an acid medium as soon as possible. Coupled with this 
is the possibility of post mortem changes occurring in 
the tissues. Some workers (Faiman et al, 1973; Sloviter 
& Connor, 197 7) found that the rate of degradation of 
noradrenaline changes with time after death. Hence» it 
can be seen that it is important to have a method of brain 
removal and dissection that can be performed rapidly and 
reproduceably to allow rapid stabilisation of the 
catecholamines.
The method of brain dissection developed by Glowinski 
and Iversen (1965) allows removal and subsequent dissection 
of a rat brain into a minimum of five regions in under five 
minutes with relative ease. This allows groups of up te 
20 animals to be killed, have their brains dissected and 
the tissue homogenised within a period of 100 minutes.
In the experimental situation, control animals are in­
cluded in every experiment to further reduce circadian 
variation,that may occur even over this time period»and 
are killed alternately with experimental animals. It is 
also obvious that long periods of time between the killing 
of an animal and the removal of its brain and subsequent 
stabilisation of the catecholamines may lead to erroneous 
results. Therefore, to standardise any degradation that 
may occur, as well as requiring a rapid dissection tech­
nique, the animal must be killed and its brain removed 
swiftly.
One method of stabilising catecholamines in the brain»
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while the animal is being killed, involves the quick 
freezing of the whole animal, or its chest and head, in 
liquid nitrogen. This freezes the tissue in situ which 
can then be removed by chipping the skull away. This 
method is satisfactory for the examination of whole brain, 
but, due to the brittleness of the frozen tissue, does not 
allow quick or accurate dissection of the brain into 
regions. The time required for dissection of tissue in 
this state usually exceeds 10 minutes (Buxton, 1974). The 
procedure is also expensive in its use of liquid nitrogen.
Decapitation of the animal, by a guillotine, combined 
with the dissection technique of Glowinski and Iversen, 
ensures, however, that the time from the instant of 
killing to final dissection of the required brain regions 
never exceeds five minutes. Although this technique may 
allow some variation as a result of fear, stress, or 
shock, plus also some enzyme degradation, this is at least 
reduced by the consistency of the technique and the 
relatively short time it takes.
Buxton (1974), on comparing the above two methods, 
suggests that the decapitation technique is superior, in 
that it gives greater reproduceability of tissue weights 
and can be performed quickly.
Another method, which at least deserves a mention, is 
the use of microwave radiation to kill animals and ”fix” 
the catecholamines in brain tissue. However, reports on 
this method indicate that higher values of catecholamines 
are detected than when conventional killing methods are
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used (Merritt, Medina & Frazer, 1975). It remains for an 
explanation of this phenomena to be found before the 
possible value of this techniquej in catecholamine 
research, can be assessed.
2.4.3 Brain Removal and Dissection
Five minutes were found to be ample time for the 
removal of a rat brain, its dissection into regions and 
subsequent homogenisation in acid medium.
Rats were first stunned by a blow on the head and then 
decapitated. The spinal cord and extraneous tissue were 
trimmed level with the base of the skull. The top of the 
skull was then cleared of skin and removed by two parallel 
cuts through the bone along the side of the cranium. The 
bone flap produced was bent forward over the snout of the 
animal exposing the brain. The brain was then cleared of 
dura and removed intact using a small, blunt, rounded 
spatula and placed on a filter paper soaked in cooled 
0.32M sucrose in preparation for dissection.
Areas of the brain containing the cortex, midbrain» 
hypothalamus and medulla were dissected out according to 
the method of Glowinski and Iversen (1966), the lines of 
dissection are shown in Figure 2.4, and the dissection 
carried out as follows.
Firstly, the cerebellum was teased away from the 
medulla and discarded and a transverse section made through 
the brain to remove the medulla-pons region (section 1).̂
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FIGURE 2.4 Diagrammatic representation of dissection
procedure ..for rat brain. . .....











c - cortex 
m - midbrain 
hi - hippocampus 
hy - hypothalamus 
me - medulla 
s - striatum 
ce - cerebellum
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A second, transverse section was made at the level of the 
optic chiasma passing also through the level of the anterior 
commissure ( section 2). This gave two parts - A and B»
Part A contained cortex and some striata. The striata: were 
removed and discarded. The striatal areas remaining in 
part B were then dissected out and discarded and the 
cortical portions peeled off and combined with part A. The 
hippocampal regions were also dissected away and discarded. 
The region containing the hypothalamus was then dissected 
out using the anterior commissure as a horizontal reference 
and the line between the posterior hypothalamus and the 
mammillary bodies as the caudal limit. The remaining 
tissue was designated midbrain.
The tissue sections were then weighed on a top pan 
balance and homogenised for 30 seconds in 8ml of 0.4N 
perchloric acid containing 0.1 % sodium metabisulphite and 
0.05% disodium EDTA using a "TRI-R" homogeniser with a 
teflon/glass pestle and mortar. The homogenate was poured 
into a Beckman 13.5ml centrifuge tube and stored in ic& 
until all the samples had been prepared. Homogenates were 
then centrifuged in a Beckman Highspeed L.50 at 17,500r.p.irk. 
for 10 minutes, after which 6ml aliquots of the particle- 
free supernatent were removed and stored in screw-capped 
tubes (Flow-labs) at -18°C until required for extraction 
and assay.
Studies on standard solutions of catecholamines and 
brain homogenate had previously shown that there was 
negligible reduction in the measurable catecholamine content
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of the supernatent over two to three weeks, if stored in 
this way.
2.4.4 Extraction and Assay of Noradrenaline and 
Dopamine
The assay of noradrenaline and dopamine was performed 
essentially according to the method of Shellenburger and 
Gordon (1971).
The first step was purification of the catecholamine 
by adsorption on to 300mg of alumina (prepared by the 
method of Anton & Sayre, 1962) at pH7.5, buffered with 
tricine buffer (17.9g tricine, 25g disodium EDTA in 1 litre 
of 0.525N sodium hydroxide). The alumina was subsequently 
washed three times with distilled water, the washings 
being discarded each time, and the adsorbed catecholamines 
finally eluted with 2.5ml of 0.05N perchloric acid. The 
samples could be stored at this stage overnight in screw- 
capped tubes at -18°C without any loss of measurable 
catecholamine concentration.
One ml aliquots of the eluate were then used to assay 
for noradrenaline and dopamine. To each aliquot was 
added 1.5ml of phosphate buffer at pH7.0 (4.27g disodium 
hydrogen phosphate, 9.52g potassium dihydrogen phosphate, 
9.0g disodium EDTA in 1 litre of distilled water and 
adjusted to pH7.0 with 5N sodium hydroxide), the sample 
being shaken to ensure mixing. This was followed by the 
addition of 0.2ml of iodine reagent (0.5g iodine.
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2.0g potassium iodide in 40ml of distilled water), the 
tube shaken again and then allowed to stand for two 
minutes at room temperature, after which 0.5ml of alkaline 
sulphite (Ig sodium sulphite, 4ml distilled water in 36ml 
5N sodium hydroxide) were added, the tube again shaken and 
allowed to stand for a further two minutes at room 
temperature. This was followed by the addition of 
0.3ml of glacial acetic acid and the tube shaken again»
The samples were placed in an oven at 100°C for five 
minutes, after which they were placed on ice for a further 
five minutes and the relative fluorescence of the samples 
read at excitation 380mu, emission 495mu (uncorrected - 
maximum fluorescence peaks for noradrenaline) to estimate 
the concentration of noradrenaline present. The samples- 
were then returned to the oven for a further 35 minutes 
followed by five minutes on ice, after which the relative 
fluorescence at excitation 325mu and emission 380mu 
(maximum fluorescence peaks for dopamine) was measured to 
give levels of dopamine in the sample.
An indication of the efficiency of recovery of cate­
cholamines from alumina was obtained by the adsorption and 
elution of aqueous catecholamine standards included in all 
assays of brain samples. Normally, the standards consisted 
of 200ng each of noradrenaline and dopamine in one sample. 
The relative fluorescence (RF) values obtained from brain 
extract samples and extracted standards were then applied 
to the following formula, allowing direct calculation of the 
concentration of noradrenaline and dopamine in the original
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tissue samples in ng/g tissue;
RF sample ( 8 + w)
concentration of   x x -------
catecholamine RF standard 6
(ng/g of wet tissue)
w
= concentration of aqueous extracted standard 
in ng.
w = wet weight of tissue in g.
The use of the above equation and aqueous standards 
included in all assays made the constant reference to 
standard curves of noradrenaline and dopamine unnecessary. 
Previous experiments had shown that, in the concentrations 
encountered in the experiments, the relationship of RF to 
concentration of catecholamine displayed a linear 
relationship (Figure 2.5).
Typical percentage recoveries of standards from 
aqueous solution were noradrenaline 75% and dopamine 67%. 
The recoveries of internal standards of catecholamines 
from brain tissue were found to be lower than the values 
quoted above. However, the difference was shown to be 
constant and reproduceable. As changes in catecholamine 
levels, and not the absolute values of concentration, were 
the main subject of interest, the discrepancy of value 
resulting from the use of aqueous standards to calculate 
recovery was thought acceptable.
Two types of blank samples were included in every
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assay:
i) reagent blank - taken through the whole 
procedure,
ii) reversed sample blank - brain extract sample 
with the order of addition of iodine reagent 
and alkaline sulphite reversed.
RF values for both types of blank were similar so the 
values obtained from reversed blanks were subtracted from 
sample RF values before application of the formula.
The values obtained for the concentrations of 
noradrenaline in various brain regions using the above 
method can be found elsewhere in this thesis and will be 
seen to be in general agreement with other published 
values (see Chapter 3).
2.4.5 Materials
perchloric acid (S.G. 1.70) 
sodium metabisulphite
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sodium sulphite
All the above chemicals were of AN ALAR grade and 
obtained from B.D.H. Ltd.
tricine, (N-tris(hydroxymethyl)methylglycine) — 
obtained from B.D.H. Biochemicals Ltd.
alumina oxide (neutral), Brockmann Grade I - 
obtained from B.D.H. Ltd.
noradrenaline, DL-arterenol - obtained from Sigma 
Chemical Co.
dopamine, 3-hydroxy tyramine - obtained from 
Koch-Light Laboratories
2.5 The Estimation of the Turnover of Noradrenaline
and Dopamine in Rat Brain
2.5.1 Introduction
In some of the experiments reported in this thesis 
the effect of antihypertensive drugs on the turnover 
of central noradrenaline and dopamine was also assessed.
Turnover may be defined as the phenomenon by which 
catecholamines are metabolised (and/or released) and then 
replaced with newly synthesised molecules. The rate limiting
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step in the synthesis of noradrenaline and dopamine is 
the conversion of tyrosine to 3,4-dihydroxyphenylalanine 
(DOPA) by the enzyme tyrosine hydroxylase (Kopin, 1968). 
Blockade of this enzyme by a tyrosine hydroxylase 
inhibitor, such as a-methyl-p-tyrosine (a-MT), will pre­
vent the synthesis of endogenous noradrenaline (Spector 
et al, 1965), and the subsequent decline of the endogenous 
concentration of noradrenaline and dopamine over a period 
of time can be equated with metabolism and release of 
the amines and, hence, an indication of "turnover" assessed. 
It has been shown that the decline of catecholamine 
concentration after synthesis inhibition occurs exponentially 
(Brodie et al, 1966), Hence, estimation of the rate of 
decline of the levels of noradrenaline and dopamine in 
various regions of the rat brain by measuring catecholamine 
levels at time zero and a specific time interval after 
synthesis inhibition with a-MT will give an indication of 
the rate of turnover of the catecholamines in the tissue 
(Brodie et al, 1966).
2.5.2 Method
In experiments involving the estimation of the rate 
of turnover of noradrenaline and dopamine in brain tissue, 
animals were dosed with the tyrosine hydroxylase inhibitor, 
a-methyl-p-tyrosine (a-MT), at 250mg/kg i.p. (as the methyl 
ester hydrochloride) dissolved in 0 , 9 %  saline. The 
animals were then killed at various times after injection.
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their brains removed and catecholamine concentration 
estimated by methods previously described (section 2.4).
Turnover was expressed as the decline in catecholamine 
concentration, estimated by measuring the levels of cate­
cholamine remaining in the brain tissue at various time 
points after injection of a-MT. The mean value (usually 
of five samples) for each time point was plotted as log. 
concentration against time after injection and the slope 
of the line produced used as an expression of rate of 
decline.
2.5.3 Results and Discussion
Using the above method» it was found that up to four" 
hours after injection of a-MT the decline in the con­
centrations of noradrenaline and dopamine was linear, both 
in whole brains (Figure 2.5) and in certain brain regions» 
such as the hypothalamus and medulla (Figure 2.7). Con­
sequently, during routine experiments, catecholamine levels 
were only estimated at two time points, those of zero 
and four hours after a-MP"«
To estimate the effects of drug treatment on cate­
cholamine turnover, the slopes produced from the results 
of control and treated animals were compared and any 
difference in the drug-treated result expressed as a 
percentage change of the control value. Tests for 
significance were performed by application of the t-test 
for comparing slopes (Bailey, 1959, p99).
FIGURE 2.6
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Decline of Noradrenaline and Dopamine in 
whole brains of. rats after synthesis 
inhibition, with g-MT 250mq/Kq i.p. at 
various time intervals.








Time in hours after a-MT
Noradrenaline
^ --- ^  Dopamine
- 86 -
FIGURE 2.7 Decline of Noradrenaline in medulla and 
hypothalamus after synthesis inhibition 
















NORMOTENSIVE AND HYPERTENSIVE ANIMALS
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3.1 Introduction
Research into the causes of hypertension has shown 
that there are a large number of differences between normo- 
tensive and hypertensive animals, probably the most 
striking of which are changes in the vascular system 
(Somylo Sc Somylo, 1968, 1970; Jones, 1976) and differences 
in central adrenergic and peripheral sympathetic activity 
(Nakamura, Gerold & Thoenen, 1971; De Champlain & Van 
Ameringen, 1975). The DOCA hypertensive rat, an experi­
mental model of hypertension used by many workers (e.g.
Finch Sc Leach, 1970; Nakamura, Gerold & Thoenen, 1971; 
Haeusler Sc Finch, 1972; Hall & Hall, 1973; Jones, 1976), 
displays a number of differences when compared to normo- 
tensive rats of the same strain. These differences appear 
to be related to the hypertension and not to other factors, 
such as environmental changes (Somylo & Somylo, 1968; 
Nakamura, Gerold & Thoenen, 1971). However, as to whether 
these changes play a causative role in the hypertension, or 
are a result of it,is still a matter for discussion.
Histological examination demonstrates differences in 
the tissues of normotensive and hypertensive animals. The 
hypertensive animal displays signs of fibroid deposition 
and vascular necrosis in the kidney (Gavras et al, 1975) and 
narrowing and constriction of the lumen of the arteries
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(Somylo & Somylo, 1968; Sevan, 1976).
It is well documented that the hypertensive animal 
shows increased vascular resistance and increased vascular 
reactivity to both endogenous and exogenous vasoconstrictor 
stimuli (Somylo & Somylo, 1970; Haeusler & Finch, 1972; 
Dupont & Sassard, 1974; Berecek & Bohr, 1976; Jones, 1976). 
Dupont and Sassard (1974), in fact, suggest that, in the 
spontaneous hypertensive rat, increased sensitivity to 
catecholamines might be one of the possible causes of 
hypertension, while Hansen & Bohr (1975) suggest that 
altered contractility and sensitivity of vascular smooth 
muscle may precede the increase in arterial blood pressure 
produced in DOCA hypertension.
It is perhaps feasible that the increased vascular 
resistance of hypertensive animals, thought to result from 
the functional changes in the vascular smooth muscle 
(Jones, 1976), may impose a greater work load on the heart, 
resulting in hypertrophy of the heart muscle. De Champlain 
et al (1967) and Nakamura, Gerold and Thoenen (1971) have 
indicated that, in the DOCA hypertensive animal, there is 
a significant correlation between the rise in systolic 
blood pressure and an increase in heart weight. Other organs 
have also been shown to hypertrophy in the hypertensive 
animal. Hall and Hall (1973) demonstrated that, as well 
as an increase in heart weight, an increase in kidney 
weight was also apparent.
However, in recent years, one of the major areas of 
research into the differences between hypertensive and
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normotensive animals has been the role of the sympathetic 
nervous system, which has been implicated in the develop­
ment of hypertension in certain animal models (Finch & 
Leach, 1970; Grewal & Kaul, 1971; Iriuchijima et al,
1975; De Champlain & Van Ameringen, 1975).
The turnover of noradrenaline in peripheral organs 
has been shown to be increased in the hypertensive animal 
(Nakamura, Gerold & Thoenen, 1971). Also increased levels of 
plasma noradrenaline have been detected (Reid, Zivin.& 
Kopin, 1975; De Champlain & Van Ameringen, 1975). These 
results imply increased sympathetic activity in the hyper­
tensive animal.
As has already been discussed in Chapter 1, central 
adrenergic neurones have been implicated in both normal 
cardiovascular control and the development of hypertension. 
Differences in the levels and turnover of catecholamines, 
in particular noradrenaline, in the brain have been 
demonstrated to be associated with hypertension (Robertson 
et al, 1958; Chalmers, 1975; Petty & Reid, 1977). Experi­
ments have shown that, in certain animal models with 
elevated blood pressure, the turnover of noradrenaline in 
the hypothalamic and medullary regions of the brain is 
depressed (Nakamura et al, 1971; Ito, Tanaka & Omae, 1975).
Whether these changes result from, or cause, the 
hypertension is again still open to discussion. However, 
Haeusler, Finch and Thoenen (1972) suggest that, in the 
DOCA hypertensive rat, this decrease in turnover may be 
associated with a "trigger" mechanism in the brain, dis-
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turbance of which may result in a self-perpetuating 
hypertensive disease.
Although, in this thesis, principal interest was in 
the relationship between central catecholamines and blood 
pressure, it was thought that a comparison of organ weight 
in normotensive and hypertensive animals would be 
instructive.
3.2 Differences in Organ and Tissue Weight
In a series of experiments comparing normotensive and 
renal/DOCA hypertensive animals (see Chapter 2), blood 
pressure, body weight, heart weight and whole brain (minus 
cerebellum) weight were measured. Table 3.1 shows a 
comparison of the results obtained.
The hearts of hypertensive animals were substantially 
heavier (P<0.001) than those of normotensive animals.
This increase in weight could not be attributable to 
greater animal size, as the mean body weight of the hyper­
tensive animals was, in fact, lower than the mean body 
weight of the normotensives (P<0.05).
Comparison of whole brain weights showed that brains 
from hypertensive animals were heavier than those from 
corresponding normotensive animals (P<0.05). The results 
for brain weight shown in Table 3.1 represent only those 
brains that were used for the determination of noradrenaline 
turnover and levels. As has been stated in Chapter 2 
(section 3.4), a small percentage of the brains from hyper-
- 92 -
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tensive rats was significantly heavier than the mean 
of the brain weights expressed in Table 3.1 (see Chapter 2, 
Table 2). These brains were very obviously oedema tous,, 
having a very spongy texture with high fluid content which 
increased their weight by up to 40%. Consequently, these 
brains were excluded from all experiments.
However, examination of the weights of various regions 
of brains from normotensive and hypertensive rats, dissected 
using the method of Glowinski and Iversen (1965), showed no 
significant differences between the two groups of animals 
(Table 3.2). This discrepancy of increased whole brain 
weight, yet with no significant differences in the weights 
of brain regions, may be explained in a number of ways.
The increase in weight of the hypertensive brain was only 
35mg over the normotensive brain weight. As this increase 
is small, the difference may have been proportioned out 
among the dissected brain regions and the difference lost 
by weighing inaccuracies. Alternatively, it is possible 
that the increase in whole brain weight was due to tissue 
oedema. Dissection of the brain would lead to some fluid 
loss and, hence, result in no difference in the weights of 
brain regions. The whole brains contained the striata and 
the hippocampi. However, it does not seem likely that 
these specific regions would be any different in hyper­
tensive rats when compared to normotensive animals.
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TABLE 3.2 ; A comparison of the, weights of various
regions dissected from the brains of 
normotensive and. renal/DOCA hypertensive 
rats (dissected using the method of 
Glowinski & Iversen (1966)),
(Mean ± S.E.M.)
(Figures in parenthesis are numbers of 
animals)
Brain Region Normotensive Hypertensive
Weight of Tissue in g
Medulla 0.197 + 0.003 (26) 0.194 + 0.004 (27) N/S
Hypothalamus 0.094 + 0.003 (26) 0.094 + 0.003 (27) N/S
Midbrain 0.217 + 0.006 (20) 0.229 + 0.006 (21) N/S
Cortex 0.946 + 0.013 (20) 0.949 + 0.015 (21) N/S
N/S = Not Significant
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3.3 Differences in Catecholamine Levels in
Brain Regions
Comparisons of various brain regions from 
normotensive and renal/DOCA hypertensive animals generally 
showed no significant differences in the levels of nora­
drenaline or dopamine (Table 3.3). However, dopamine^ 
levels in the hypothalamus of hypertensive animals wer& 
shown to be significantly reduced when compared to levels 
in normotensive animals. Detailed examination of the 
noradrenaline results shows that, although not significant, 
the mean level of noradrenaline, in all brain regions ex­
cept the hypothalamus, is higher than that of corresponding 
controls. It is perhaps possible that such a small increase 
is genuinely related to the hypertension and that the 
increase may be significant if larger groups of animals 
were to be examined.
3.4 Differences in Central Catecholamine Turnover
Turnover of noradrenaline and dopamine was estimated 
in brain tissue by calculating the rate of decline of the 
catecholamines after inhibition of synthesis by a-methyl— 
p-tyrosine, as described in Chapter 2, section 5.
The turnover of both noradrenaline and dopamine was 
found to be significantly decreased in the whole brains of 
renal/DOCA hypertensive rats when compared to age-matched
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TABLE 3.3 ; Comparison, of. the levels of Noradrenaline
and. Dopamine in four areas .of. brains, from 
normotensive and renal/DOCA hypertensive 
rats. . .
(Mean ± S.E.M.)
(Figures in parenthesis are numbers of 
animals)
Region
Levels of Catecholamine ng/g Tissue 
Normotensive Hypertensive
Noradrenaline
Medulla 530.7 + 28.2 (14) 570.4 + 15.7 (15)
Hypothalamus 1177.6 + 37.3 (13) 1152.9 + 62.9 (15)
Midbrain 477.6 + 19.6 (14) 505.4 + 27.9 (15)
Cortex 270.5 + 10.5 (14) 287.7 + 15.4 (15)
Dopamine
Medulla NOT DETECTABLE
18.2Hypothalamus 404.4 + 37.0 (9) 271.8 + (9)
Midbrain 138.4 + 13.4 (9) 133.0 + 12.1 (10)
Cortex 484.4 + 58.8 (9) 465.9 + 33.7 (10)
* ie P<0.01
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normotensives (Figure 3.1, Table 3.4). Noradrenaline 
turnover was found to be decreased by 30.1% of the control 
normotensive^value, while dopamirie was decreased by 29»5% 
of the normotensive control value, both changes being 
significant at the P<0.01 level.
This phenomenon was further examined by estimating 
the turnover in various regions of the rat brain. The two 
areas chosen for examination were the hypothalamus and 
medulla, two areas which have been shown to be closely 
associated with the central control of blood pressure 
(see Chapter 1, Introduction).
After the administration of a-MT and the resultant 
inhibition of synthesis of catecholamines, it was found 
that, over the time period used to determine turnover rate 
(i.e. 4 hours), the concentrations of dopamine fell to 
levels that were below the level of sensitivity of the 
assay. Therefore, as the level of dopamine could not be 
accurately ascertained, results presented for turnover in 
hypothalamus and medulla are only for noradrenaline^
However, it was found that, in the hypertensive 
animal, the turnover of noradrenaline was decreased in bothr 
the brain regions studied when compared to values obtained 
from normotensive animals (Table 3.5). In the medulla, the 
turnover was found to be decreased by 24.2% of the control 
value, significant at the P < 0.001 level (Table 3.5,
Figure 3.2). In the hypothalamus, however, although 
turnover appeared to be reduced by 20.6% of the control 
value, the change was found to be non-significant (Figure 3.3).
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FIGURE 3.1 Comparison of the rate of decline of. 
noradrenaline, after synthesis inhibition 
by g-MT .(250mq/Kq i.p. ) in the whole 
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FIGURE 3.2 Comparison of the rate of decline of 
Noradrenaline after synthesis inhibition 
by g-MT in the medullae of normotensive 











FIGURE 3.3 Comparion of the rate, of. decline of . 
Noradrenaline in the hypothalami of. normo­
tensive. and. renal/DOCA hypertensive rats 
















Although referred to as a **^renal/DOCA” hypertensive 
rat, the model of hypertension used throughout this thesis 
resembles more closely the standard DOCA-saline model of 
hypertension used by many other workers (Finch & Leach, 
1970; Nakamura, Gerold & Thoenen, 1971; Gavras et al» 
1975; Reid, Zivin & Kopin, 1975). Consequently, the 
results presented in this Chapter would tend to confirm 
those presented by other workers who have examined this 
model of hypertension.
For example, in the hypertensive animal, heart weight 
has been shown to be greater than in normotensives, an 
observation in agreement with the results of De Champlain 
et al (1967) and Nakamura, Gerold and Thoenen (1971).
However, comparison of the endogenous levels of nora­
drenaline and dopamine, in various regions of the brains- 
from hypertensive and normotensive rats, showed no signifi­
cant differences, with the exception of the dopamine con­
tent of the hypothalamus which was significantly reduced in 
the hypertensive animal,
Nakamura, Gerold and Thoenen (1971), reporting on 
experiments using the DOCA-saline hypertensive rat and 
matched controls, showed that, on measuring noradrenaline 
content of the hypothalamus, medulla and residual brain 
four weeks after the induction of hypertension, they were 
able to show a significant increase in the noradrenaline 
content of the medulla of the hypertensive animals.
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Increases were also present in the hypothalamus and the 
rest of the brain, but were not statistically significant. 
This is a trend that is repeated "in the results presented 
in this thesis, where levels appear to be higher in 
hypertensive medulla, midbrain and cortex but not signifi­
cantly so. It is possible, as is discussed in section 3.3, 
that those increases could well be significant if larger 
groups of animals were to be examined. As the areas of 
brain examined were gross in comparison to the nuclei and 
pathways within them, which may be concerned with blood 
pressure regulation, it might not be unreasonable to suggest 
that a small change in detectable noradrenaline levels may 
represent a significant change in a discrete area concerned 
with blood pressure. The question may also be asked - 
what degree of change may be relevant? A small change 
in levels may well represent a major change in the status 
of the regulatory system.
It is interesting to note that similar observations 
by other workers on spontaneously hypertensive (SH) rats have 
resulted in conflicting results. Robertson et al (1968) 
indicated that, in certain areas of the brains of SH-rats, 
noradrenaline levels were increased when compared to values 
obtained from age-matched controls. Conversely, Yamori, 
Lovenberg and Sjoerdsma (1970) reported that they found in 
the SH-rat the concentration of noradrenaline in the lower 
brain stem and hypothalamus was significantly reduced when 
compared with control animals. Although these two groups 
of workers used different strains of SH-rats, Robertson et
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al using the New Zealand strain while Yamori et al used 
the Japanese Okamoto strain, it is still, interesting, 
however, that contrasting results"have been presented.
However, later work by Yamabe, De Jong and Lovenberg 
(1973) has indicated that these previously reported 
differences in noradrenaline levels between SH-rats and 
control normotensives may not be attributable to the 
hypertension but may be solely attributable to genetic 
variation and the possibility that the control animals used 
may not, in fact, be suitable animals to compare with an 
inbred SH strain.
If one accepts, however, that the levels of nora­
drenaline in various brain regions are maintained as a 
result of a dynamic balance between synthesis, efflux and 
metabolism (Brodie et al, 1966), it might be expected that 
catecholamine levels would remain static. Hence, a 
measurement of ”turnover” would probably be a better guide 
to the state of neural activity, the rate of turnover 
varying, increasing or decreasing as the demand for, or 
utilisation of, noradrenaline changed.
The results reported in this thesis are again in 
agreement with those reported by Nakamura, Gerold and 
Thoenen (1971). In the hypertensive animal, the turnover 
of noradrenaline and dopamine is decreased in the whole 
brain and also in the medullary and hypothalamic regions. 
It is not possible to decide from these results whether 
the decrease in noradrenaline turnover is a result of, or 
a causative factor in, the hypertension. It is clear.
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however, that the decrease in turnover is in some way 
related to the hypertension and not to other factors.
Accepting the idea that in a large number of areas 
of the brain noradrenaline produces a predominantly 
inhibitory effect on blood pressure (see Chapter 1), then 
the decrease in noradrenaline turnover and hence,presumably, 
a decreased availability of noradrenaline at certain central 
synapses may imply a causative role in hypertension, or at 
least a role in the development of the hypertension.
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CHAPTER 4
THE EFFECTS OF CLONIDINE ON BLOOD PRESSURE 




In this Chapter, an attempt'is made to correlate the 
blood pressure-lowering action of clonidine treatment with 
possible effects on the levels and turnover of central 
catecholamines.
In considering the central action of clonidine, the 
probability that hypertension is associated with altered 
catecholamine metabolism in the brain must also be taken 
into account (see Chapter 3 and, for example, Nakamura,
Gerold & Thoenen, 1971; Chalmers, 1975; Ito et al,
1975). It might be expected that, under these circumstances, 
a drug such as clonidine which exerts its action by 
stimulating a-receptors (see Chapter 1, section 1.4) might, 
as a consequence, disturb or alter the metabolism of central 
catecholamines to produce its hypotensive action.
Available evidence indicates that clonidine treat­
ment causes a decrease in the turnover of both noradrenaline 
and dopamine in certain brain structures (Laverty & Taylor, 
1969; Anden et al, 1970; Braestrup, 1974; Rochette 
& Bralet, 1975; Scheel-Kruger, Braestrup & Nielsen, 1975). 
However, all these reports present results on the effects 
of single acute doses of clonidine, invariably administered 
to normotensive animals only.
The results presented in this thesis demonstrate the 
effects of more prolonged clonidine administration on 
blood pressure and central catecholamine levels and 
turnover in both normotensive and hypertensive rats.
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4.2 Effects on Blood Pressure
4.2.1 Method
To examine the effects of prolonged clonidine 
administration on blood pressure, rats were dosed twice 
daily for a total of seven days. Drug was given at 
09.00h and 17.OOh each day and administered by the 
intraperitoneal route (i.p.). The drug was given as 
the hydrochloride dissolved in 0.9% saline. Control 
animals were included in all experiments and were given 
0.9% saline, Iml/Kg, instead of a drug-containing solution.
In the examination of the effects of clonidine in 
hypertensive animals, the control group always consisted 
of hypertensive animals from the same batch as the test 
group.
Using the tail cuff method, as described in Chapter 2, 
the blood pressure of each experimental animal was 
measured on the morning before the first dose of drug 
(given at 17.OOh) and two hours after the last morning 
dose of the drug seven days later. The two series of 
blood pressure measurements were performed at the same 
time each day to reduce any possible difference due to 
circadian variation. The blood pressure of test and control 
animals were measured alternately to further reduce possible 
circadian effects and also to ensure an equal drug effect 
in relation to the time after injection.
The effects of this dosing schedule with clonidine was
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examined in three animal models, normotensive controls, 
renal/DOCA hypertensives (see Chapter 2) and also in one 
strain of spontaneously hypertensive (SH) rat. The 
results obtained from the experiments using the SH-rat 
are presented in section 4.5.
4.2.2 Results
Clonidine, when administered according to the schedule 
outlined above, produced a dose-related decrease in the 
blood pressure of normotensive animals over the dose range 
20ug/Kg to lOOug/Kg. Figure 4.1 is a dose response 
curve of clonidine against percentage decrease in blood 
pressure. As can be seen, over the dose range examined the 
response pattern is relatively linear.
The dose levels of 50ug/Kg and lOOug/Kg both produced 
significant falls in blood pressure and were therefore 
chosen as the doses upon which further investigations would 
be carried out.
Administration of these doses of clonidine to renal/ 
DOCA hypertensive rats produced significant falls in blood 
pressure (P < 0.01 at both doses), 14.1% and 20.1% respect­
ively for the low and high doses. In terms of percentage 
decrease of pre-treatment values, the falls in blood 
pressure can be seen to be comparable with those obtained 
from the treatment of normotensive animals (Figure 4.1).
- Ill -
FIGURE 4.1 A dose response curve for the effect of 
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4.2.3 Discussion
The results presented above'indicate that clonidine 
caused a dose-related decrease in blood pressure in both 
normotensive and hypertensive animals. In terms of per­
centage decrease from pre-treatment and untreated control 
values, the drug appears to be equipotent in both animal 
models. However, in terms of blood pressure decrease 
expressed in mmHg, the result in hypertensive animals 
after clonidine treatment is one and a half to two times 
larger than that found in normotensives. Table 4.1 shows 
the actual blood pressure values obtained before and after 
treatment in both normotensive and hypertensive animals.
As the dose levels of 50ug/Kg and lOOug/Kg of 
clonidine produced significant effects on blood pressure, 
these doses were used in further investigations where 
the effects of clonidine on the levels and turnover of 
endogenous noradrenaline were examined.
4.3 Effects on Endogenous Catecholamine Levels
in Brain Regions
4.3.1 Introduction
A number of drugs which produce their functional 
effects by interfering with central catecholaminergic 
systems have been shown to produce changes in the endogenous
— 113 —
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levels of the catecholamine. For example» levels of 
endogenous noradrenaline and dopamine are changed by 
dosing with (•*+)-amphetamine (Costa & Groppetti, 1970; 
Groppetti, Naimzada & Costa, 1971; Riffee & Gerald,
1976) while chronic dosing with the tricyclic anti­
depressant desmethylimipramine (DMI) produces decreases 
in noradrenaline but not dopamine concentration (Roffler- 
Tarlov, Schildkraut & Draskoczy, 1973).
Available reports on the effects of acute dosing of 
rats with clonidine indicates little or no effect on 
endogenous catecholamine levels when doses, similar to 
those producing blood pressure effects, are used. However, 
higher doses (i.e. 2.5mg/Kg) have been reported to produce 
some increases in endogenous catecholamines (cited by 
Zaimis in Conolly, 1970, p54; Laverty & Taylor, 1969; 
Rochette, Bralet & Bralet, 1974; Braestrup & Nielsen,
1976). A paper by Sugimoto, Hashida & Kasahara (1976) 
has indicated that chronic dosing of spontaneously hyper­
tensive rats with clonidine may result in an increase in 
the endogenous levels of brain noradrenaline.
However, as the majority of previously presented 
results were produced using acute dosing with clonidine 
and as certain drugs affecting catecholaminergic systems, 
for example, DMI, produce different effects depending on 
whether acute or chronic dosing is used (Roffler-Tarlov, 
Schildkraut & Draskoczy, 1973), it was thought that an 
examination of the effects of more prolonged dosing with 




Groups of ten animals were dosed with clonidine at 
either 50ug/Kg or lOOug/Kg i.p. using the schedule outlined 
in section 4.2.1. On the final day, the last dose of 
clonidine was administered at 08,30h and the animals 
killed two hours later. Age-matched control animals 
were included in all experiments and dosed with 0.9% 
saline.
Control and test animals were killed in alternating 
order to equalise the possible effects of circadian 
variation over the killing period and also to equalise 
the effect of the drug between these two groups. Brains 
were removed and dissected into regions using the method 
of Glowinski and Iversen (1966), previously described in 
Chapter 2. Catecholamines in the brain samples were ex­
tracted and assayed fluorimetrically using the methods of 
Anton and Sayre (1962) and Shellenburger and Gordon (1971), 
details of which are given in Chapter 2.
Four brain regions were examined, those designated 
cortex, midbrain, hypothalamus and medulla. Total brain 
levels were calculated from the sum of the above parts, 
and therefore did not include striatal, cerebellum or 
hippocampal regions.
Differences between the mean catecholamine levels for 
each region, comparing control and drug treated animals.
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were examined for significance using the t-test.
4.3.3 Results
Examination of the results obtained from these 
experiments indicates that prolonged clonidine admini­
stration may have some effects on the endogenous levels 
of central catecholamines. However, the results do not 
appear consistent or dose-related.
In normotensive animals, clonidine at 50ug/Kg or 
lOOug/Kg i.p. produced no significant changes in the 
endogenous levels of noradrenaline, with the exception 
of levels in the medullary region of rats dosed with 
clonidine at 50ug/Kg where noradrenaline levels were 
significantly increased (Figure 4.2). Consideration of 
the dopamine results, however, showed an increase in 
dopamine levels in the cortex and whole brain in rats 
receiving clonidine at 50ug/Kg, while in rats receiving 
the higher dose, dopamine levels were only significantly 
increased in the midbrain and hypothalamic regions 
(Figure 4.3).
The lower dose administered to hypertensive animals 
produced increases in endogenous noradrenaline content 
of the cortex, midbrain, medulla and whole brain, while at 
the higher dose, the increase in noradrenaline was found 
to be significant only in the cortex and whole brain 
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4.3.4 Discussion
On the whole, the results reported in these experi­
ments agree with results from other sources (see section 
4.3.1) that clonidine produces no change or, at least, a 
slight increase in the endogenous levels of catecholamines 
in the brain. The results obtained, however, are not 
consistent enough to enable any firm conclusions to be 
made.
Examination of the results does show a general trend 
of increased catecholamine levels after clonidine therapy, 
but the majority of the changes are not significant. It 
is possible that the examination of greater numbers of 
animals may show that these increases are significant even 
though they are small. However, the value of the results 
so obtained would probably not warrant the use of the 
number of animals needed.
It is perhaps possible that the measured small change in 
endogenous catecholamine levels represents;
i) a significant change in the status of central 
adrenergic activity (even although the change is small) ;
ii) a large change occurring in some more discrete 
part of the gross brain areas studied.
While the first possibility may be hard to assess, the 
second possibility could be checked by examining very small
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areas of the brains by utilising methods discussed in 
Chapter 2, section 2.4.1.
However, the lack of effect Of clonidine in raising 
endogenous catecholamine level does not exclude effects 
on other parts of the adrenergic systems, for example, 
effects on the turnover of the catecholamines. The 
following section examines this possibility.
4.4 Effects on Central Catecholamine Turnover
4.4.1 Introduction
Clonidine, when given in an acute dose to normotensive 
animals, has been shown to decrease the turnover of nora­
drenaline and, to a lesser extent, dopamine in both 
peripheral tissues (Bralet & Rochette, 1973) and in 
certain brain tissues (Anden et al, 1970; Rochette & 
Bralet, 1975; Rochette, Bralet & Bralet, 1974;
Braestrup, 1974). Prolonged dosing with clonidine has also 
been demonstrated to produce a decrease in the activity of 
the enzyme tyrosine hydroxylase in the spinal cord 
(Reid, 1975).
In this thesis, the results of prolonged clonidine 
administration on the turnover of noradrenaline and dopa­
mine were assessed in the whole brains of both normotensive 
and hypertensive rats and also in two specific brain 
regions implicated in blood pressure control and the site
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of action of clonidine, the medulla and the hypothalamus.
4.4.2 Method
Animals were dosed twice daily with clonidine, as 
described in section 4.2.1. Blood pressures were measured 
before commencing the dosing and again two hours after 
the last morning dose of clonidine, given at 08.30h. 
Immediately after the measurement of blood pressure, the 
animals were dosed with the synthesis inhibitor a-methy1 - 
p-tyrosine (a-MT) at 250mg/Kg i.p. and killed four hours 
later.
Untreated control animals were included in all 
experiments and, in all procedures, including blood pressure 
measurements, dosing with a-MT and killing, they were 
alternated with test animals to proportion equally any 
effects due to circadian variation.
On killing, the brains were removed, dissected where 
necessary and homogenised in 0.4N perchloric acid in 
preparation for extraction and assay of catecholamines by 
methods previously described.
Catecholamine concentrations at time zero and four 
hours after a-MT were estimated and regression analysis 
applied to the results. The resultant slopes were then 
compared by t-test and any change in turnover, induced by 
the drug in the test animal, was expressed as a percentage 
change of the control value.
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4.4.3 Results
'4.4.3.1 Effects on the Turnover of Catecholamines 
in Whole Brain
In normotensive animals, clonidine, at 50ug/Kg i.p., 
produced a 12.1% decrease in blood pressure (P^O.Ol) but 
no significant change in the turnover of either nora­
drenaline or dopamine (Figure 4.5, Table 4.2). When the 
dose was increased to lOOug/Kg, a significant reduction 
in the turnover of noradrenaline, as well as a 2 0 .6 % 
decrease in blood pressure (P<0.01), was found (Figure 
4.6, Table 4.2). However, little effect was found on 
dopamine turnover.
Application of the same dose levels of clonidine to 
renal/DOCA hypertensive animals produced similar results. 
Both doses produced significant falls in blood pressure and 
also decreases in the turnover of both noradrenaline and 
dopamine. The only statistically significant result, how­
ever, was the decrease in noradrenaline turnover produced 
by the higher dose of clonidine, where the turnover was 
decreased by 40.5% of the control value (Figure 4.7,
Table 4.2).
4.4.3.2 Effects on Catecholamine Turnover 
in Brain Regions
The two brain areas studied were the hypothalamus and
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FIGURE 4.5 The ef fect- of Clonidine. 50uq/Ka i^p. on 
the, turnover, of catecholamines, in the 
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FIGURE 4.6 The effect of Clonidine lOOuq/Kg i.p, on 
the turnover, of cahecholamines in the 
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FIGURE 4.7 The effect of Clonidine.,. 50uq/Kq and lOOug/Ka. 
on. the turnover of. Noradrenaline in the whole 
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the medulla. Results are only presented for effects on 
noradrenaline turnover for reasons previously discussed 
(Chapter 3, section 3.4).
The effect of only one dose level of clonidine, that 
of lOOug/Kg, was examined. This dose was chosen as it 
had been shown to produce both significant falls in 
blood pressure and significant decreases in the turnover 
of noradrenaline in the whole brain of both normotensive 
and renal/DOCA hypertensive rats (Table 4.2).
In the normotensive animal, this dose of clonidine 
was found to reduce noradrenaline turnover in the medulla 
by 42.5% (P<0.05) of the control value, while in the 
hypothalamus, turnover was decreased by 24.9% of control 
values but was not significant (Table 4.3). In the 
renal/DOCA hypertensive rat, turnover was only reduced by 
21.5% (P <0.09 of control values in the medulla, while in 
the hypothalamus, turnover appeared to be unaffected 
(Table 4.3).
4.4.4 Discussion
The results presented above tend to confirm the find­
ings of others that the administration of clonidine 
results in a decrease in the turnover of central catechol­
amines (see section 4.4.1). A major difference between 
this and previously reported work is the dosing schedule 
and the animal models used. Previous work utilised acute 
dosing, invariably in normotensive animals, while here
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more prolonged dosing with clonidine, in both normotensive 
and hypertensive animal models, has been used. .
In experiments examining the effects in whole brain, 
Clonidine produced substantial decreases in the turnover 
of noradrenaline, both in the normotensive and hypertensive 
models, the turnover decrease being smaller in the hyper­
tensive model. This was also reflected on the examination 
of turnover changes, after clonidine,in hypothalamus and 
medulla. Although decreases occurred in the two regions, 
in both animal models, the decrease was smaller in the 
hypertensives. In the light of results presented in 
Chapter 3, the smaller decrease in noradrenaline turnover 
in hypertensive animals might not be unexpected, as, when 
compared to age-matched normotensive controls, the 
turnover of noradrenaline in hypertensive brains is already 
depressed. This may reflect some basal limit to the 
possible reduction of turnover, lower than which cannot be 
reached by drug action.
However, if the hypothesis that hypertension is, in 
some way, associated with decreased turnover of central 
catecholamines, in particular noradrenaline (see Chapter 3), 
is accepted, then it might be expected that relief or 
reversal of the hypertension would be associated with a 
reversal of the turnover effect. In fact, drug treatment 
exacerbates the turnover effect yet still produces a 
decrease in blood pressure.
Assuming that both effects are produced by a-receptor 
stimulation by the drug, at least two possibilities could
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exist:
i) thaj: drug effects on turnover and blood 
pressure are not related;
ii) that clonidine has two sites of action 
centrally producing different effects.
A fuller discussion on the above will be presented in the 
final Chapter of this thesis.
4.5 Effects of Clonidine on Blood Pressure and
Central Catecholamine Turnover in the 
Spontaneously Hypertensive Rat
4.5.1 Introduction
It has been suggested that the spontaneously hyperten­
sive (SH) rat is the animal model that most closely 
resembles human 'Essential " hypertension (Grollman, 1972). 
Consequently, the importance and use of the SH-rat in 
cardiovascular research has increased and it has become 
the topic of an increasing number of publications (e.g. 
Okamoto, 1972; Hill, 1976; Roba, 1976).
Two major colony-types of SH-rat are presently 
commercially available and in use. One is a Japanese strain 
developed by selective inbreeding of Wistar rats at Kyoto
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University, Japan, (Okamoto et al, 1972) while the second, 
although also derived from original Wistar stock, has been 
developed at Otago University in New Zealand (Phelan et al, 
1972). Both strains have been developed by successive 
brother-sister mating of rats that displayed higher than 
normal blood pressures when compared to the mean blood 
pressure of the original stock. Inbreeding through over 
21 generations has, by now, produced, from a biological 
viewpoint, ’’pure” inbred strains.
The SH-rats display a consistent and reproduceable 
elevated blood pressure and also other differences from 
control animals that make them a separate strain (Okamoto,
1972).
A small breeding colony of the New Zealand strain 
was kindly donated by Dr. M. Armstrong (Wellcome Research) 
for use in this project. Unfortunately, problems in 
breeding occurred resulting in the production of small 
litters and weak animals. As a result, animals sufficient 
for only one experiment were produced. However, the 
results obtained from this experiment were thought to be 
sufficiently interesting to warrant inclusion in this 
thesis.
4.5.2 Method and Results
Animals were dosed with clonidine, lOOug/Kg i.p., or 
saline, Iml/Kg, using the schedule described previously 
(section 4.4.2).
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The mean systolic blood pressure before treatment 
was 208 + 4mmHg (mean + S.E.M., n = 19). Clonidine 
treatment produced a 25.0% fall in the mean systolic blood 
pressure (P< 0.001) and also significant decreases in the 
turnover of both noradrenaline and dopamine when comparing 
the decline of endogenous levels in whole brain after 
synthesis inhibition with a-MT (Figure 4.8).
The turnover of noradrenaline was decreased by 66.4% 
of the control value (P<0.001) and dopamine turnover 
decreased by 19.8% of the control value (P<0.001).
4.5.3 Discussion
A comparison of the results obtained from SH-rats 
with those obtained from normotensive and renal/DOCA 
hypertensives appears to indicate that the SH-rat is more 
susceptible to clonidine treatment than the other models, 
with larger decreases in both blood pressure and central 
noradrenaline occurring. These results would tend to 
agree with those of Ohkusu (1971) who came to a similar 
conclusion. However, it is not possible from these 
results to offer an explanation of this apparently 
greater susceptibility, except perhaps to say that it 
could be due to a strain difference in the animals.
It is interesting, however, that the effect of 
clonidine in lowering blood pressure and central cate­
cholamine turnover is common with all three animal models 
examined.'
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FIGURE 4.8 The effect, of. Clonidine 10Ouq/Kq- on . 
ca-hacholamine turnover in. the whole brains 
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4.6 General Discussion
The results presented in thiè Chapter certainly 
indicate that there appears to be associated with the 
blood pressure-lowering effect of clonidine a reduction 
in central catecholamine turnover. However, for reasons 
discussed in section 4.4.4, it is possible that the 
turnover effect is not causally related to the hypoten­
sive action, but is either secondary to it or, indeed, 
totally unrelated.
A discussion on how the blood pressure-lowering 
action and the reduction in central catecholamine turnover 
may be achieved by clonidine will be presented in the 
final Chapter of this thesis.
It was thought, however, that an examination of 
the interaction said to occur between clonidine and the 
tricyclic antidepressant desmethylimipramine (DMI) would 
help to clarify the mechanisms by which clonidine produces 
its effects. Hence, the following Chapter reports on the 
effects of combined clonidine and DMI treatment with 
relation to the hypotensive action and reduction in 
central catecholamine turnover produced by clonidine.
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CHAPTER 5
AN EXAMINATION OF THE INTERACTION 
BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE 




The simultaneous administration of a number of 
different drugs is all too common in modern therapy and 
the fact that interactions can occur between certain drugs 
has become a well recognised problem. These interactions 
can result in a potentiation of the effect of one of the 
drugs (i.e. warfarin potentiation by aspirin) or, altern­
atively, in a reduction in the efficiency of one of the 
drugs (i.e. simultaneous administration of phenobarbitones 
which induces microsomalenzyme activity).
An important group of compounds in which clinical 
interactions have been reported are the antihypertensive 
agents (see, for example, Stafford & Fann, 1977; Van 
Zwieten, 1975a). In particular, both the centrally acting 
antihypertensive drugs clonidine and a-methyldopa have 
sedative properties that are potentially enhanced by other 
drugs such as anxiolytics, hypnotics, antiepileptics or 
anaesthetics, which also have sedative properties.
A more important interaction involving clonidine 
has been with the tricyclic antidepressant desmethylimipra- 
mine (DMI). Briant, Reid and Dollery (1973) reported that 
simultaneous administration of these two drugs clinically 
could result in an interaction causing a reduction in 
the hypotensive action of clonidine. Further work by 
these authors showed that this interaction could also be 
demonstrated in rabbits (Reid, Briant & Dollery, 1973). 
Other workers contested these results and implied that no
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interaction occurred either in the rabbit (Hoefke & 
Warnke-Sachs, 1974) or the rat (Scholtysik & Salzmann»
1973). However, later work by a 'number of other workers 
has confirmed the findings of Briant et al and demonstrated 
that an interaction does occur, and in a variety of animal 
species including the rat (Finch et al, 1975; Kaul &
Grewal» 1975) and also anaesthetised cats (Van Spanning 
& Van Zwieten, 1973; Van Zwieten, 1975a and b>»
Similar interactions have been reported to occur 
between other centrally active antihypertensive drugs 
(i.e. a-methyldopa) and a variety of other drugs including 
other antidepressants and neuroleptic agents (Van Zwieten, 
1975a and b, 1975, 1977).
Reid, Briant and Dollery (1973), working on the basis 
that DMI acts primarily by the blockade of pre-synaptic 
uptake systems of noradrenaline, suggested that the site 
of the clonidine/DMI interaction, and hence possibly 
the site of action of clonidine itself, was on the pre- 
synaptic neurone, implying that clonidine produced its 
effect by some action on endogenous noradrenaline. However, 
other evidence suggests that clonidine acts post-synaptically, 
as it has been demonstrated that the hypotensive action of 
clonidine still occurs even after depletion of central 
noradrenaline by reserpine and/or a-methyl-p-tyrosine 
treatment (Haeusler, 1974; Kobinger & Fichier, 1975,
1976).
Hence, it has been postulated that, if the inter­
action occurs at a central site, then it may be a result
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of the a-adrenolytic properties of DMI in blocking the 
a-receptor normally stimulated by clonidine or, altern­
atively, a peripheral effect of uptake blockade of nora­
drenaline increasing the concentration of noradrenaline 
at peripheral receptors, resulting in a "physiological" 
antagonism (Haeusler, 1974; Van Spanning & Van Zwieten, 
1973; Van Zwieten, 1975a).
Most of the previous work performed on the interaction 
has involved the acute administration of the drugs by a 
variety of routes with subsequent blood pressure recording.
In anaesthetised cats, administration was by the vertebral 
arteries (see, for example. Van Zwieten, 1975a, 1976, 1977), 
in conscious rabbits by a cannulated ear vein (Reid, Briant 
& Dollery, 1973) and in conscious rats either intraperiton- 
eally (Finch et al, 1975) or orally (Kaul & Grewal, 1975).
Little information is available on the interaction 
with regards to effects on the central catecholaminergic 
systems. Consequently, it was thought that an investi­
gation of possible effects on these systems during the 
interaction would be instructive.
5.2 Method
Previous work on the clonidine/DMI interaction 
generally involved pretreatment of the animals with the 
antidepressant drug and subsequent examination of any 
reduction in the hypotensive effect of clonidine 
administration (for references see Introduction).
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In fact, from a clinical point of view, the reverse 
situation is more important. If a hypertensive patient is 
well controlled on clonidine and also needs antidepressant 
therapy, administration of DMI concurrently with clonidine 
would result in a reversal of the hypotensive effect of 
clonidine and loss of control of the hypertension. It 
was therefore decided to use this type of situation 
experimentally.
The effects of clonidine were established by dosing 
according to the schedule described in Chapter 4 
and then challenged with two doses of the antidepressant 
drug. A reappraisal was then made of any effects on 
blood pressure and central noradrenaline turnover.
Pilot experiments indicated that a dose of 3mg/Kg i.p. 
of DMI would produce an antagonism of the hypotensive 
effect of lOOug/Kg i.p. of clonidine in normotensive rats, 
so these two dose levels were incorporated into the dosing 
schedule described below.
Both drugs were administered i.p. as the hydrochloride 
dissolved in 0.9% saline solution. Control animals were 
included in all experiments and given saline (Iral/Kg)? 
instead of drug, except in experiments involving the 
comparison of effects due to clonidine alone and the 
combination of clonidine and DMI therapy, where the 
"control" animals therefore received clonidine.
The dosing schedule for the administration of both 
drugs is described below:
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Day 1: Blood pressures measured in the morning.
First dose of clonidine or saline given 
at I7.00h.
Day 2-7; Animals dosed twice daily with either
clonidine or saline at 09.00h and 
17.00h.
Day 7; Concurrent with the I7.00h dose of
clonidine (or saline), the first dose 
of DMI (or saline) was administered.
Day 8: Last doses of all drugs given at
08.30h and blood pressures measured 
2 hours later.
This was followed by the administration 
of a-MT 250mg/Kg i.p., after which the 
animals were killed and their brains 
removed 4 hours later.
On killing, the brains were removed, dissected where 
necessary and the tissue prepared for extraction and 
assay of catecholamines as previously described (see 
Chapter 2). Turnover rates were examined by comparing 
the slopes of the decline of noradrenaline,after synthesis 
inhibitiorv of control and drug treated animals.
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5.3 Results
5.3.1 Effects on Blood Pressure
In normotensive animals, the administration of two- 
doses of DMI 3mg/Kg i.p. (15.5h and 2h before blood 
pressure measurements) produced some effect on blood 
pressure, reducing untreated control blood pressures by 
14.4% (P<0.001, Figure 5.1, Table 5.1). Clonidine 
lOOug/Kg i.p., when administered twice daily for seven 
days, also produced a fall in blood pressure, 18.0% of 
the control untreated value (P <0.001, Figure 5.1, Table 
5.1). The combined administration of clonidine and DMI, 
given according to the schedule laid out in the previous 
section, also resulted in a significant fall in blood 
pressure, but only by 10.2% of the control untreated 
value (P <0.001, Figure 5.1, Table 5.1). However, ort 
comparison with the fall in blood pressure produced by 
clonidine treatment alone, this fall was found to be 
significantly smaller. Calculation of the difference ’ 
showed that the inclusion of DMI in the dosage regimeit 
had reduced the clonidine response by 43.5% (P%r0.002y 
Fi^yre 5.1, Table 5.1).
A similar result was apparent when the experiments 
were repeated using hypertensive animals. DMI 3mg/Kg i.p, 
again produced a significant decrease in the control 
values (9.8%, P <0.005, Figure 5.2, Table 5.2), while 
clonidine administration produced a 21.6% decrease lit
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FIGURE 5.1 The effect of Clonidine., DMI and a. . 
combination, of these two drugs on the 
blood pressure of normotensive rats.
Mean Control Systolic B.P. =
145.6 + 1.5mmHg (n=23)
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FIGURE 5.2 The, ef f ect of Clonidine,- DMI. and a..combination, of these two, drugs on. the 
blood pressure of renal/DOCA hypertensive 
rats.
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control blood pressures (P <0.001, Figure 5.2, Table 5.2). 
The combination of clonidine and DMI treatment again 
resulted in a smaller decrease in blood pressure (18.0%,
P <0.001) than that produced by clonidine alone and was 
found to be a 15% reduction of the response due to 
clonidine (Figure 5.2, Table 5.2). This was not found to 
be statistically significant.
5.3.2 Effects on the Turnover of Noradrenaline
in Whole Brain
The effect of the various dosage regimen on central 
noradrenaline turnover was, at first, examined in whole 
brains of normotensive animals (Table 5.3). DMI treatment 
produced very little change in the turnover of noradrena­
line in the whole brain, while clonidine, as previously 
shown, produced a significant decrease (P<0.01) when 
compared to saline controls. The decrease was 48.7% of 
the control value.
When the combination of clonidine and DMI therapy 
was compared to that of clonidine alone, it was found that 
the combination therapy produced a potentiation of the 
turnover decrease caused by clonidine treatment alone. 
Although this decrease was 19.5%, it was found to be non­
significant. However, this is a 19.5% decrease on a turn­
over rate already depressed by 48.7%.
The above result would indicate that, regarding turn­
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in a potentiation of the effect of clonidine to decrease 
turnover, even though there is an antagonism of the 
hypotensive action.
Whole brain contains a large number of cate­
cholaminergic neurones and pathways, many of which are 
not related to blood pressure control. As a result of 
this, changes in turnover, in more discrete areas of the 
brain concerned with blood pressure regulation, may well 
be masked. Therefore, an examination of changes in more 
discrete areas would certainly be of great value.
The above experiments were repeated and an examina­
tion for effects on turnover was carried out, concentrating 
on two areas of the brain which have been implicated in 
blood pressure control and the site of action of clonidine. 
These two areas were the medulla and the hypothalamus.
5.3.3 Effects on Noradrenaline Turnover in
Medulla and Hypothalamus
The effect of the various treatmaits. with clonidine,
DMI and a combination of the two drugs on noradrenaline 
turnover in medulla and hypothalamus, was examined in both 
normotensive and hypertensive animals.
In the normotensive animal (Table 5.4), DMI 3mg/Kg i.p. 
produced falls in the turnover of noradrenaline in both 
the medulla and the hypothalamus but the decreases were 
non-significant. Clonidine produced a significant decrease 
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and a 24.9% (non-significant) decrease in the hypothalamus. 
When clonidine and DMI were given as a combined treatment 
and compared-to effects produced by clonidine treatment 
alone, it was found that the combined therapy produced a 
49.3% decrease in noradrenaline turnover in the medulla 
(P<0.05) but no change in the turnover in the hypothalamus. 
This decrease of 49.3% was a further decrease on nora­
drenaline turnover already depressed by 42.6% due to 
clonidine and represents a turnover decrease, therefore, 
of around more than 60% from saline treated control 
animals.
When the experiments were repeated on hypertensive 
animals, a similar profile of results was obtained 
(Table 5.5). DMI produced a significant decrease in 
noradrenaline turnover in the medulla of 33.6% (P<0.01) 
but little change in the hypothalamus. Clonidine produced 
only a 21.5% (P<0.05) decrease in noradrenaline turnover 
in the medulla but, again, little change in the hypo­
thalamus. The small decrease in medulla noradrenaline 
turnover is not entirely unexpected in the light of the 
results presented in Chapter 3, which show that, in the 
hypertensive animal, turnover is already significantly 
reduced when compared to normotensive controls. However, 
when the result of combined treatment with clonidine and 
DMI was compared with that obtained from clonidine treat­
ment alone, it was found that, in the medulla, turnover 
wars further decreased by 56.6% (P-<0.01). This represents 
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of around 60%. Effectively no change was found in the 
hypothalamus.
5.4 Discussion
The results presented in this Chapter confirm the 
findings of other workers (see Introduction) that an inter­
action does occur between clonidine and the tricyclic 
antidepressant desmethylimipramine, which results in a 
reduction of the hypotensive effect of clonidine. However, 
with respect to effects on central noradrenaline turnover, 
DMI treatment appears to potentiate the effect produced 
by clonidine.
If gross changes are compared, then, in general, the 
results obtained from experiments involving normotensive 
animals are similar to those from hypertensives.
For ease of comparison, the results from this Chapter 
are presented as a summary table (Table 5.6).
Clonidine lOOug/Kg i.p., when given twice daily for 
seven days, produced effects on blood pressure and also 
on central noradrenaline turnover. Treatment with DMI 
alone, two doses of 3mg/Kg i.p., also produced decreases 
in blood pressure and decreases in central noradrenaline 
turnover, but to a lesser extent than the effect produced 
by clonidine treatment. When the two drugs are admini­
stered in combination, an interaction occurs which mani­
fests as opposite effects on blood pressure and central
- 154 -
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noradrenaline turnover. The combination results in a 
reduction of the hypotensive effect of clonidine but, 
conversely, causes a potentiation of the decrease in 
noradrenaline turnover resulting from clonidine-only 
administration.
Examination of the results in detail shows that there 
are anomalies not explained by this simplified version.
The turnover changes resulting from clonidine treatment 
appear to be substantially larger in the normotensive 
animal than in the hypertensive animal. This is probably 
due to the already reduced noradrenaline turnover found 
in the hypertensive animal as previously discussed. Also, 
the interaction resulting in a decrease in the hypoten­
sive effect of clonidine appears again more pronounced in 
the normotensive animal than in the hypertensives. This 
may possibly be due to the wider variation in recorded 
blood pressure for the hypertensives, resulting in a 
greater variation of effect.
It is interesting to note that nearly all the 
significant turnover effects, both the reductions produced 
by clonidine and DMI when administered alone and also the 
potentiation of the clonidine effect by DMI when the two 
drugs are administered concurrently, appear to be confined 
to the medullary area. This may well be taken as an 
indication that the site of action of clonidine is located 
within the medulla.
If the idea advanced in the previous Chapter is 
accepted, that the turnover decrease produced by clonidine
- 156 -
is unrelated to its hypotensive effect, then the 
potentiation of the turnover effect by DMI may also be 
unrelated to the antagonistic effects of DMI on the hypo­
tensive response to clonidine.
A discussion oh the possible explanations which may 
be put forward to explain these two effects and also on- 
the various sites and mechanisms possibly involved in the 
interaction will be presented in the final Chapter of this 
thesis.
However, in an attempt to gain more information on 
drug effects on turnover and also to provide more 
information on the DMI interaction, the following Chapter 
presents results of an examination into the effects of 




THE EFFECTS OF OTHER DRUGS,
BOTH ALONE AND IN COMBINATION,
ON BLOOD PRESSURE AND CENTRAL NORADRENALINE TURNOVER
- 158 -
6.1 Introduction
In the preceeding Chapter, results of an examination 
into the interaction occurring between clonidine and DMI 
were presented. It was demonstrated that effects on 
blood pressure and central noradrenaline turnover were 
associated with the interaction.
This Chapter presents results obtained from an examin­
ation of a variety of miscellaneous drugs. The drugs were 
chosen as they produce effects either on blood pressure 
or on central noradrenaline turnover and it was thought 
that the results obtained from their examination would be 
of some value in attempting to clarify the mechanism of 
action of clonidine.
In the first instance, the effects of two other anti­
hyper tens ive agents were examined. The two drugs were 
a-methyldopa, said to work by a central mechanism (see 
Chapter 1 for references), and guanethidine, an adrenergic 
neurone blocker said to be devoid of central hypotensive 
activity (Wilhelm & De Stevens, 1975; Baum, Shropshire & 
Varner, 1972).
It has been reported that these two compounds also 
display an interaction with the tricyclic antidepressants, 
especially DMI (Kaumann, Basso & Aramendia, 1965; Cocco & 
Ague, 1977). As this interaction occurs with both cen­
trally acting antihypertensives (i.e. clonidine and 
a-methyldopa) and peripherally acting compounds (i.e. 
guanethidine), it was thought that an examination of the
- 159 -
interaction occurring between DMI and the latter two 
compounds would provide additional information towards the 
determination of the possible site and mechanism of the 
interaction occurring between DMI and clonidine*
As clonidine is reported to exert its effects by 
a-receptor stimulation (see, for example. Van Zwieten*^ 
1973, 1975a), it was thought that an examination of the 
effects of an a-blocking agent on central noradrenaline 
turnover would also be a useful comparison.
Finally, results are presented of an examination of 
an interesting interaction reported to occur clinically 
between clonidine and the 3-blocking antihypertensive 
drug, sotalol (Saarimaa, 1976).
6.2 Guanethidine and a-methyldopa
6.2.1 Guanethidine
6.2.1.1 Introduction
Guanethidine is one of a large group of compounds 
which exert a hypotensive action by adrenergic neurone 
blockade (see, for example, Laverty, 1973; Wilhelm & De 
Stevens, 1976). Its action depends on the uptake of the 
drug into the adrenergic neurone where it prevents the 
release of noradrenaline normally resulting from stimuli* 
at ion of the nerve. This is achieved partially by inter-
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ference with transmission of the nerve impulse and 
partially by displacement of noradrenaline from storage 
sites within-the neurone (Wilhelm & De Stevens, 1976).
The antihypertensive action appears to be a result 
solely of a peripheral effect with no involvement of a 
central component (Baum, Shropshire & Varner, 1972).
Guanethidine is known to interact with the tricyclic 
antidepressants resulting in a reduction in the efficacy 
of the hypotensive drug (Kaumann, Basso & Aramendia, 1965; 
Stafford & Fann, 1977; Cocco & Ague, 1977).
The purpose, therefore, of including an investigation 
into the effects of guanethidine in this study was two­
fold;
1. to see if a peripherally acting antihyper­
tensive would produce any effects on 
central noradrenaline turnover which could 
be collated with its hypotensive action;
2. if it could be shown that guanethidine had
no central component to its action, yet
still displayed an interaction with DMI, 
this might be evidence for a peripheral 
mechanism for the interaction. If so,
it may be possible to suggest that the 
clonidine/DMI interaction may be mediated, 
partially at least, by a peripheral component.
- 161 -
Guanethidine was, therefore, examined using a similar 
dosage schedule to that used in the investigation into 
the effects of clonidine and the clonidine/DMI inter­
action ( see Chapter 5). The effects of the drug on blooch 
pressure and central noradrenaline turnover was assessed»
6.2.1.2 Method
To determine the effects of guanethidine treatment on 
blood pressure and central noradrenaline turnover» 
guanethidine monosulphate (Ismelin) was administered at 
a dose of 3mg/Kg i.p. twice daily for seven days to 
groups of normotensive rats. The drug was dissolved in
0.9% saline. Consequently, controls received saline only 
at a dose of Iml/Kg i.p. Blood pressure was measured 
before commencement of dosing and two hours after the last 
morning dose of drug seven days later.
In experiments examining the interaction between 
guanethidine and DMI, guanethidine was administered twice 
daily for six days and blood pressure measured two hours 
after the last morning dose on the sixth day. DMIV- 
3mg/Kg i.p., was then included in a similar way to that 
described for clonidine/DMI experiments (see Chapter 5, 
section 5.2). Final blood pressure measurements were 
taken two hours after the last combined morning doses of 
guanethidine and DMI which were given at 08.30h on the 
seventh day.
Estimations of noradrenaline turnover were performed
— 162 —
by injecting the animals with a-MT 250mg/Kg i.p. and 
killing them four hours later. Brain regions were 
dissected out and levels of noradrenaline estimated by 
methods described previously (Chapter 2).
6.2.1.3 Results
6.2.1.3.1 Effects on Blood Pressure (Figure 6.1)
Guanethidine, when given at 3mg/Kg i.p. for seven 
days, produced a 21.6% decrease in blood pressure (P<0.001) 
As previously demonstrated (see Chapter 5), DMI 3mg/Kg i.p. 
(two doses) also displayed some effects on blood pressure, 
producing a 14.4% decrease (P <0.001).
In the series of experiments examining the interaction 
between guanethidine and DMI, after seven days of dosing 
guanethidine produced an 18.5% decrease in blood pressure 
(P <0.001). However, the combination of guanethidine and 
DMI resulted in a 10.3% fall only (P<0.001) when compared 
to untreated controls, indicating an interaction between 
guanethidine and DMI. This represented a reduction of 
the guanethidine response of 44% (P<0.01).
6.2.1.3.2 Effects on Central Noradrenaline Turnover 
(Table 6.1)
Guanethidine, although said to have no central effects 
and thought not to cross the blood brain barrier, produced
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FIGURE 6.1 The effect of Guanethidine and DMI, administered alone and in combination» 
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The combination of guanethidine and DMf 
reduced the guanethidine response by 44% (P<0.01).
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some effects on central noradrenaline turnover.
A significant reduction in turnover was found in the 
hypothalamus i30.8%, P<0.02) but little effect was noted 
in the medulla. DMI treatment, as previously demonstrated 
(see Chapter 5), also appeared to produce some effect on 
noradrenaline turnover in the medulla and hypothalamus. 
However, these decreases were not found .to be statistically 
significant.
The combination of guanethidine and DMI, when compared 
to a control group consisting of animals receiving only 
guanethidine, appeared to result in a potentiation of the 
turnover decreases apparently resulting from guanethidine 
treatment. This seemed to occur both in the medulla and 
the hypothalamus. The greater effect was apparent in the 
hypothalamus, but statistical evaluation of the results 
showed no significant difference from guanethidine-treated 
controls (Table 6.1),
6.2.1.4 Discussion
The results presented above confirm the findings of 
others (see section 6.2.1.1) that an interaction occurs 
between guanethidine and DMI, resulting in a reduction of 
the hypotensive action of guanethidine. They also show 
that the interaction can be demonstrated in the normotensive 
rat.
As DMI is said to exert its antidepressant effect by 
a central mechanism (see, for example, Byck, 1975),
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the first thought is that its interaction witit 
guanethidine may be a result of a central effect»
Early work on the mechanism of action of guanethidine 
indicated that intracisternal administration of the drug 
to dogs resulted in a central inhibition of vasomotor 
tone and, hence, a reduction in blood pressure (Kaneko, 
McCubbin & Page, 1962). These results led the authors to 
suggest that, on chronic guanethidine administration, 
small amounts of the drug may cross the blood brain 
barrier and hence contribute with a central effect to the 
hypotensive action of the drug.
A more recent paper by Ito, Tanaka and Omae (1975), 
who injected guanethidine intracisternally into rats, 
presents results which appear to be at variance with the 
work by Kaneko et al. Ito et al show that, after intra- 
cisternal administration in rats, guanethidine produced 
not a decrease in blood pressure but an increase.
Perhaps species difference may account for this apparent 
conflict of results.
However, Baum, Shropshire and Varner (1972), also 
using rats, concluded from their experiments, administering^ 
guanethidine systemically (via oral dosing), that there 
was no significant central component to the hypotensive 
action of guanethidine.
It would therefore seem that, at least in the rat, 
the hypotensive effect of guanethidine is mediated by a 
peripheral action.
Early work on the possible effects of guanethidine
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on central endogenous noradrenaline indicated that 
systemic administration of the drug might produce some 
decreases in the endogenous levels of noradrenaline in 
certain brain areas. Sanan and Vogt (1962) showed some 
effects but their results were very variable, which led 
them to suggest that the effects were a result of a 
reflex action. Dagirmanjian (1963) showed that prolonged 
dosing with guanethidine produced a significant decrease 
in the level of noradrenaline in the hypothalamus and 
suggested that either this was a direct drug effect, 
implying that guanethidine crossed the blood brain barrier, 
or, if not, then the decrease was a reflex action in 
sympathetic centres in response to the hypotension caused 
by the drug.
It is interesting that in the experiments reported 
in this Chapter, guanethidine caused a significant decrease 
in noradrenaline turnover in the hypothalamus but not in 
the medulla. This is the reverse of that produced by 
clonidine, a drug known to cross the blood brain barrier 
and exert its effect by a central mechanism. On this 
basis, it may be possible to argue that the decrease in 
noradrenaline turnover associated with guanethidine treat­
ment may be of reflex origin. However, this does not 
exclude the possibility of a direct action of guanethidine 
in certain brain areas, producing a reduction in blood 
pressure by reducing noradrenaline turnover at some 
pressor site in the brain.
The results presented by Ito et al (1975) on the
— 168 —
effects of intracistemal administration of guanethidine 
show that this treatment produces a significant decrease 
in turnover in the hypothalamic-medullary brain area, yet 
an elevation in blood pressure. Although this may be 
evidence for the hypothesis that decreased central nora­
drenaline turnover is associated with hypertension, it 
does not clarify how systemic guanethidine administration 
causes a significant decrease in hypothalamic noradrenaline 
turnover. If the drug is not able to cross the blood 
brain barrier, then it may be reasonable to suggest that 
the effect is, in some way, reflex originated, as, on 
the basis of Ito et al * s results, if the drug did pass 
the blood brain barrier, one might expect an increase in 
blood pressure.
Administration of DMI along with guanethidine results 
in a potentiation of the decrease in noradrenaline turn­
over associated with guanethidine treatment while 
producing an antagonism of the hypotensive action. This 
result does not lend itself to easy explanation.
If the apparent central effects of guanethidine are 
reflex in origin, it is perhaps possible that the poteiî p 
tiation by DMI reflects a summation of the effects of the 
reflex and the DMI-induced effects. This would imply, 
perhaps, that the antagonism of guanethidine by DMI is of 
peripheral origin, an action that certainly occurs (e.g.
Koe & Constantine, 1972). However, if the antagonism- 
occurs at a peripheral site, preventing the effect of 
guanethidine to lower blood pressure, it might be expected
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that the central effects of guanethidine on noradrenaline 
turnover, if reflex in origin, would also be reversed, 
but as is seen, they are potentiated.
It is obvious that more work needs to be performed 
on this subject before a satisfactory explanation of all 
the results can be made.
6.2.2 g-methyldopa
6.2.2.1 Introduction
Alpha-methyldopa is an antihypertensive drug which 
exerts its action in à similar way to clonidine, by the 
stimulation of a-receptors (see, for example. Van Zwieten, 
1973, 1975a). It has also been reported to display a 
similar interaction with the tricyclic antidepressants 
(see Kale & Satoskar, 1970; Van Zwieten, 1973, 1975a & b).
6.2.2.2 Method
The dosing schedule used was the same as that used 
for the clonidine/DMI investigation (Chapter 5, section 
5.2) with the substitution of a-methyldopa 250mg/Kg for 
clonidine. The drug was administered orally as the base 
suspended in 5% acacia solution in distilled water.
Control animals were given 5% acacia Iml/Kg instead of 
the drug-containing solution.
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Blood pressure measurements were taken and brain 
samples obtained for turnover studies using methods . 
described previously.
5.2.2.3 Results
6.2.2.3.1 Effects on Blood Pressure (Figure 6.2)
The administration of a-methyldopa, 250mg/Kg p.o., 
twice daily for seven days produced a 15.8% decrease 
(P <0.001) in blood pressure compared to control animals 
receiving vehicle only.
When a-methyldopa and DMI were given on a combined 
schedule, after seven days a-methyldopa alone produced a 
15% fall in blood pressure while the groups of animals 
receiving the combined therapy displayed only a 7.4% fall 
in blood pressure when compared to untreated control 
blood pressure values. Both falls were significantly 
different from the control values (Figure 6.2). The 
response resulting from the combined a-methyldopa/DMI 
treatment represents a reduction in the a-methyldopa 
response of 50.7% (P< 0.001).
6.2.2.3.2 Effects on Noradrenaline Turnover
When the effect of a-methyldopa on noradrenaline 
turnover was assessed, it was found that the levels of 
endogenous noradrenaline appeared to be substantially
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FIGURE 6.2 The effects of g-methyldopa and DMI, administered alone and in combination, 
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decreased. Comparison with the values obtained from 
control animals showed an 80% decrease in medullary nora­
drenaline and an 82.5% decrease in hypothalamic nora­
drenaline (both significant at P <O.OOX)'.
The administration of a-MT did not produce any change 
in this effect, either at time zero or four hours after 
the administration of the synthesis inhibitor
Similar results were obtained when the combination 
of a-methyldopa/DMI was examined. As a result, it was not 
possible to assess the effects of the above treatments on 
central noradrenaline turnover.
6.2.2.4 Discussion
Regarding the interaction between a-methyldopa and 
DMI, the above results of effects on blood pressure would 
appear to confirm the findings of others that such an 
interaction can be demonstrated experimentally (see* 
section 6.2.2.1).
However, no effects on noradrenaline turnover were 
measured due to the apparent depletion of central nora^ 
drenaline by the drug. An explanation of this effect may 
be offered considering that in vivo a-methyldopa is con­
verted to its active metabolite a-methylhoradrenaline (see 
Chapter 1, section 1.4.3.1). This then displaces and 
replaces the endogenous noradrenaline in the storage sites 
in the neurone. Stimulation of the neurone results in the 
release of a-methylnoradrenaline to act on the same
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receptors stimulated by endogenous noradrenaline or 
clonidine to decrease blood pressure.
Hence, the apparent depletion in endogenous nora­
drenaline would seem to reflect the degree of displacement 
by a-methylnoradrenaline.
The assay method used for detecting catecholamines 
in this thesis did not allow the estimation of a-methyl­
noradrenaline to be carried out simultaneously. However, 
it was demonstrated that a-methylnoradrenaline did not 
interfere with the noradrenaline determination. A 
simple experiment compared standard solutions of both 
noradrenaline and a-methylnoradrenaline, alone and in 
mixed solutions. Table 6.2 shows that there is apparently 
no significant interference between the two compounds at 
the assay wavelengths used for noradrenaline.
It can also be seen from the Table that, although 
a-methylnoradrenaline appears to display some fluorescence 
at the noradrenaline wavelengths, it is less than one fif­
teenth that of the noradrenaline fluorescence. This is a 
figure comparable to that found by Anton and Sayre (1962).
It is interesting to note that the DMI treatment did 
not alter the degree of apparent noradrenaline depletion 
by a-methyldopa. This would perhaps indicate that, if 
the depletion is a function of a-methyldopa entering the 
neurone to be converted to a-methylnoradrenaline, then it 
would appear that the DMI does not affect the uptake of 
a-methyldopa into the neurone. Therefore, if this is so, 
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action of a-methyldopa by DMI is not due to a blockade 
of pre-synaptic uptake. In this case, it might be 
reasonable to suggest that the antagonism is due either 
to the post-synaptic a-adrenolytic property of DMI 
blocking the actions of a-methylnoradrenaline released 
from the central neurone, or an effect on the release of 
a-methylnoradrenaline from the neurone, or a peripheral 
effect, that of peripheral uptake blockade of noradrenaline.
6.2.3 Discussion
It is interesting that the hypotensive actions of 
clonidine, a-methyldopa and guanethidine are all antagonised 
by DMI treatment. As the antagonism occurs with both the 
centrally acting and the peripherally acting drugs, it is 
possible to propose a number of situations for the 
interaction.
Firstly, as the interaction occurs with guanethidine, 
which apparently has no central component to its anti­
hypertensive activity, it is tempting to suggest that the 
interaction between DMI and the centrally acting compounds 
would also be a result of a peripheral effect, in that DMI 
is causing a potentiation of peripheral noradrenaline.
Secondly, if the above hypothesis is wrong, then 
the mechanism of the interaction may involve different 
sites for each of the drugs involved. These may vary from 
a-block centrally to a general potentiation of central 
pressor mechanisms overcoming the hypotensive action of
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the drugs (c.f. Discussion, final Chapter).
A further discussion on these possibilities will 
be attempted in the final Chapter of this thesis.
6,3 Phenoxybenzamine, an g-blocking Agent;
Effects on Central Noradrenaline Turnover
6.3.1 Introduction
If clonidine, as an a-receptor-stimulating agent, 
causes a decrease in the turnover of central noradrenaline 
(see Chapter 4), then it might be expected that the reverse 
would result from the administration of an a-blocking 
agent. This has been demonstrated in the whole brain by 
Anden et al (1970).
6.3.2 Method
Phenoxybenzamine was administered to normotensive 
rats at a dose of 20mg/Kg i.p. as the hydrochloride dis&- 
solved in 0.9% saline. This dose was chosen as it had been 
shown by previous workers to produce a significant effect 
on central noradrenaline turnover in the rat (AndÀi et al, 
1970) . In these present experiments, two doses of the 
drug were administered, two hours and 15 hours before 
the administration of a-MT for turnover studies.
Estimates of noradrenaline turnover in the medulla
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and hypothalamus were obtained using methods described 
previously.
6.3.3 Results
A comparison of the slopes of the decline of nora­
drenaline after a-MT between control animals receiving 
saline and test animals receiving phenoxybenzamine 
indicates that the a-blocking drug caused substantial and 
significant increases in the turnover of noradrenaline in 
both the medulla and the hypothalamus (Table 6.3).
The increase in the medulla was 67.3% (P<0.02), 
while in the hypothalamus the increase was greater,
80. 8% (P <0.002) .
6.3.4 Discussion
The above results, when compared to those obtained 
for clonidine (see Chapter 4), demonstrate that a-agonists 
(represented by clonidine) and a-blockers (represented by 
phenoxybenzamine) produce opposite effects on central 
noradrenaline turnover. This result verifies the findings 
of Anden et al (1970) who showed a similar result in 
whole brain.
It is interesting also that the a-blocker shows a 
greater effect in the hypothalamus than the medulla, while 
the a-agonist shows the reverse of this, with a greater 
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An attempt will be made in the final Chapter of this 
thesis to offer an explanation of the possible mechanisms 
by which a-agpnists and a-blockers produce their effects 
on central noradrenaline turnover.
5.4 An Interaction between Clonidine and the
g-blocking Antihypertensive Drug Sotalol
5.4.1 Introduction
Sotalol is a derivative of the phenyl-ethanolamine 
type of g-blockers, of which the first was pronethalol 
(Figure 6.3). Both these and other g-blockers have been 
used successfully in the treatment of hypertension 
(Wilhelm & De Stevens, 1976; Clarkson, 1976).
Recently, a report has appeared in the literature 
that indicates an apparent interaction between sotalol and 
the centrally acting antihypertensive clonidine when both 
drugs are administered concurrently (Saarimaa, 1976)̂ .
This interaction results in a reduction in the hypotensive 
effects of both drugs. In the majority of patients in 
which the interaction occurred, blood pressure approached 
pre-treatment levels (i.e. the level before any therapy what­
soever) . Removal of one of the drugs resulted in blood 
pressure returning to the level produced by single drug 
therapy.
With the recent evidence that certain g-blocking
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drugs may have a central component to their hypotensive 
action (see, for example. Day & Roach, 1975; Lewis, 1975; 
Day, Peters & Roach, 1976; Kievans, Kovacs & Kelly, 1976), 
the interaction between sotalol and clonidine was thought 
to be of sufficient interest to merit an examination in 
this thesis, especially as a large part of the work 
presented here was concerned with the interaction of 
clonidine with another drug (DMI), also resulting in a 
reduction of the hypotensive action of clonidine.
A study was made of the sotalol/clonidine interaction, 
therefore, in a similar way to that applied to the 
clonidine/DMI interaction.
6.4.2 Method
In order to find out if sotalol alone produced any 
correlatable effects on blood pressure and central nora­
drenaline turnover, the drug was administered to normo­
tensive rats at a dose of lOmg/Kg i.p, twice daily for 
seven days. The drug was given as the hydrochloride 
(obtained from BDH Chemicals Ltd.) dissolved in 0.9% saline. 
Control animals received saline only at a dose of Iml/Kg 
i.p.
Blood pressure was measured before the start of 
dosing and again two hours after the last morning dose of 
the drug. Noradrenaline turnover was estimated as 
previously described.
To examine for an interaction between sotalol and
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clonidine, two groups of normotensive rats were dose<& 
with clonidine at a dose of lOOug/Kg i.p. twice daily for 
seven days. Blood pressure was measured before the dosing 
started and, as usual, again on the seventh day. Both 
groups of animals continued to receive clonidine for a 
further seven days with the concurrent administration to 
one group of sotalol lOmg/Kg i.p. At the end of this 
second seven day dosing period, the blood pressures of all 
animals were again measured two hours after the last 
morning doses of the two drugs. Estimation of the turnover 
of noradrenaline was carried out on the medulla and 
hypothalamus of both groups of animals.
6.4.3 Results
6.4.3.1 Effects on Blood Pressure 
(Figure 6.4, Table 6.4)
Sotalol, lOmg/Kg i.p. administered twice daily for 
seven days, produced a 20.5% decrease (P<0.001) in control 
blood pressure values. In the examination of the inter­
action between clonidine and sotalol, clonidine, lOOug/Kg
i.p. given for seven days, produced a 21% decrease 
(P <0.001) in control blood pressure values. However» 
when sotalol was administered concurrently with clonidine, 
the result was to produce a reversal of the hypotensive 
effects of both clonidine and sotalol, producing na signi­
ficant difference between the blood pressure of this group
— 183 —
FIGURE 6.4 The effects of Clonidine and Sotalol and combined administration of the two 
drugs on blood pressure.
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and the control untreated value. This represented an 
83.9% reversal of the hypotensive effect of clonidine and 
also a similar degree of reversal of the hypotensive 
effect of sotalol.
6.4.3.2 Effects on Noradrenaline Turnover
Table 6.5 shows the effects of the above treatments 
on the turnover of noradrenaline in the medulla and hypo­
thalamus .
The Table shows that clonidine produced a significant 
decrease of 42.6% in the turnover of noradrenaline in the 
medulla and a small, but non-significant, change in the 
hypothalamus. Sotalol treatment apparently produced a 
small decrease in turnover in the medulla (not significant) 
but had little effect on the turnover in the hypothalamus.
Comparison of the effects of combined clonidine and 
sotalol treatment with a control group consisting of 
animals receiving only clonidine showed a result similar 
to that obtained with combined clonidine/DMI treatment.
The combined treatment caused a significant potentiation 
of the turnover decrease in the medulla associated with 
clonidine (37.6%, P<0.05), while, in the hypothalamus, 
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The results presented above show that the interaction 
between clonidine and sotalol reported to occur clinically 
(Saarimaa, 1976) can be demonstrated in the normotensive 
rat.
Both clonidine and sotalol produce a similar hypo­
tensive effect in the doses examined when administered 
separately. Yet, on combined administration, they appear 
to reduce the hypotensive effects of each other. However, 
the order of drug administration dictated by the dosing 
schedule used in the above experiments implies that 
sotalol is antagonising the clonidine.
The result that combined application of the drugs 
produces an antagonism of the blood pressure effect of 
clonidine, yet an apparent potentiation of the turnover 
effects does not allow a simple explanation of the inter­
action.
With recent evidence that a number of 3-blockers may 
have a central component to their hypotensive action 
(for references see section 6.4.1), it is tempting to 
speculate that the interaction between clonidine and 
sotalol may occur in the central nervous system.
However, available evidence suggests that sotalol is 
one 3-blocking drug which does not have a central component 
to its hypotensive action (i.e. Garvey & Ram, 1975;
Kievans, Kovacs & Kelly; 1976). These results do appear 
to be at variance with other reports which indicate a
- 188 -
central action (e.g. Day, Peters & Roach, 1976). It is» 
perhaps, possible that this disagreement of results may 
be attributable to either strain differences of the cats 
used in the experiments or possible differences in 
experimental procedures. For example, Garvey and' Ram 
and Kievans et al used anaesthetised cats, while Day et al 
used conscious cats#
Fuxe et al (1976) have demonstrated that the P-blocker 
propranolol (said to have a central component to its 
hypotensive action, see Day, Peters & Roach, 1976), when 
given intraperitoneally, produces decreases in the turn­
over of noradrenaline in various regions of the brain.
If it is accepted, therefore, that drugs acting by a 
central mechanism (i.e. clonidine, a-methyldopa» 
propranolol, etc.) may directly or indirectly produce 
effects on central catecholamine metabolism, then it 
would seem, from the results presented in this thesis, 
that, as sotalol produces very little effect on nora­
drenaline turnover, it might be considered to have no 
central effect.
However, this idea may be too simplistic as the' 
combination of clonidine and sotalol results in a signifi­
cant potentiation of the clonidine effect on turnover.
This would indicate some central effect of sotalol but it 
is possible that the effect is unrelated to the hypotensive 
action of the drug.
Fuxe et al (1976) suggest that the central effects 
of P-blockers may well be mediated by effects on
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adrenaline receptors. This type of possibility cannot 
be excluded with regard to the results in this thesis as 
only effects^on noradrenergic systems have been estimated.
It is also possible that effects on transmitter 
systems other than those mentioned above may result in, 
or contribute to, the interaction. Certainly, evidence 
is available showing that pharmacological manipulation of 
central cholinergic and serotonergic transmitter systems 
will also produce effects on blood pressure (e.g. Laubie, 
1975; Bhargava, 1976).
The possibility of Central effects occurring as a 
result of reflex activity also cannot be excluded.
Further comments on the clonidine/sotalol interaction 






The primary aim of this thesis was to examine the 
effects of clonidine on catecholamine metabolism in the 
brain. An attempt has been made to correlate changes 
produced with the hypotensive action of the drug, in the 
hope that the results so obtained would.indicate the 
mechanism of action of clonidine. In pursuing this 
objective, two animal models, normotensive and renal/DOCA 
hypertensive rats, have been used.
The results of this study indicated that prolonged, 
as opposed to acute, treatment with clonidine (e.g. Anden 
et al, 1970), as well as producing significant falls in 
blood pressure, also produces significant changes in the 
turnover of catecholamines, in particular noradrenaline.
This effect occurs in both normotensive and hypertensive 
rats.
The results presented in Chapter 4, on the effects of 
clonidine on central catecholamines, and also the results 
presented in Chapter 5, on the interaction between clonidine 
and the tricyclic antidepressant DMI, suggest that the 
effects of clonidine on central noradrenaline turnover 
(to be referred to as the biochemical effects) are not 
directly related to what might be described as the functional 
effect, namely, the hypotensive action of the drug.
A discussion on the possible mechanisms by which the 
above effects occur is presented in this Discussion 
chapter.'
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The interaction between clonidine and DMI originally 
led to the proposal that clonidine produced its hypotensive 
action by an effect on pre-synaptic noradrenergic neurones 
located in the central nervous system (Reid, Briant & 
Dollery, 1973). However, subsequent work by other workers 
(e.g. Haeusler, 1974; Kobinger & Pichler, 1975, 1976)» 
together with the results presented in this thesis, suggest 
that the hypotensive action of clonidine is mediated by 
stimulation of post-synaptic a-receptors.
Although it has been proposed that the a-receptor 
blocking properties of DMI account for the interaction 
between clonidine and DMI (see Van Spanning & Van Zwieten, 
1973; Van Zwieten, 1975a), it is possible that the 
interaction is not solely mediated by a central mechanisms 
This may be substantiated by the fact that a similar 
interaction occurs between DMI and other antihypertensive 
and cardioactive drugs, some of which have no central 
activity (Kaumann, Basso & Aramendia, 1965; Van Zwieten» 
1975a, 1976; Stafford & Fann, 1977; Cocco & Ague, 1977)►
This situation has been examined by the inclusion in 
this thesis of a study of the interaction between DMI an# 
both a-methyldopa and guanethidine. A discussion of the 
possible sites and mechanisms involved in the above inter­
actions is also presented here.
An attempt is also made to relate the observed 
effects of clonidine on blood pressure and central cate­
cholamine metabolism in relation to the clinical use of̂  
clonidine as an antihypertensive agent. In the light of
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the above results, suggestions are made which may explain 
the occurrence of particular effects during clonidine 
therapy.
Finally, suggestions are made for further work 
indicating areas of possible interest, both directly and 
indirectly related to the problem studied and arising 
from the current work.
However, firstly, the involvement of central cate­
cholamines in blood pressure control and hypertension will 
be discussed.
7.2 Central Catecholamines and Blood Pressure
Regulation
It is now well established that central catecholamin- 
ergic neurones and the peripheral sympathetic nervous 
system play a very important part in the regulation of 
blood pressure and also that the central mechanisms are 
heavily implicated in the development of hypertension 
(see Chapters 1 and 2 and, for example, Chalmers, 1975;
De Champlain & Van Ameringen, 1975; Fuxe et al, 1975; 
Haeusler, 1976).
The discovery of drugs like a-methyldopa and 
clonidine, which exert their antihypertensive action 
apparently by central noradrenergic mechanisms, has 
tended to confirm the role of central catecholaminergic 
neurones in blood pressure control (Van Zwieten, 1973,
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1975a; Haeusler, 1975; Kobinger, 1976)*
Available evidence indicates that these central 
noradrenergic^ neurones, implicated in blood pressure 
control, display a predominantly inhibitory role (e.g. 
Gagnon & Melville, 1968; De Jong, 1974; Struyker- 
Boudier et al, 1975; Elliott & Clark, 1977). For instance, 
apart from the results presented by the workers mentioned 
above involving the application of exogenous noradrenaline 
to various areas of the brain resulting in depressor 
effects (see Chapter 1), it has been observed that, in 
certain models of hypertension, there is a decrease in 
the turnover of noradrenaline in areas of the brain 
which are associated with central regulation of blood 
pressure. Also, concomitant with this is an increased 
turnover of noradrenaline in peripheral organs (Yamori et 
al, 1970; Nakamura, Gerold & Thoenen, 1971; Chalmers & 
Reid, 1972; Haeusler, Finch & Thoenen, 1972). The 
implication of these results is that this decrease in 
central turnover represents a decrease in the availability 
of noradrenaline at a central receptor, the stimulation of 
which normally produces a controlling inhibition of 
sympathetic vasomotor outflow. This results in an increase 
in sympathetic outflow (reflected by an increase in 
peripheral noradrenaline turnover) and, consequently, an 
elevation in blood pressure.
It is difficult, however, to ascertain from the 
above results whether the alteration in central nora­
drenaline turnover is causal in the development of the-
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hypertension or somehow represents a reflex response to 
the increased blood pressure.
If these, changes do occur at some inhibitory synapse 
and the changes are a result of a reflex effect to 
increase this inhibitory influence, then one might expect 
that turnover would increase (reflecting increased 
activity of the inhibitory neurone), My results do not 
support this idea as they show a decrease in turnover.
This implies either an aberration of the inhibitory system 
or, if a reflex, a decrease in some noradrenergic pressor 
system. Haeusler, Finch and Thoenen (1972) suggest that 
the decrease in turnover found in hypertensive animals is 
a disturbance in the control of a central "trigger" 
mechanism which finally results in a self-perpetuating 
hypertensive disease.
Ito, Tanaka and Omae (1975) showed that the intra- 
cisternal administration of guanethidine resulted in a 
decrease in turnover of noradrenaline in the hypothalamic- 
medullary area. Associated with this was an elevation in 
blood pressure. This result supports the idea of decreased 
central noradrenaline turnover being causal in hypertension 
and also that noradrenaline plays a predominantly in­
hibitory role in central blood pressure regulation.
The results presented in Chapter 3 of this thesis 
confirm the findings of others (see above) that associated 
with hypertension in the DOCA-hypertensive rat is a 
decrease in central noradrenaline turnover in brain areas 
which are said to be important in blood pressure control
- 196 -
(see Chapter 1).
Although there are reports that changes in endogenous 
levels of central noradrenaline can be correlated with 
elevated blood pressure and hypertension (Robertson et al» 
1968; Nakamura, Gerold & Thoenen, 1971; Petty & Reid, 
1977), the results presented in Chapter 3 of this thesis, 
examining levels of noradrenaline in a variety of brain 
regions, do not, on the whole, show any significant 
differences between normotensive and hypertensive animals.
7.3 Comments on the Measurement of Noradrenaline in
Gross Regions of the Brain
The measurement of endogenous levels of noradrenaline, 
in both whole brain and relatively gross regions such as 
medulla, hypothalamus, cortex, etc., may not accurately 
reflect central catecholaminergic neurone activity in a 
particular pathway. Definite conclusions cannot really be 
drawn from the study of such gross areas as they may con­
tain nuclei and neurone pathways which in some cases may» 
in no way, be associated with the particular functional 
parameter measured (in the case of the present work, 
blood pressure). It is perhaps also possible that some 
of the neurones may be producing opposite changes and, 
hence, the measurement of endogenous levels may, in fact, 
result in either an exaggeration or a much reduced estimate 
of the status of any particular neurone system.
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If one accepts the idea that levels of endogenous 
catecholamines in neurones are maintained by a dynamic 
balance between, on the one hand, synthesis and, on the 
other, release and metabolism (Brodie et al, 1965), then 
the measurement of the "turnover" of noradrenaline may 
well be considered a better guide to neurone activity 
than static levels.
However, the argument put forward above concerning 
the validity of the measurement of endogenous levels of 
catecholamines applies equally well to turnover estimations. 
Any measured change in catecholamine turnover may reflect 
the final result of an equation involving both increases 
and decreases in turnover occurring in a variety of 
neurones and pathways, some of which may not be related to 
either the parameter studied or, if drug effects are being 
studied, the direct action of the drug at its "target" 
synapse.
It is clear, therefore, that one must examine much 
more discrete areas of the brain to allow definite 
correlation between a specific parameter measured (i.e. 
blood pressure) and any central effect that might occur at 
a neurone or synapse involved in the central control of 
the parameter. This may be particularly relevant in the 
examination of drug effects, as the drug could well 
produce opposing effects within a certain brain region.
To this end, techniques of microdissection of specific 
brain nuclei (e.g. Palkovits, 1973) may be of use in 
providing clearer information on any such changes mentioned
- 198 -
above.
However, at the start of this project, such methods 
were only just becoming available (see Chapter 2) and, 
due to reasons discussed in Chapter 2, they were not 
employed in this thesis. Even considering the above 
comments, however, the results presented in this thesis, 
on changes in gross brain regions, may.be of some value 
in determining the mechanism of action of clonidine.
As a working hypothesis to offer an explanation of 
the effects of various drugs on the central noradrenergic 
systems in relation to blood pressure control, the 
hypothesis that blood pressure regulation is mediated by 
a central mechanism in which noradrenaline plays a 
predominantly inhibitory role will be advanced. It will 
also be assumed that the measured turnover decrease 
described in Chapter 3 is associated with the hypertension 
(indicating an aberration of the inhibitory controlling 
mechanism of blood pressure) and that the drug-induced 
changes in turnover (cf. Chapter 4) occur at the site of 
this controlling mechanism.
7.4 The Mechanism of Action of Clonidine
In this thesis, results have been presented on the 
effects of prolonged clonidine administration on the levels 
and turnover of central catecholamines and an attempt mader 
to correlate such changes with the hypotensive action of
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the drug.
The effects of clonidine on the levels of endogenous 
noradrenaline in various regions from the brains of both 
normotensive and hypertensive animals are neither con­
sistent nor conclusive (see Chapter 4).
However, examination of the results presented in 
Chapter 4 (Figures 4.2, 4.3 and 4.4) does appear to 
indicate a general trend of increased endogenous nora­
drenaline concentration after clonidine treatment. It can 
be said that, if an increase is not statistically signifi­
cant, then it occurs merely by chance. This may be so, 
but the results mentioned above seem to show too con­
sistently a trend of increased concentration after clonidine 
for this apparent effect to be discarded completely.
It has been reported by others that clonidine does 
produce significant increases in brain noradrenaline 
levels but, in these experiments, the drug has either been 
administered in high doses or for a long time (see, for 
example, Laverty & Taylor, 1959; Conolly, 1970, cited by 
Zaimis, p54; Rochette, Bralet & Bralet, 1974; Braestrup 
& Nielsen, 1976; Sugimoto, Hashida & Kasahara, 1976).
It is, perhaps, possible that these increases occur 
because clonidine decreases the release of noradrenaline 
(see later). However, as the increases are small and, in 
most cases, not statistically significant, their possible 
relevance is difficult to ascertain.
It may be that the use of greater numbers of animals 
may provide a clearer indication of a possible connection
— 200 — =*
between these increased levels and the action of 
clonidine. However, it must be considered whether the 
value of any jresult so obtained would outweigh and justify 
the expenditure of both time and animals, as the value of 
the measurement of levels of endogenous noradrenaline may 
be limited (as discussed in section 7.3).
If the hypothesis that decreased central noradrenaline- 
turnover is associated with hypertension is correct, then 
it might not be unreasonable to expect that an antihyper­
tensive drug producing its effects by a central mechanism 
might exert its action by producing, in some way, a 
reversal of this turnover effect, or, in the case of the 
normotensive animal, cause an increase in noradrenaline 
turnover at the inhibitory synapses.
In fact, as demonstrated by others using acute dosing 
with clonidine (e.g. Anden et al, 1970) and the results, 
presented in Chapter 4 of this thesis, from the use of 
prolonged dosing, although clonidine produces a hypotensive 
effect, it causes a decrease in central noradrenaline 
turnover. This effect occurs in both the medulla and the 
hypothalamus and in both normotensive and hypertensive 
animals. The effect was, however, more pronounced in the 
medulla, the area in which clonidine is thought to have 
its predominant site of action (i.e. Kobinger, 1975, 1976; 
Van Zwieten, 1975a; Haeusler, 1975).
Questions already become evident from these results.
If decreased turnover of noradrenaline is associated with 
increased blood pressure (see earlier) and if clonidine
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further decreases noradrenaline turnover, is this drug- 
induced decrease related to the drug's hypotensive 
action?
The answer to this question would appear to be that 
the effects of clonidine on noradrenaline turnover and 
blood pressure are not related, a conclusion supported 
by the results of Anden et al (1976), However, these 
workers used not blood pressure as the functional para­
meter affected by clonidine, but hindlimb flexor reflex 
activity in rats and the potentiation of apomorphine- 
induced hypermotility in mice. It may be that the effects 
of clonidine on blood pressure may not be comparable to 
these other parameters.
However, the idea that there is no relation between 
the turnover effects and the blood pressure lowering 
effects of clonidine appears to be further substantiated 
by the results obtained from the interaction between 
clonidine and DMI (Chapter 5). This line of argument will 
be considered again later in this section and also in 
the next section in the light of the clonidine/DMI results.
If it is to be assumed there is no relation between 
these two effects, then some explanation must be found for 
this phenomenon. There seems little reason to doubt that 
clonidine produces its hypotensive action by the stimu­
lation of a-receptors which appear to be located predom­
inantly in the medullary axis of the brain (Kobinger, 1975, 
1976; Van Zwieten, 1973, 1975a; Haeusler, 1973, 1975). 
However, there is still controversy as to where these
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a-receptors are situated and whether they are on a pre^ 
or post-synaptic neurone.
In the periphery, clonidine stimulates post-synaptic 
a-receptors, resulting in a vasoconstriction, an action 
which is said to be responsible for the initial hyper­
tensive effect of clonidine on intravenous administration 
(Zaimis, 1970; Van Zwieten, 1975a). However, there is 
also considerable evidence indicating that, in the 
periphery, clonidine also stimulates pre-synaptic a- 
receptors to prevent the release of noradrenaline from the 
post-ganglionic nerve ending (Armstrong & Boura, 1973;
Starke & Altman, 1973; Doxey, 1977; Scriabine & Stavorski, 
1977). Evidence is also available to indicate that 
clonidine displays a greater affinity for pre-synaptier- 
a-receptors than post-synaptic a-receptors, at least in 
the periphery (Starke et al, 1974; Starke, Endo & Taube, 
1975).
As a result, it has been suggested that the central 
hypotensive action of clonidine is also mediated by pre- 
synaptic a-receptors (Starke & Montel, 1973; Starke,
Montel & Altman, 1973). An attempt to explain the inter—  
action between clonidine and DMI has also led to a 
similar conclusion that clonidine*s action is mediated by 
an effect on a pre-synaptic neurone site (see Reid, Briant 
& Dollery, 1973; and Chapter 5).
If the conclusions from these experiments are correct,
it might be expected that clonidine acts by releasing^
• - - •• •
endogenous noradrenaline from central neurones. However,
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a number of workers have shown that even after almost 
total depletion of central noradrenaline with a combination 
of reserpine-and a-MT treatment, the central hypotensive 
action of clonidine could still be demonstrated (Haeusler, 
1974; Kobinger & Pichler, 1975, 1976). This would 
therefore argue in favour of a post-synaptic site for the 
hypotensive action of clonidine, but does not explain how 
the effects on turnover are mediated.
The simplest explanation is that clonidine produces 
both effects by a-receptor stimulation (see Anden et al,
1970, 1976), but that, apart from their common cause, the 
two effects are not directly related. The turnover effect 
might be regarded therefore as a side effect of the drug 
treatment.
If both the effects are apparently mediated by a- 
receptor stimulation, yet are unrelated to each other, 
then it is not unreasonable to assume that the a-receptors 
themselves may differ (see Anden et al, 1976). If we 
assume that both a-receptors producing the different 
effects are positioned close to one another (i.e. within 
the same synapse at which stimulation by clonidine produces, 
a fall in blood pressure), then the following explanation 
may be advanced.
Figure 7.1 is a diagrammatic representation of a 
hypothetical synapse at which clonidine is supposed to act.
It might be supposed that, in the normal state, noradrenaline 
is released in response to impulses from baroreceptors to 
stimulate the post-synaptic a-receptor on a neurone
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which inhibits sympathetic outflow and hence results in 
controlling decreases in blood pressure (Figure 7.1(a)).
The presence of clonidine in the synapse stimulates the 
post-synaptic a-receptor to decrease blood pressure. The 
decrease in noradrenaline turnover may then result 
either from the presence of a feed-back inhibition 
loop from the post- to the pre-synaptic neurone, decreasing 
the release of noradrenaline and hence indirectly 
decreasing turnover, or from the stimulation by clonidine 
of pre-synaptic a-receptors direct to inhibit the release 
of noradrenaline from the neurone. This too would result 
in decreased turnover by product inhibition of synthesis 
by noradrenaline (Figure 7.1(b)).
As has been stated, the presence of pre-synaptic 
a-receptors in the periphery is well documented (see 
earlier and also, for example. Langer et al, 1975, 1977; 
Starke, Taube & Borowski, 1977) as is the effect on these 
receptors of clonidine (Armstrong & Boura, 1973; Starke & 
Altman, 1973; Doxey, 1977; Scriabine & Stavorski, 1977). 
It has also been shown that clonidine will reduce the 
release of noradrenaline from field stimulated brain 
slices (Starke & Montel, 1973; Farnebo & Hamberger, 1971) 
so that the postulated effects on the hypothetical synapse 
described above are well within the bounds of possibility. 
Therefore, if it is accepted that clonidine produces its 
effects by stimulation of post-synaptic a-receptors, the 
turnover effect certainly appears to be incidental to this 
main action.
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Anden et al (1976) suggest that small doses of 
clonidine may produce a hypotensive effect by a pre^ 
synaptic action, inferring that the hypotensive effect of 
clonidine may be related to the biochemical effect» This 
is an observation basically at variance with the ideas 
developed in this thesis.
However, for clonidine to act via a pre-synaptic 
mechanism to decrease blood pressure, in the hypothetical 
synapse detailed earlier, the drug would have to function 
as an a-receptor antagonist. This might be expected to 
increase the release, and hence increase the turnover, 
of noradrenaline (cf. results from phenoxybenzamine. 
Chapter 6.3). This does not occur. Therefore, even on 
this basis, it would appear that the hypotensive action of 
clonidine is mediated by the stimulation of central post- 
synaptic receptors.
This does not, however, preclude the possibility of 
a pre-synaptic agonist effect, decreasing the release of 
noradrenaline at some other noradrenergic synapse, possibly 
situated on a pressor pathway (for example, possibly in 
the hypothalamus) or in the periphery (Starke et al» 1974).
The line of argument developed in this section, that 
the biochemical (turnover) effects of clonidine appear 
unrelated to the functional (hypotensive) effect, would 
seem to be further substantiated when the results of the 
clonidine/DMI interaction are examined. These results 
are discussed in the next section»
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7.5 The Interaction between Clonidine and DMI
The tricyclic antidepressants, including DMI, display 
some cardiovascular effects in that they produce small 
decreases in blood pressure (Kaumann, Basso & Aramendia, 
1965; Van Spanning & Van Zwieten, 1973; Bobkiewicz et al, 
1975). Their effect may be explained by the action of 
the drugs in blocking the uptake of noradrenaline into 
the pre-synaptic neurone. This increases the availability 
of noradrenaline at the post-synaptic receptor and, if 
such an effect occurs at a synapse which has an inhibitory 
effect on blood pressure (see earlier), then a fall in 
blood pressure would result. DMI also appears to have an 
effect on central noradrenaline turnover and, although, in 
this thesis, the effect was not statistically significant, 
this is a comparable result to that obtained by Leonard 
and Kafoe (1976) after chronic dosing with DMI.
As has been previously stated, clonidine causes a 
significant decrease in blood pressure and also a signifi­
cant decrease in noradrenaline turnover, particularly in 
the medullary brain area.
The combined administration of clonidine and DMI, 
following the dosing schedule detailed in Chapter 5.2, 
results in an antagonism of the hypotensive effects of 
clonidine, yet an apparent potentiation of the turnover 
effects.
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If the hypothesis of decreased central noradrenaline 
turnover being associated with hypertension (or elevated 
blood pressure) is sound, then the fact that DMI causes a 
potentiation of the turnover decreases resulting from 
clonidine treatment would seem to be further evidence 
that drug-induced biochemical effects (at least in 
relation to clonidine) are unrelated to their functional 
effects.
How can we therefore explain both the antagonism of 
the hypotensive effects of clonidine by DMI and the 
potentiation of the turnover effects?
If we consider that the interaction occurs at the 
central synapse at which clonidine acts, which will 
again be represented by the hypothetical model proposed in 
the previous section, then the following explanation may 
be advanced.
As has been stated earlier, clonidine stimulates the 
post-synaptic receptor to bring about a fall in blood 
pressure and produces its turnover effects by either a 
feed-back loop or, more likely, stimulation of pre-synaptic 
a-receptors to decrease release and, therefore, turnover 
of noradrenaline (Figure 7.2(a)).
The effects of DMI could probably occur in much the 
same way, with the uptake blockade effect of DMI increasing 
noradrenaline concentration in the synaptic cleft, which 
might be expected to exert both an increase in post-synaptic 
a-receptor stimulation (hence a decrease in blood pressure) 
and also an increase in pre-synaptic receptor stimulation
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to decrease turnover (Figure 7.2(b)).
When clonidine and DMI are given concurrently, it 
might be expected that, as DMI potentiates the effect of 
central noradrenaline (e.g. see Nakamura & Fukushima*
1975), it may result in an apparent potentiation of 
clonidine. In fact, it antagonises the hypotensive action 
of clonidine yet potentiates the turnover effects. This, 
effect of DMI to potentiate the effects of noradrenaline 
may be considered in an explanation of the potentiation 
of the turnover effects of clonidine. It might be that 
the apparent potentiation of the clonidine effect is an 
addition of the effects produced by clonidine and the 
increased noradrenaline concentration in the synaptic 
cleft due to uptake blockade by DMI, resulting in increased 
pre-synaptic stimulation (Figure 7.2(c)).
But why does not a similar effect occur at the post- 
synaptic receptor, producing a potentiation of the 
hypotensive response also?
One explanation may lie in the a-blocking properties 
of DMI (McCulloch & Story, 1972). It has been suggested 
that the antagonism of the hypotensive action of clonidine 
by DMI is a result of a-receptor blockade of the post- 
synaptic receptors stimulated by clonidine (Van Spanning 
& Van Zwieten, 1973; Van Zwieten, 1975a).
It has been suggested earlier that the decrease in 
noradrenaline turnover produced by clonidine is caused 
either by feed-back inhibition or by stimulation of pre- 
synaptic a-receptors. If either of these mechanisms are
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FIGURE 7.2 Diagrammatical summary of the mechanisms 
by which Clonidine, DMI and combined 
























involved (both initiated by a-receptors), it is difficult 
to see how the observed potentiation of the turnover 
effects, yet antagonism of the hypotensive effect, could 
occur unless pre- and post-synaptic receptors are 
different. In this case, if the turnover decrease was 
associated with the stimulation of the post-synaptic 
receptor, it might be expected that a-block of the 
clonidine effect would antagonise this feed-back turnover 
effect. This does not occur and would imply a pre— 
synaptic mechanism for the turnover effects.
It has been shown by others that some a-blockers 
appear to display a certain degree ofspecificity towards 
pre- or post-synaptic a-receptors, demonstrated by the 
a-blockers affecting either the turnover or functional 
effects of clonidine and other drugs (Anden et al, 1970; 
Anden, Grabowska & Strombom, 1976). It is perhaps possible* 
therefore, that DMI shows a greater affinity for central 
post-synaptic a-receptors than pre-synaptic receptors 
with respect to its a-blocking properties. This would 
result in the antagonism of the hypotensive effect but 
not the turnover decreasing effects if these are mediated 
by pre-synaptic a-receptor stimulation. However, without 
more results any further comment would be speculative.
If, however, the idea of a-receptor antagonism by 
DMI is not correct and the drug does not antagonise 
preferentially the post-synaptic action of clonidine, 
there must be other mechanisms involved in the interaction..
An obvious site must be in the periphery with DMI
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acting as an uptake blocker and, as a result, potentiating 
the peripheral effects of noradrenaline. This might 
result in vasoconstriction and hence an increase in 
blood pressure. The antagonism might then be considered 
a physiological antagonism rather than a true pharma­
cological action.
As it has been shown that DMI potentiates the effects 
of noradrenaline at certain central sites (Nakamura & 
Fukushima, 1976), it is possible that this could also 
occur at some noradrenergic synapse in the brain which is 
located on a pressor pathway and results in an effect which 
has more significance than the inhibitory effect of 
clonidine.
It is obvious that more exact experiments need to be- 
carried out before any definite conclusion as to the 
mechanism by which this interaction occurs can be drawn.
However, the results from the examination of the 
interaction reported in this thesis, on the basis of the 
arguments presented above, would appear to verify the 
hypothesis that the decrease in central noradrenaline 
turnover, resulting from clonidine administration, is 
unrelated to the hypotensive effect of the drug.
The results may also be interpreted as further 
evidence for a post-synaptic action of clonidine.
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7. 6 Effects of other Drugs
Guanethidine & a-methyldopa
Interaction with DMI is not confined to clonidine 
but is a property shared by a number of other drugs which 
affect the cardiovascular system (Cocco & Ague, 1977).
In this thesis, it has been demonstrated that 
a-methyldopa and the peripherally acting antihypertensive 
guanethidine interact with DMI, confirming the reports of 
others (Kaumann, Basso & Aramendia, 1955; Stafford &
Fann, 1977; Van Zwieten, 1975a, 1976).
The effects produced by guanethidine will be con­
sidered first.
Guanethidine is not thought to have a central 
component to its hypotensive action nor be able to 
cross the blood brain barrier (Wilhelm & De Stevens, 1976; 
Baum, Shropshire & Varner, 1972). Yet, in the experiments 
in this thesis, it produced, in addition to a reduction in 
blood pressure, a significant reduction in the turnover of 
noradrenaline in the hypothalamus. There was little 
change in the turnover of noradrenaline in the medulla.
Although only a single dose study was performed, 
this result is in apparent conflict to the results 
obtained after clonidine treatment, where the apparently 
greater effect on noradrenaline turnover occurred in the 
medulla. These differing effects may imply that the drugs, 
if both acting by a central mechanism, act at different
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sites. Or, if it is accepted that guanethidine does not 
enter the brain, then the effect related to guanethidine 
treatment may be of reflex origin, the decrease in turn­
over representing a decreased activity of an inhibitory 
pathway normally activated by, for example, baroreceptors 
and terminating in the hypothalamus (cf. Chapter 1,
Figure 1.3; Calaresu & Thomas, 1975>.
If, however, this is a reflex effect, one might 
expect that on administration of DMI, which antagonises 
the hypotensive effect of guanethidine by a peripheral 
mechanism, preventing the uptake of the drug into the 
neurone (Koe & Constantine, 1972; Stafford & Fann, 1977), 
then the reflex decrease in hypothalamic noradrenaline 
turnover would be reversed. This would occur as a result 
of the blood pressure rising, hence increasing baroreceptor 
activity, and thus restoring the activity of the inhibitory 
pathway proposed above. As can be seen from the results 
in Chapter 6, this does not occur and, in fact, the 
decrease in noradrenaline turnover is apparently poten­
tiated.
Ito et al (1975) report that intracisternal admini­
stration of guanethidine results in decreases in nora­
drenaline turnover in areas concerned with blood pressure 
control (i.e. hypothalamus and medulla), but, at the same^ 
time, produces an elevation in blood pressure.
It is perhaps possible that, on long term admini­
stration of guanethidine, small quantities of the drug 
enter the brain in sufficient amounts to produce an effect
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on noradrenaline turnover, similar to that resulting from 
intracisternal administration. This could result in an 
increased sympathetic outflow and, consequently, an 
elevation in blood pressure. However, one would expect 
this to be more than compensated for by the profound 
peripheral adrenergic neurone blockade produced by the 
drug, a situation possible when considering that postural 
hypotension occurs with guanethidine treatment, indicating 
some block of centrally mediated reflex control of blood 
pressure.
If, therefore, the DMI interaction is due to a 
peripheral blockade of the uptake of guanethidine into 
the neurone, this would result in a less profound neurone 
blockade, which might allow some emergence of the central 
pressor effects. , Equally, by the same argument, one might 
expect that a similar blockade of any central effects of 
guanethidine would occur when, in fact, as shown by the 
results in Chapter 6, the turnover effects produced by 
guanethidine are potentiated by DMI. The explanation of 
the DMI antagonism and the effects of guanethidine becomes 
therefore complicated.
The results obtained from the examination of 
a-methyldopa and DMI confirm that an interaction occurs 
between the two drugs. However, because a-methyldopa 
causes a depletion of noradrenaline (see Chapter 6, section
2.2.4), no results on turnover were obtained.
The interaction between a-methyldopa and DMI does not 
involve the uptake blockade properties of DMI, This has
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been demonstrated by Van Zwieten (1976) in experiments . 
where cocaine (which blocks the uptake mechanism of the 
neurone) failed to abolish the hypotensive actions of 
a-methyldopa (and clonidine) and where Ipindole, a 
tricyclic antidepressant with no uptake blockade properties, 
still produced an antagonism of the a-methyldopa (and - 
clonidine) response»
The inference from these experiments is that, if 
the interaction between centrally acting antihypertensives 
and the tricyclic antidepressants is a result of a central 
mechanism, it would seem probable that it is a result of 
effects on post-synaptic a-receptors by the antidepressant 
drugs (i.e. a-block).
This does not, however, exclude other sites for the 
interaction, sites which may be as, or more, important as 
the mechanisms proposed above, or may at least contribute 
to the central mechanism. Therefore, with particular 
reference to the drugs examined in this thesis, the 
following may be proposed sites of the interactions with 
DMI which may work separately or in conjunction to 
result in the interactions
1. central a-blockade of post-synaptic 
a-receptors;
2. potentiation of peripheral noradrenaline^
3. a general potentiation of adrenergic/
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noradrenergic pressor mechanisms in the 
central nervous system;
and, particularly relevant to guanethidine and other 
peripherally acting compounds,
4. uptake blockade of the antihypertensive 
drug into the neurone.
It is perhaps possible that no unified hypothesis 
can be forwarded to explain all the interactions and that 
each interaction is a result of a different mechanism 
(i.e. for clonidine, central a-block, while for 
guanethidine, peripheral uptake blockade of the drug).
Phenoxybenzamine
The increase in noradrenaline turnover produced 
by treatment with phenoxybenzamine is not altogether 
surprising. It might be expected that, if an a-agonist 
(i.e. clonidine) produces decreases in turnover, then by 
the same mechanism, an a-blocker might have the opposite 
effect.
If the explanation for the effects produced by 
clonidine, detailed in section 7.4, are correct, then it 
would follow that an a-blocker would prevent the stimu­
lation by noradrenaline of pre-synaptic a-receptors. This 
would result in an increase in the release of noradrenaline
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and hence an increase in turnover, which does occur (see 
Chapter 6 and, for example, And^ et al, 1970) *
The effect of the a-blocker is more pronounced in the 
hypothalamus than the medulla* It is difficult to offer 
any explanation for this. As phenoxybenzamine causes 
hypotension by a peripheral a-blocking effect, it might 
be that central turnover changes may reflect a reflex 
action. This, however, is difficult to accept if the 
line of argument discussed earlier with respect to 
guanethidine is correct, as there it was implied that 
peripherally induced hypotension may reflexly result in a 
decreased central noradrenaline turnover.
It is more probable that the turnover effects of 
phenoxybenzamine are due to a direct drug effect, on 
central noradrenergic neurones, but not necessarily those 
involved in blood pressure control.
Clonidine and Sotalol
The interaction between clonidine and the p-blocking 
drug sotalol is a surprising phenomenon. One might expect 
that, as the two drugs work by different mechanisms to 
decrease blood pressure, there would, at the least, be no 
interaction or, alternatively, an additive or synergistic 
effect.
As demonstrated from the report by Saarimaa (1976) 
and also by the results of the animal study presented in 
Chapter 6 of this thesis, this does not occur. In fact.
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the reverse occurs with a nearly complete antagonism of 
the hypotensive effects of both drugs.
Another interesting report on the effects between 
clonidine and p-blockers details a case history of a 
patient who abruptly ceased taking clonidine after 
inclusion of the 3-blocker Timolol in his dosage regimen 
(Bailey & Neale, 1976). The result was the manifestation 
of a severe hypertensive crisis and the display of classic 
clonidine withdrawal symptoms (see Hansson et al, 1973).
The crisis was controlled and reduced by the re-intro­
duction of clonidine therapy. The authors suggest that 
the rebound blood pressure effect was exacerbated by the 
presence of the 3-blocker due to its ability to increase 
peripheral vascular resistance. However, it is not 
possible to ascertain from the paper whether, in fact, the 
3-blocker had any part in the hypertensive crisis, as one 
is not able to say whether such a rebound hypertensive 
crisis would not have occurred anyway on cessation of 
clonidine therapy (see section 7.8).
In the experiments on the clonidine/sotalol inter­
action reported in Chapter 6 of this thesis, as well as 
producing a marked antagonism of the hypotensive action 
of clonidine, sotalol also produced an apparent significant 
potentiation of the decreased noradrenaline turnover which 
results from clonidine treatment. This occurred only in 
the medullary region, in which sotalol itself had no 
significant effect.
If,'as has been discussed in Chapter 6, section 6.4.4,
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sotalol has no central component to its hypotensive 
action and does not cross the blood brain barrier, then 
the antagonism of the hypotensive action of clonidine, 
coupled with a potentiation of the turnover response, 
becomes difficult to reconcile.
The antagonism of the blood pressure response may be 
a result of one of the peripheral 3-blocking actions of 
sotalol resulting in a blockade of 3-vasodilatory 
mechanisms. This might result in more pronounced effects 
from a-vasoconstrictor mechanisms. If this were so, the 
peripheral effect of clonidine (i.e. vasoconstriction) may 
well be potentiated and become significant.
However, the central effects allow no easy explanation 
to be made for their occurrence without more information 
from experiments investigating the central effects of 
3-blockers in general and sotalol in particular. It 
would certainly be of value to ascertain if this inter­
action can be shown to occur with other 3-blockers, in 
particular those which are reputed to have a central 
component to their mechanism such as propranolol (e.g. Day 
et al, 1976) and which also produce changes in central 
catecholamine turnover (see Chapter 6, section 6.4.4, and 
Fuxe et al, 1976).
As discussed in Chapter 6, section 6.4.4, the 
possibility of effects on other central mechanisms cannot 
be fully excluded so that adrenergic neurone systems 
(Fuxe et al, 1976) or cholinergic and serotonergic systems 
(e.g. Laubie, 1976; Bhargava, 1976) may also be involved.
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However, to ascertain this, much work would need to be- 
done on the topic.
Possibly crucial in this respect would be definite 
evidence as to whether sotalol has a central action or 
not. Again, this is an area in which more detailed work 
requires to be carried out.
Therefore, although an explanation- has been offered 
for a peripheral mechanism of the antagonism of clonidine 
by sotalol, on the available evidence, it is not possible 
to offer a satisfactory explanation of the central 
effects.
7.7 The Localisation of the Central Effects
of Clonidine
If the hypothetical synapse proposed in section 7.4 
is accepted as that at which clonidine produces its 
effects, then where might this synapse be located?
Ample evidence is available to confirm that the 
predominant hypotensive action of clonidine is mediated; 
by an effect in the medulla (for references see section
7.4).
Early work by Schmitt (1971) and Haeusler (1973b) led 
to the proposal that the baroreceptor reflex arc and the 
Nucleus Tractus Solitarii (NTS) were important in the hypo­
tensive action of clonidine, stimulation by clonidine of 
a-receptors located in the NTS being responsible for the
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blood pressure lowering action. There have, however, been 
some conflicting results from more recent work on this 
area of the medulla. Laubie et al (1976) demonstrated 
that, after the NTS in the dog has been lesioned, the 
bradycardiac, but not the hypotensive, effect of clonidine 
is decreased. This observation has also been made in the 
cat by Antonaccio and Hailey (1977). However, Lipski et 
al (1977) have shown that, after NTS lesioning in the 
rat, the hypotensive effect of clonidine is decreased.
They propose species difference and incomplete lesioning 
of the NTS in larger animals (such as cats and dogs) to 
account for this conflicting result.
Therefore, if the NTS in the rat is the predominant 
site for the hypotensive action of clonidine, then it may 
not be unreasonable to suggest that the hypothetical 
synapse proposed earlier is located in this area. Hence 
the effect of clonidine to decrease noradrenaline turnover 
in the medulla may be explained by the discussion presented 
in section 7.4.
The effects of clonidine on noradrenaline turnover in 
the hypothalamus is not, however, so easily explained.
If, as proposed by Calaresu and Thomas (1975), there 
is an inhibitory connection between the NTS and the hypo­
thalamus (Figure 1.3, Chapter 1) and this synapse at the 
hypothalamic end is noradrenergically innervated, if the 
neurone is stimulated by clonidine in the NTS, it might be 
expected that an increase in turnover would result in the 
hypothalamus. This does not apparently occur. Therefore,
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either the synapse, if it exists, is not. noradrenergically. 
innervated or the hypothalamic turnover decreases reflect 
an effect on_other noradrenergic neurone systems,
Clonidine has been shown to produce depressor effects 
when injected stereo-taxically into the anterior and posterior 
hypothalamus (Struyker^Boudier & Van Rossum, 1972; Struyker- 
Boudier et al, 1974). This indicates the presence of a-receptors 
and, hence, possibly noradrenergic neurones in these areas, 
which may be affected in a similar way to that proposed 
for noradrenergic nerve endings in the NTS. Clonidine 
has also been shown to reduce the pressor effect of 
electrical stimulation of the hypothalamus (Philippu, 1976), 
presumably by decreasing the release of noradrenaline 
initiated by electrical stimulation. This too might be 
expected to result in a decrease in noradrenaline turn­
over .
It is perhaps possible, therefore, that the hypo­
thalamic turnover decrease reflects the effect of the 
inhibitory pathway activated by clonidine on a nora­
drenergic pressor system in the hypothalamus, as it has 
also been demonstrated that clonidine applied to the NTS 
will decrease the pressor response from electrical 
stimulation of the hypothalamus (Philippu, 1976).
The effects of clonidine on noradrenaline turnover 
in the hypothalamus is, however, less than in the 
medulla and is of secondary importance to the drug’s 
hypotensive action in the medulla (Van Zwieten, 1975a),
Regarding the potentiation of the turnover effects of
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clonidine by DMI, the discussion presented in section 7.5 
may well be applied to the specific areas discussed 
above.
It may be that the interaction between DMI and 
clonidine involves two actions of DMI at separate sites in 
the brain. For example, a-block of the effects of 
clonidine in the NTS, yet a potentiation of the nora­
drenergic pressor system in the hypothalamus. Philippu 
(19"7’5) indicates that 3-blockers will reduce the pressor 
response from electrical stimulation of the hypothalamus, 
implying that these pressor responses may be mediated by 
3-receptors and, hence, be unaffected by a-block from the 
DMI. This suggestion is feasible considering that some 
3-blockers are thought to exert their hypotensive actions 
by a central effect (e.g. Day, Peters & Roach, 1976).
However, the effects produced by guanethidine and 
phenoxybenzamine on noradrenaline turnover are not easy 
to explain within the context of the discussion presented 
above. Until it is made clear whether the effects pro­
duced by these drugs are due to a reflex effect or a direct 
drug action, it is not possible to offer an acceptable 
explanation.
7.8 Clinical Implications of the Effects of
Clonidine reported in this Thesis
Clonidine is an antihypertensive drug widely used in
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the treatment of hypertension and, although it has some 
side effects, mainly sedation and the production of 
dry-mouth, it produces an effective control of blood 
pressure (Callingham, 1971; Bostock, 1975; Fragachan et 
al, 1975; Kosman, 1975; Conolly, 1975; Wilhelm & De 
Stevens, 1976; Dollery, 1976).
There are two major factors associated with clonidine 
treatment which are causes for concern.
The first is the interaction of clonidine with other 
drugs resulting in a loss of the hypotensive effects of 
clonidine. This is particularly relevant with the tricyclic 
antidepressants which have been shown to antagonise the 
action of clonidine clinically (Briant, Reid & Dollery,
1973) and also in experimental animals (Van Zwieten, 1975a? 
Chapter 5 of this thesis). Also, as has been previously 
discussed, it appears that certain 3-blockers may also 
produce an antagonism of the clonidine response (see 
section 7.6).
Animal experiments have also indicated that other 
psychotropic drugs may produce adverse actionswhen 
administered with clonidine (Van Zwieten, 1976, 1977)»
The second major factor important in clonidine 
therapy and probably one of the more important factors 
as it is more likely to occur due to "patient error" is the 
"rebound" hypertensive crisis that is reported to occur 
on abrupt cessation of clonidine treatment (Hansson et al, 
1973; Hunyor et al, 1973; Bailey, 1975; Goldberg et al, 
1976; Bailey & Neale, 1976; Pettinger, 1975)* It is to
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this phenomenon that the findings of this thesis may be 
relevant.
The withdrawal phenomenon and blood pressure crisis 
have been shown to be associated in man with an increased 
sympathetic activity (Hansson et al, 1973) and have also 
been demonstrated in animal experiments (Cavero et al,
1977; Dix & Johnson, 1977; Grimes, 1974, unpublished 
observations; Petty, 1975, unpublished observations).
Assuming that in man blood pressure is controlled 
by a noradrenergic mechanism which has an inhibitory 
controlling function on blood pressure and that clonidine 
acts and produces its effects on this mechanism in much 
the same way as in animals (see sections 7.2 and 7.4), 
then it is possible that the decrease in central nora­
drenaline turnover resulting from clonidine treatment 
could also occur in man.
It has been said that the pre-synaptic effects of 
clonidine persist longer than the post-synaptic effects 
after removal of clonidine (cited by Sleight, 1976). If 
so, then the hypotensive effect of clonidine ceases soon 
after ceasing therapy, but the decreased central nora­
drenaline turnover persists (accepting the argument set 
forth that this is a result of a pre-synaptic effect) and 
at a lower level than existed before clonidine treatment 
was initiated. Hence, the normal function of the 
inhibitory controlling pathway is impaired, which results 
in increased sympathetic outflow from the brain and, there­
fore, increased sympathetic activity resulting in vaso­
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constriction and raised blood pressure. The idea of 
increased sympathetic activity seems to be substantiated 
by the fact that the "overshoot" crisis can be controlled 
by return to clonidine therapy or by combined admini­
stration of a- and 3-blocker therapy*
7.9 Conclusions
The major conclusion to be drawn from this thesis 
is that prolonged dosing with clonidine results both in a 
fall in blood pressure and a decrease in central nora­
drenaline turnover. It would appear that the effect on 
turnover, however, is not directly related to the hypo­
tensive action of the drug, but seems to be an incidental 
effect mediated by the stimulation of pre-synaptic a- 
receptors by clonidine.
The results of the examination of the clonidine/DMI 
interaction appear to confirm this idea and also indicate 
that the interaction itself (antagonism of the hypotensive 
action of clonidine) is not related to the effect of DKI 
to block central pre-synaptic uptake mechanisms. Various 
other mechanisms have been suggested which may solely or 
partially be responsible for this interaction.
On the basis of the results obtained, the thesis 
argues for a post-synaptic site for the a-receptors 
stimulated by clonidine to decrease blood pressure.
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7.10 Suggestions for Further Work
Apart from continuing the research into the causes 
of hypertension and the relationship of central 
regulatory control mechanisms to elevated blood pressure, 
there are three major suggestions for further work 
arising from this thesis:
1. As suggested in section 7.3, the examination of
gross brain areas may not provide a clear indication 
of the true state of neurone activity in the central 
nervous system. The estimation of turnover in much 
more discrete areas, such as individual brain 
nuclei (i.e. NTS or hypothalamic nuclei), using 
methods outlined in Chapter 2, section 2, and 
correlation of any such changes with blood pressure 
may be of greater value in determining the function 
of central noradrenergic neurones in blood pressure 
control and also the effect of drugs on these 
systems.
These types of experiments could be performed in 
conjunction with stereo-taxic application of drugs 
to certain brain areas (i.e. clonidine on to the 
NTS) with concurrent measurement of noradrenaline 
turnover in other brain areas.
The peripheral manipulation of blood pressure by 
peripherally acting drugs or mechanical means, 
inducing reflex effects, could also be performed and
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correlated with changes in turnover in specific 
brain nuclei.
Experiments of this type might shed light on the 
cause of the apparent central effects produced by 
compounds such as guanethidine and sotalol, which are 
not thought to enter the brain (see earlier discussion), 
The results of such experiments may also aid in a 
greater understanding of the central pathways 
involved in blood pressure control.
2. Further study of the interaction between clonidine 
and, for example, the tricyclic antidepressants. 
Experiments involving the concurrent recordings of 
central sympathetic outflow, blood pressure and 
possibly peripheral nerve activity (i.e. by turnover 
estimations or measurement of labelled transmitter 
release) may help determination of whether the 
interactions are a result of a central or a peripheral 
effect. Again, the results of such experiments may 
also provide explanations towards determining the 
true site of action of central ly acting antihyperten^ 
sives.
3. A more detailed study of the clonidine/sotalol inter­
action to attempt to define the true cause of this 
interaction.
It also would certainly be of value to see if the 
interaction could be demonstrated with other 3-blockers,
— 231 —
Examination of 3-blockers in general in a similar way 
to that outlined in Suggestion 1 may provide inform­
ation both on the effects and site of action of 
3-blockers in the brain and also possible central 
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T he e ffec t o f  ch ro n ic  c lon id ine  ad m in is tra tio n  o n  ca techo lam ine  m etabo lism  
in th e  ra t b rain
A J D R A P E R , D. G R IM ES* and F.H. R E D F E R N  {S ch o o l  o f  P h arm acy  and Ph arm aco logy ,
Univers i ty  o f  B a th )
T he an tih y p erten siv e  d rug  clon id ine  is th o u g h t to  have a cen tral ac tion  [ 2 ] ,  
a lthough  th e re  is co n flic ting  evidence o f its e ffe c t on  am ine  m etabo lism  in th e  
brain  [ 1 ] .
In th e  w ork rep o rted  he re  we have exam ined  th e  e ffec ts o f  ch ron ic  c lon id ine
on  th e  levels and tu rn o v e r o f no rad renaline  (N A ) and dopam ine (D A ) in d iscre te  
brain  regions o f  no rm o tensive  and hypertensive  ra ts . C lonid ine (50 ^g /k g  o r 
100 pg /kg  i.p .) tw ice daily  fo r  7 days, in no rm o tensive  rats p roduced  sign ifican t 
falls in b lood  p ressure, b u t no significan t changes in DA o r NA levels o f the  
co rtex , m idbra in , h y p o th a lam u s o r m edulla.
In renal hypertensive  ra ts , the b lood p ressure falls w ere greater, an d  w ere 
accom panied  by sign ifican t increases in w hole brain levels o f NA {P < 0 .0 1 ). 
Increase o f NA in d iscre te  brain  regions was ap p a ren tly  confined  to  th e  c o rte x , 
th e  incresisi' being g rea te r a f te r  tlie low er dose o f c lon id ine . L ittle  change in 
DA level was observed in any  region of th e  brain . In spon taneously  hypertensive  
rats a fte r  7 Pays tre a tm e n t w ith 100  pg /kg  c lon id ine  i.p . tw ice daily  th e re  w as 
a sign ifican t decrease (P < 0 .0 0 1 ) in bo th  NA and  DA tu rn o v e r e stim ated  in  
w hole brain. T he re la tion  o f  these results to  th e  an tihypertensive  ac tion  o f  
c lon id ine  will be d iscussed.
1 Ancien, N .E ., C orrodi, H., F u x e , K., H dk felt, T ., R yd in , C ., S vcnsson , T ., e t  a l.. E v idence
for a central noradrenaline rccep lor stim u lation  by c lo n id in e . L ife S ci., 9 ( 1 9 7 0 )  5 1 3 —5 2 3 .
2 Van Z'A’icten , P.A ., 'I’he central action  o f  a iitibypertensive drugs, m ediated  via central
a-receptors, J. Pharm. Pharm acol., 35  (1 9 7 3 )  8 9 —9 5 .
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THE INTERACTION BETWEEN CLONIDINE AND DESMETHYLIMIPRAMINE.*
EFFECTS ON BLOOD PRESSURE AND CENTRAL CATECHOLAMINE METABOLISM
A.J. Draper, D. Grimes, P.K. Redfern, Dept, of Pharmacology,
University of Bath, Claverton Down, Bath BA2 7AY.
Evidence has recently been presented which suggests an interaction between the 
centrally acting antihypertensive clonidine and the tricyclic antidepressant 
drug desmethylimipramine (DMI) which could lead to a reduction in the clinical 
efficacy of the hypotensive agent. (Briant & Reid 1972; Van Zwieten 1975).
We have examined the effect of these two drugs, alone and in combination, on 
blood pressure and noradrenaline (NA) metabolism in normotensive rats.
DMI 2mg/)cg i.p. given 20h and 6h before Icilling produced a 12.0% fall in blood 
pressure (p<O.OOi). As has previously been shown, (Draper & others 1976), 
clonidine also produced a significant fall in blood pressure of 20% when given 
in a dose of lOO pg/kg i.p. daily for 7 days. However, when DMI was given at the 
end of the period of clonidine treatment, the fall in blood pressure was only 
12.4%, significantly less (p<0.001) than the fall recorded after clonidine alone.
This result lends weight to the belief that the antihypertensive effect of 
clonidine may be antagonised by DMI. We have also investigated the possibility 
that interaction between the two drugs involves the metabolism of NA at central 
synapses. Turnover of NA was assessed in medulla and hypothalamus of 
normotensive rars by measuring the rate of decline of NA levels after
administration of =-methyl-p-tyrosine. We have previously shown that treatment
with clonidine for 7 days produces a significant decrease in whole brain turnover 
in both normotensive and hypertensive animals. (Draper & others 1976).
In the present experiments clonidine alone produced significant decreases in 
the Medulla and Hypothalamus. Treatment with DMI alone also produ c e d  decreases 
in the turnover of NA in Medulla and Hypothalamus but less than that 
attributable to Clonidine. Combination of DMI and clonidine resulted in a further
decreased rate of turnover in both medulla and hypothalamus, when compared to
values from Clonidine treated animals. The reason for this effect is not 
clear, although it might be suggested that pretreatment with clonidine results 
in a changed sensitivity of central pre- or post-synaptic receptors, such that 
tne accumulated NA resulting from DMI-blockade of re-upta)te is capable of 
producing a secondary inhibition of NA synthesis.
It can however be concluded that the reported antagonism of clonidines' 
hypotensive action by DMI is not easily explained by any simple interaction at 
central adrenergic synapses.
Draper, A . J . , D. Grimes, P.M. Redfern (1976) Neuroscience Letters, in press. 
Briant, R . H . , and J.L. Reid, (1972). Brit.J.Pharmacol. 46, 563 P.
Van Zwieten, P.A. (1975). Arch.Int.Pharmacodyn. 214, 12-30.
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The effect o f prolonged clonidine administration on catecholamine
metabolism in the rat brain
175
A n t h o n y  J. D r a p e r ,  D a v i d  G r im e s ,  P e t e r  H. R e d f e r n * ,  Pharmacology Group, School o f  Pharmacy and Pharma- 
cology. University o f  Bath, Bath, Avon, U.K.
Acute doses of the antihypertensive drug clonidine 
cause a decrease in the turnover of central catechol­
amines (Laverty & Taylor, 1969, Andén, Corrodi 
& others, 1970), although the extent of the decrease 
appears widely variable. We have examined the effects 
o f more prolonged clonidine administration on both 
blood pressure and central catecholamine turnover, in 
normotensive and two types of hypertensive rat, 
namely renal clip/DOCA rats, and New Zealand 
spontaneously hypertensive rats (SH-rats).
Male rats of the CFY strain were used, normotensive 
animals at 200-250 g, while hypertensive animals were 
used 4 to 5 weeks after surgery on 70-90 g animals, 
made hypertensix’e by a modification of the method of 
Finch & Leach (1970), in which the left renal artery was 
occluded with a silver clip, and a 25 mg pellet of 
deoxycorticosterone acetate was implanted subcutane- 
ously. These animals had free access to 1 % saline; 
increases in mean systolic blood pressure of 70 mmHg 
(219 i  5 mmHg, mean rt s.e.m., n - 20) over that of 
control animals (144 i  2 mmHg, n — 20) resulted. 
SH-rats were from a colony of the New Zealand strain 
raised in our own laboratories, with blood pressures 
o f 208 i  4 mmHg (n =  19). All blood pressures were 
measured in the conscious restrained animal by the 
tail cuff method before dosing and on the sixth day. 
Clonidine hydrochloride in 0 9 % saline was given 
intraperitoneally twice daily at 9.00 and 17.00 h for 7 
days, controls were given saline. Statistical significances 
were determined using Student’s /-test.
To estimate the effect of clonidine on the concentra­
tion of noradrenaline and dopamine in the brain, 
animals were killed 2 h after the last morning dose of 
clonidine, the brains dissected into regions (Glowinski 
& Iversen, 1966) and the catecholamines extracted 
according to Anton & Sayre (1962) and then assayed 
fluorimetrically (Shellenberger & G ordon, 1971).
The turnover of the two amines was estimated in 
whole brains by measuring the rate of decline of the 
amine concentrations after synthesis inhibition with 
a-methyl-/»-tyrosine methyl ester hydrochloride (a-MT) 
(250 mg k g - \  i.p.) (Brodie, Costa & others, 1966). 
Concentrations of the amines were measured at time 
0 and 4 h after a-M T, previous experiments having 
shown that the decline was linear over this period. 
Turnover rates were compared by log-linear regression 
analysis of the results and comparison of the resultant 
slopes by /-test. In clonidine-trcated animals, a-M T was 
administered 2 h after the last morning dose, and the 
animals killed 4 h later.
• Correspondence.
Drugs used were: clonidine hydrochloride (B o e h -  
ringcr-lngelheim), a-methyl-/?-tyrosine methyl e s te r  
hydrochloride, (Sigma) and deoxycorticosterone a c e ta te  
(Organon).
In normotensive animals clonidine (50 o r  100 A tgkg“ \  
i.p.) produced significant falls in blood pressure (12 1 
and 20-6 "o, f  <  0 001 for both), but produced n o  
significant changes in the concentration o f  the a m in e s  
in brain regions (cortex, midbrain, hypothalamus, a n d  
medulla-pons) or whole brain. However in the renal/ 
DOCA hypertensive animal the same doses of c lo n id in e  
not only produced similar significant changes in  b lo o d  
pressure (15T and 20 9 % for the low and high doses o f  
clonidine, f  <  0 01) but also significant increases in the 
concentrations of noradrenaline (Fig. 1), in certain 
brain areas no consistent changes were found in 
dopamine concentration.
The rate of decline of noradrenaline concentration 
after synthesis inhibition with a-M T was measured 
in whole brains of normotensive and renal/DOCA 
hypertensive rats. In the latter, the rate of decline was 
significantly decreased by 30 1 % of the control value 
(Table 1). Similar results were obtained for the rate o f  
decline of dopamine concentrations (Table 1).
When these experiments were repeated using c lo n i-  
dine-treated animals it was found that in all animals 
clonidine produced significant and dose related de­
creases in the turnover of both amines (a s  well a s  
significant falls in blood pressure (Table 2).





b da c e
F ig .  1. The effect of clonidine 1 0 0 /x g k g “  ̂ (i.p.) twice 
daily for 7 days on the concentrations of noradrenaline 
in rat brain (ng g-* tissue). Open columns represent 
control values, hatched columns represent clonidine 
treated values. Values are the mean of 10 samples 
(± s.e .m .) * P <  0  0 5 , ** P < 0  0 1 . a-Cortex, b-mid- 
brain, c-hypothalamus, d-medulla pons, e— total brain.
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Table 1. Rate o f  decline o f  catecholamine concentrations 
in the brains o f  normotensive and renal! DOC A hyper­
tensive rats after synthesis inhibition. Blood pressures 
were measured, and concentrations of noradrenaline 
(NA) and dopamine (DA) estimated after synthesis 
inhibition by a-methyl-/?-tyrosine (250 mg k g - \  i.p.). 





No. of mm Hg Rates of decline 







in the rate of 
decline 
Significance
10 144 ±  2 0 07662 0 1357
10 219 ±  5 0-05359 0 0952
—  P <  0-001
30 1% 
f <  0 01
29-6%
P< 0-01
The rate of decline of amine concentration after 
synthesis inhibition is presumably related to the rate 
at which the amines are released from their binding 
sites within the nerve endings, and subsequently des­
troyed and/or removed from the brain.
We have demonstrated that this ‘turnover* rate of 
noradrenaline is significantly less in hypertensive than 
in normotensive animals, confirming the results of 
Nakam ura, Gerold & Thoenen, (1971) and Ito, 
Tanaka & Omac, (1975). While noradrenaline can be 
shown to be either depressor or pressor depending 
on the area of the brain to which it is applied, (Gagnon 
& Melville, 1968; Phillipu, Przuntek & others, 1971), 
it is now widely believed to have a predominantly 
inhibiting influence on blood pressure (De Jong, 
1974; Struykier Boudier, Smeets & others, 1975) a 
hypothesis with which our results are compatible.
This inhibitory influence of noradrenaline on blood 
pressure is thought to be mediated via a-adrenoceptors 
(Haeusler, 1974; De Jong 1974) and it is also believed 
that clonidine’s action on these same a-receptors 
accounts for the drug’s antihypertensive action (Andén 
& others, 1970; Van Zwieten, 1973; Kobinger & 
Pichler, 1974). Such an action might be brought about 
either by a post-synaptic action in which clonidine 
replaced noradrenaline as an a-adrcnoceptor agonist, 
or by an action on pre-synaptic a-adrenoceptors.
For a presynaptic action to be compatible with the 
hypothesized inhibitory role of noradrenaline, it must 
be assumed that clonidine is acting presynaptically 
as an antagonist to noradrenaline at a-adrenoceptors 
on the pre-synaptic membrane (Stjarne, 1975) and 
allowing more noradrenaline to be released in re­
sponse to stimulation of the presynaptic neuron. In
Table 2. The effect o f  clonidine on blood pressttre, and on 
the rate o f  decline o f  noradrenaline (NA) and dopamine 
(DA) in the brains o f  normotensive and hypertensive 
rats. Clonidine (50 or 100 fig k g " \  i.p.) was given twice 
daily for 7 days. Blood pressures were measured the 
day before killing, and the rate of decline of NA and 
DA estimated after synthesis inhibition by a-methyl-/?- 
tyrosine. Results are expressed as percentage decrease 
from corresponding untreated normotensive and 
untreated hypertensive animals.
Drug and % decrease % decrease in
dose pg kg-^ n in b.p. rate of decline
NA DA
Normotensives
Clonidine 50 10 12-1%*** 10-7% 5 % t
Clonidine 100 10 20-6%*** 48-7%** 5%
Renal/DOCA
hypertensive
Clonidine 50 6 15-1%** 15-9% 2 2%
Clonidine 100 7 20-9%** 40-5%* 12-1%
New Zealand
S.H.
Clonidine 100 8 26-0%*** 66-4%*** 19-8%***
* =  f  <  0 05; •* =  / ’ <  0-01; 
t  =  increase.
P <  0-001;
other words the fall in blood pressure produced by 
clonidine would be associated with an increased 
turnover of noradrenaline. But we have found that 
the rate of decline of noradrenaline following syn­
thesis inhibition to be significantly slowed by clonidine 
given over seven days at 100 ^g kg~^ (a decrease also 
occurred at 50 ^g kg“  ̂ but was not statistically signifi­
cant). This occurred in normotensive rats, and in 
hypertensive rats in which noradrenaline turnover was 
already significantly reduced.
Using another functional model, Andén, Grabowska 
& Strombom (1976) have suggested that the metabolic 
and functional effects of clonidine are unrelated, being 
mediated by pre- and post-synaptic a-adrenoceptors 
respectively. While we cannot rule out the possibility 
that a similar separation occurs in the areas of the 
brain responsible for blood pressure control, there 
seems no reason to suppose that bombardment of 
post-synaptic a-receptors should not be responsible 
for both the recorded fall in blood pressure and the 
decreased turnover of noradrenaline, by a feedback 
homeostatic mechanism.
Thus our results using prolonged clonidine admini­
stration arc compatible with the hypothesis that the 
antihypcrtensive effect of clonidine is brought about 
by an agonist action on post-synaptic receptors.
The work was supported by a University of Bath 
Research Fund grant awarded to one of us (D. G ). 
Clonidine was kindly donated by Boehringer-Ingel- 
heim Ltd. December 20, 1976
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